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G protein-coupled receptors (GPCRs) are a diverse super family of seven transmembrane 
spanning proteins whose primary function is to initiate the activation of intracellular signalling 
pathways following stimulation by extracellular stimuli, which include photons, amines, 
lipids, ions, peptides and proteins. Due to the ubiquitous expression of GPCRs throughout 
various tissues, they are implicated in the regulation of a variety of diverse physiological 
processes, such as secretion of the blood glucose controlling hormones insulin, glucagon and 
somatostatin from islets. As a result, GPCRs are being identified as therapeutic targets for the 
treatment of type-2 diabetes. 
Despite the large array of potential GPCR targets available, only a handful of GPCRs have 
proven to be successful clinical targets, which may partially be due to the lack of availability 
of suitable translational models that reflect the human GPCR landscape. The aim of the 
experiments described in this thesis was to compare the mRNA expression profiles of all 
GPCRs (the GPCRome) and all GPCR peptide ligands (the Secretome) in human and mouse 
islets in order to determine the suitability of using mouse islets as a translational model for 
predicting the role of islet GPCRs and GPCR peptide ligands in human islet function. In 
addition, some experiments demonstrate how the GPCRome and Secretome data were used to 
assess the role of CXCL14 in islet function. 
Quantitative real-time PCR (qPCR) was used to compare the mRNA expression profiles of 
376 GPCRs and 159 GPCR peptide ligands in human islets with their orthologous counterparts 
in islets isolated from two strains of mice (outbred ICR mice and inbred C57/BL6 mice). A 
reasonable degree of similarity in GPCR mRNA expression between human islets and islets 
from each mouse strain was found (r2 = 0.360 vs. ICR; r2 = 0.304 vs C57), with a highly similar 
expression profile observed between the ICR and the C57 mouse strains (r2 = 0.946). 
Regression analysis of GPCR peptide ligand mRNA expression revealed that human islets 
exhibit a reasonable degree of similarity compared to islets of both mouse strains (r2 = 0.245 
vs. ICR; r2 = 0.225 vs. C57) with a highly similar expression profile observed between the two 
mouse strains (r2 = 0.968). 
In the process of quantifying the GPCR peptide ligand mRNA expression profiles, it was 
revealed that the orphan chemokine CXCL14 is expressed by both mouse and human islets. 
Studies have shown that CXCL14 knockout mice are protected from hyperglycaemia and 
hyperinsulinemia and they have improved insulin sensitivity. However, CXCL14’s role in 
islet function has yet to be explored. The experiments described in this thesis demonstrate that 




mechanism that is not transduced through a Gαi-mediated reduction in intracellular cAMP, 
but is likely to occur through an inhibition of glucose uptake or glucokinase activity. Further 
experiments designed to elucidate the target involved in CXCL14 function revealed that 
CXCL14 is neither an agonist nor an antagonist for the CXCR7 receptor and the putative 
CXCR4 receptor, and thus these receptors are not responsible for mediating CXCL14 
function. 
In summary, the experiments described in this thesis reveal that human and mouse islets 
exhibit some degree of similarity in GPCR and GPCR peptide ligand mRNA expression, but 
the suitability of using mouse islets as surrogates for predicting human islet physiology is 
receptor/receptor family specific. This thesis also reveals how the GPCRome and Secretome 
data can be employed to investigate the role of particular ligands, such as CXCL14, and 
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1.1 The islets of Langerhans 
1.1.1 Islet structure 
The islets of Langerhans, which are the endocrine component of the pancreas, 
constitute 1-4% of the total pancreatic mass, whilst the remaining proportion of the 
pancreas is comprised of exocrine tissue (Dolensek et al., 2015). Each islet is 
approximately 100-200µm in diameter (Jo et al., 2007) with approximately a million 
islets found in the healthy human pancreas and approximately 1000 islets found in the 
mouse pancreas (Bonnevie-Nielsen et al., 1983). Whilst the pancreas size and 
therefore number of islets is proportional to the size of the species, the actual size of 
islets remains similar between species (Kim et al., 2009). Each mammalian islet 
contains approximately 50 to 3000 cells, which can be categorised into five cell types: 
glucagon secreting α-cells; insulin secreting β-cells, somatostatin secreting δ-cells; 
pancreatic polypeptide releasing cells and ghrelin expressing ε-cells (Rutter et al., 
2015). Despite similarities in size and cell type presence of islets between human and 
rodent islets, the proportion and distribution of the five cells types of the islet varies. 
For instance, the proportions of α-, β-, δ-cells within the human islet are approximately 
40, 50, 10% respectively, whereas in mouse islets the proportions are approximately 
15-20, 60-80, 10% respectively (Steiner et al., 2010). Not only do the proportion of 
islet cells differ between human and rodent islets but the arrangement of these cells 
within islets also varies. Within rodent islets a core of β-cells surrounded by a mantle 
of α-cells and δ-cells is observed, whereas the arrangement of such cells within human 
islets is less defined and found to be more interspersed with each other (Cabrera et al., 
2006) (Figure 1.1.1). 




Figure 1.1.1 Architecture of the islets of Langerhans. The figure depicts a cross 
section of a (a) mouse and (b) human islet stained for insulin, glucagon and 
somatostatin as indicated by red, green and blue immunofluorescence respectively 
(Wang et al., 2015). 
 
Islets are highly vascularised (see Figure 1.1.2) and despite only accounting for 
approximately 3% of the pancreatic mass, receive 15% of the total pancreatic blood 
supply (Jansson et al., 2016). There are two distinct blood flow patterns within the 
mouse islet: inner to outer, in which flow travels from the β-cell core to the outer layer 
of other cell types, and top to bottom, in which flow travels from one side of the islet 
to the other irrespective of cell type. The inner to outer flow is proposed to support the 
concept that β-cell secretory products can regulate the function of cells downstream, 
for example the regulation of glucagon secretion from α-cells (Nyman et al., 2008). 
Whilst these blood flow patterns have been observed in mouse islets, the fact that cell 
type distribution varies more in human islets suggests the pattern of flow in human 
islets may differ compared to mouse islets. 




Figure 1.1.2 Visualisation of islet vasculature. Islet β-cells highlighted with GFP 
fluorescence and islet vasculature observed by Rhodamine dextran infusion (red) in 
the left and centre panels respectively. Right panel depicts a superimposed image. 
(Nyman et al., 2008). 
 
The extensive vascularisation of islets is an integral component of their primary role 
to sense fluctuations in blood nutrients and respond accordingly in an endocrine 
manner to maintain glucose homeostasis.  
 
1.1.2 The regulation of glucose homeostasis 
Mammalian cells, in particular the brain, utilise glucose as a primary source of energy 
in the form of ATP, which is necessary for many metabolic processes (Hoyer, 1990). 
Due to the significant involvement of glucose in essential cellular processes, the 
circulating levels of glucose are meticulously monitored and controlled in order to 
maintain euglycemia, i.e. ~3-5mM blood glucose. The maintenance of glucose 
homeostasis is a co-ordinated and complex series of processes that involves the 
endocrine pancreas, liver, adipose tissue, skeletal muscle, gastro-intestinal tract and 
the central nervous system. The principal pancreatic endocrine hormone involved in 
the reversal of postprandial elevation in blood glucose is insulin, which functions by 
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enhancing glucose uptake into insulin-sensitive tissues and promoting it’s storage in 
macromolecules. 
Following elevations in blood glucose, the β-cells of the islets of Langerhans secrete 
insulin, which functions by binding to cell surface insulin receptors within target 
tissues. The insulin receptor (IR) is a membrane bound (αβ)2-type receptor tyrosine 
kinase, which is composed of two αβ-heterodimers. Each heterodimer consists of an 
extracellular hormone-binding α-subunit and a transmembrane spanning β-subunit 
containing an intracellular tyrosine kinase binding domain. The α- and β-subunits of 
each heterodimer are linked by a disulphide bridge and the two heterodimers linked 
by four disulphide bridges between the α–subunits (Tatulian, 2015). 
 
Figure 1.1.3 An illustration of the structure of the insulin receptor (Tatulian, 
2015). The two α-subunits of the receptor are quadruply disulfide-linked, and each α-
chain is disulfide-linked to a β- chain. Once bound to insulin (black hexagon), each β-
chain phosphorylates its counterpart at tyrosines 1158, 1162, and 1163. 
 
Upon insulin binding, the receptor undergoes a conformational change which 
promotes the autophosphorylation of three tyrosine residues located on each β-subunit 
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of the heterodimer, thus disinhibiting the tyrosine kinase activity of the receptor. This 
allows for the phosphorylation of downstream signalling molecules such as the insulin 
receptor substrate proteins (IRS) of which there are four members, IRS1-4 (Sesti, 
2000). IRS1 and 2 are ubiquitously expressed throughout insulin sensitive tissues 
whereas IRS3 is predominantly expressed within adipocytes (Zhou et al., 1999). IRS 
proteins are classed as adapter proteins that have no intrinsic catalytic activity, but 
once phosphorylated reveal sites of binding for Src homology proteins, such as 
phosphatidylinositol-3-kinase (PI3K) and growth factor receptor-bound protein 2/son 
of sevenless (Grb2/SOS). The PI3K pathway mediates translocation of glucose 
transporter 4 (GLUT4) to the plasma membrane of adipocytes and myocytes following 
phosphorylation of the membrane lipid phosphatidylinositol 4,5 bisphosphate (PIP2) 
to phosphatidylinositol 3,4,5 trisphosphate (PIP3,) the recruitment of Akt2 and the 
subsequent phosphorylation of Akt2 by PDK1 (Tatulian, 2015). The increased 
translocation of GLUT4 to the plasma membrane facilitates glucose uptake, thus 
reducing circulating blood glucose levels. In addition to GLUT4 translocation, the 
interaction of IRS with Grb2 induces the binding of Grb2 to SOS and the activation of 
Ras protein, resulting in the nuclear translocation of MAPK and the regulation of 
transcription factors which modulate gene expression, proliferation and differentiation 
(Brown et al., 2015). Thus, the role of IRS proteins are essential to insulin’s 
mechanism of action in regulating cell metabolism and growth. 
As previously mentioned, the process of glucose uptake is facilitated by glucose 
uptake transporters. The GLUT protein family consists of 14 members grouped into 
three major classes based on sequence homology and substrate selectivity (Aparicio 
et al., 2010). GLUT4 is predominantly expressed in myocytes and adipocytes and is 
responsible for the majority of total glucose uptake during periods of elevated blood 
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glucose; muscle ~85%, adipose tissue ~15% (Govers, 2014). Cellular uptake of 
glucose via GLUT4 is an energy-independent process that can only occur down a 
concentration gradient. The GLUT2 isoform, on the other hand, is expressed in the 
intestine, kidney, liver and β-cells of pancreatic islets and it has a distinctly different 
glucose uptake kinetic profile to GLUT4 (Mueckler, 1994). GLUT2 is a high capacity, 
low affinity transporter with a Km for glucose of ~17mM. This high capacity and low 
affinity allows for a large influx of glucose and is one of the key underlying factors 
responsible for mediating the secretion of insulin from β-cells during hyperglycaemic 
episodes (Leturque et al., 2009). 
In contrast to maintaining glucose homeostasis during hyperglycaemia, processes also 
exist to modify glucose homeostasis during periods of hypoglycaemia. In the event of 
hypoglycaemia, glucagon is secreted from the α-cells of the islets to promote hepatic 
glucose production by promoting glycogenolysis and gluconeogenesis. These events 
are mediated through the glucagon receptor (GCGR), which couples principally 
through the Gαs-coupled signalling cascade but also through Gαq (Han et al., 2015). 
Activation of the Gαs pathway promotes activation of the membrane bound adenylate 
cyclase enzyme which increases intracellular cAMP generation and subsequently 
activates protein kinase A (PKA). PKA phosphorylates glycogen phosphorylase 
kinase, which subsequently phosphorylates the serine-14 residue of glycogen 
phosphorylase resulting in glycogenolysis (Jiang and Zhang, 2003). 
 
1.1.3 Insulin biosynthesis and storage 
The ability of β-cells to release insulin quickly in response to elevated blood glucose 
levels and to replenish insulin stores in preparation for the next episode of elevated 
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blood glucose means that they are highly specialised for the production and storage of 
insulin. The human insulin gene is located on the short arm of chromosome 11 and is 
comprised of 1335 base pairs (Bell et al., 1980). Transcription of the gene encodes an 
mRNA molecule of 600 nucleotides which when translated produces the 11.5kDa 
polypeptide preproinsulin. Following production, preproinsulin is released into the 
lumen of the rough endoplasmic reticulum (Halban, 1991) and cleaved by proteolytic 
enzymes to generate a 9kDa peptide, proinsulin, which is comprised of an A chain (21 
amino acids) and a B chain (30 amino acids) of insulin linked by a 31 amino acid C-
peptide (Orci et al., 1988). The purpose of the C-peptide is to contribute to the post-
translational modification of proinsulin before it is transported in microvesicles to the 
Golgi apparatus and packaged into secretory granules. Conversion of proinsulin into 
insulin occurs within the calcium-rich acidic environment of the maturing secretory 
granule (Hutton, 1982), a process which is mediated by two endopeptidases: pro-
hormone convertase 2 and 3, and carboxypeptidase H (removes C-peptide) (Davidson 
and Hutton, 1987). The newly synthesised 5.8kDa insulin peptide and the C-peptide 
are stored together in secretory granules along with divalent cations such as 
magnesium (70mM), calcium (120mM), and importantly, zinc (20mM), which is 
essential for the crystallisation and stabilisation of mature insulin protein within the 
secretory granule. 
 
1.1.4 Regulation of insulin secretion from islets of Langerhans 
The release of insulin from secretory vesicles is a multistep process that requires the 
translocation of vesicles to the plasma membrane, vesicle docking and the fusion of 
vesicles with the plasma membrane. Regulation of this process is mediated by a variety 
of mediators including nutrients, hormones, and neurotransmitters. 
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1.1.4.1 Glucose-induced insulin secretion 
Glucose is the principal physiological secretagogue for insulin secretion. Glucose-
induced insulin secretion is mediated through the uptake of glucose into the β-cells via 
insulin-independent glucose uptake transporters (GLUTs), in particular GLUT-2, 
whilst GLUT-1 and -3 in have also been implicated in glucose uptake into human β-
cells (Thorens, 2015). GLUT2 is a high capacity low affinity transporter with a Km for 
glucose of ~17mM. This high capacity and low affinity allows for a large influx of 
extracellular glucose, thus promoting a rapid equilibration of extracellular glucose 
with that present inside the cell and it is therefore fundamental in mediating insulin 
secretion from β-cells during periods of elevated blood glucose levels (Leturque et al., 
2009). During these periods, glucose is taken up into the β-cell and is phosphorylated 
to glucose-6-phosphate (G6P) by the rate-limiting intracellular enzyme glucokinase 
(Matschinsky, 1996), which is the first step in the glycolytic pathway. The end product 
of glycolysis is the generation of pyruvate which is fed into the tricarboxylic acid 
(TCA) cycle in the mitochondria, resulting in increased ATP production and 
subsequent elevations in cytosolic ATP levels. This surge in cytosolic ATP increases 
the ATP:ADP  ratio and subsequently leads to closure of ATP-sensitive K+ (KATP) 
channels following binding of ATP to the Kir6.2 subunit. Consequently, a reduction 
in intracellular K+ efflux induces depolarisation of the plasma membrane and 
activation of voltage-gated Ca2+ channels (Yang and Berggren, 2006). The resulting 
effect is an influx of extracellular calcium which in turn prompts the activation of 
calcium sensing secretory granule-associated small N-ethylmaleimide-sensitive factor 
receptor (SNARE) proteins, which promote fusion of the vesicle with the plasma 
membrane (Sudhof and Rothman, 2009). 
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Glucose-induced insulin release displays a biphasic pattern consisting of a prompt 
short-lived (0-10mins) release of insulin followed by a stable and prolonged phase of 
release (Del Prato et al., 2002). First-phase insulin release has a lower glucose 
threshold than the late-phase suggesting that alternative mechanisms exist for each 
phase (Nesher and Cerasi, 1987). The mechanisms underlying this biphasic pattern of 
insulin release are not entirely understood but it has been proposed that the β-cell 
contains two distinct pools of insulin granules: 1) a small labile pool that is primed for 
immediate release and 2) a larger pool that feeds slowly into the labile pool (Grodsky 
et al., 1969). Following exhaustion of the labile pool and subsequent ending of first 
phase release, translocation of granules from the large pool replenishes the system and 
initiates the second phase of insulin release (Nesher and Cerasi, 2002). 
Glucose-induced increases in cytosolic calcium within β-cells also promote the 
activation of additional effector molecules, such as calcium-calmodulin-dependent 
protein kinases (CaMKs), phospholipase C (PLC) and cytosolic phospholipase A2 
(cPLA2): 
Calcium/calmodulin-dependent protein kinases (CaMKs) 
Calcium/calmodulin-dependent protein kinases (CaMKs) are a class of calcium-
sensitive enzymes that are activated in the presence of intracellular Ca2+ and the Ca2+-
binding protein calmodulin (CaM). The β-cells express several kinases that are 
activated by Ca2+ and CaM, including the myosin light chain kinase (MLCK), CaMK 
II, CaMK III and CaMK IV (MacDonald and Kowluru, 1982), (Jones and Persaud, 
1998) (Hughes et al., 1993) (Persaud et al., 2011). CaMK II has been implicated in the 
modulation of Ca2+-induced insulin secretion following results indicating that a loss 
of secretory responsiveness is accompanied by a reduction in Ca2+-dependent 
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phosphorylation of endogenous islet substrates for CaMK II (Jones et al., 1992). Such 
substrates for CaMK II include MAP-2 and synapsin I, which facilitate the trafficking 
of insulin secretory granules (Easom, 1999). 
PLC/ protein kinase C (PKC) signalling pathway 
PLC is a membrane bound phospholipase that plays a key role in the PLC/PKC 
intracellular signalling pathway, which is also implicated in non-nutrient induced 
insulin secretion following Gαq-coupled GPCR activation. In brief, PLC hydrolises 
membrane-bound phosphatidyl-4,5,-biphosphate (PIP2) into two second messengers: 
inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG). The generation of IP3 
activates IP3-receptor gated calcium channels on the endoplasmic reticulum resulting 
in mobilisation of calcium from internal stores and consequently potentiating glucose-
induced insulin secretion. DAG generation results in translocation of DAG sensitive 
protein kinase C isoforms to the β-cell plasma membrane. The role of PKC in glucose-
induced insulin secretion is unclear, with reports suggesting that down regulation of 
PKC isoforms in β-cells does not affect glucose-induced insulin secretion (Persaud 
and Jones, 1993), whereas the potentiation of insulin secretion with Gαq-coupled 
receptor agonists was abolished following down regulation of PKC (Persaud et al., 
1991). This suggests that DAG-sensitive PKC isoforms are not important for glucose-
induced insulin secretion but are for non-nutrient potentiation of insulin secretion. 
 
cPLA2 
Elevations in intracellular calcium levels within β-cells can activate the calcium-
sensitive cytosolic PLA2 (cPLA2) enzyme, which hydrolyses membrane 
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phosphatidylcholine to generate arachidonic acid. By itself, arachidonic acid 
stimulates insulin secretion from dispersed rat endocrine-enriched pancreatic cells 
(Metz et al., 1983). However, metabolism of arachidonic acid via the cyclooxygenase 
and lipoxygenase pathways results in the generation of prostaglandins, thromboxanes, 
hydroxyeicosatetrenoic acids (HETES), hydroperoxyeicosatretenoic acids (HPETES), 
which have unclear effects on insulin release (Walsh and Pek, 1984) (Metz et al., 
1984). This lack of clarity on the role of arachidonic acid metabolites on islet function 
is in part due to the reliance on the usage of poorly selective COX and LOX inhibitors. 
 
While glucose is the principal stimulus for insulin release from β-cells, alternative 
mechanisms exist to potentiate and modulate this effect, for example through, GPCR-
mediated mechanisms. 
 
1.1.4.2 GPCR-mediated regulation of insulin secretion 
G-protein-coupled receptors are a diverse family of seven transmembrane bound 
proteins whose primary function is to initiate the activation of intracellular signalling 
pathways following the binding of extracellular ligands (Bohme and Beck-Sickinger, 
2009). Examples of GPCR ligands that regulate insulin secretion include intra-islet 
peptides (glucagon and somatostatin), neurotransmitters (acetylcholine and 
adrenaline), neuropeptides (VIP, PACAP and galanin), incretins (GLP-1 and GIP), 
divalent cations (Ca2+, Zn2+) and free-fatty acids. Ligand activation of GPCRs results 
in a conformational alteration in receptor structure, thus allowing the intracellular 
regions of the receptor to interact with intracellular effector molecules such as 
heterotrimeric G-proteins, consisting of α, β and γ subunits, and β-arrestins 
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(Jastrzebska, 2013) (see section 1.3 for a comprehensive review of GPCR structure 
and function). The activation of specific GPCR-coupled intracellular signalling 
pathways is dependent on the class of α-subunit that is associated with the 
heterotrimeric G-protein complex of which there are 4 main classes: Gαs, Gαq, Gαi 
and Gα12/13. GPCR-mediated effects on insulin secretion vary depending on which 
α-subunit class is associated with the receptor. 
Gαs-coupled GPCRs 
GPCRs that couple through Gαs proteins activate membrane bound adenylate cyclase 
enzymes, which convert intracellular ATP to the second messenger 3’,5’-cyclic AMP 
(cAMP). Elevations in intracellular cAMP result in the activation of protein kinase A 
(PKA) and exchange proteins activated by cAMP (EPACs), which are involved in the 
potentiation of insulin secretion by non-nutrients at stimulatory concentrations of 
glucose. Examples of GPCRs that couple through Gαs to potentiate glucose-induced 
insulin secretion include the glucagon receptor (GCGR), the glucagon-like peptide 1 
receptor (GLP-1R) and the glucose-dependent insulinotropic receptor (GPR119). 
Gαi-coupled GPCRs 
In contrast to Gαs-coupled GPCRs, GPCRs that couple to Gαi subunits inhibit 
adenylate cyclase activity, which consequently reduces intracellular cAMP levels and 
results in inhibition of insulin secretion. Examples of Gαi-coupled GPCRs include the 
five somatostatin receptors (SSTR1-5), the ghrelin receptor (GHRL), neuropeptide Y 
receptor 1 (NPYR1) and α2 adrenergic receptors (ADRA2A). 
 
 




Gαq-coupled receptors activate the PLC pathway to generate the intracellular 
signalling molecules IP3 and DAG (as described in section 1.1.4.1), resulting in the 
activation of PKC by DAG in addition to IP3-mediated mobilisation of calcium from 
internal stores within the endoplasmic reticulum. Examples of Gαq-coupled receptors 
include the kisspeptin receptor (KISS1R/GPR54) and the potential T2DM drug targets 
free fatty acid receptor 1 (FFAR1 or GPR40) and free fatty acid receptor 4 (FFAR4 or 
GPR120). 
 
1.2 Diabetes mellitus 
Diabetes mellitus (DM) is a metabolic disorder characterised by chronically elevated 
blood glucose levels (hyperglycaemia) resulting from either a complete absence or a 
relative lack of insulin (Meetoo et al., 2007). The criteria set by the World Health 
Organisation (WHO) for the diagnosis of diabetes can be defined as glycated 
haemoglobin (HbA1c) of ≥ 6.5%, fasting plasma glucose concentrations of 7.0mM, 
plasma glucose levels ≥ 11.1mM for 2 hours following oral consumption of 75g of 
glucose or random plasma glucose levels of 11.1mM (American Diabetes, 2016). The 
consequence of chronic hyperglycaemia include microvascular complications, such as 
retinopathy, nephropathy and neuropathy (Jackson et al., 2014), in addition to 
macrovascular complications, such as myocardial infarction and stroke. 
In addition to the detrimental health implications of diabetes, the economic cost 
associated with the treatment of diabetes and its comorbidities, both for healthcare 
services and loss of productivity to society, are large. In the UK alone, approximately 
9% of the NHS budget is spent on treating diabetes and its associated complications, 
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equating to approximately £10 billion per year (Meetoo et al., 2007). Furthermore, 
according to current trends, the cost of treating diabetes is increasing, which is 
evidenced by historic figures released by the American Diabetes Association (ADA) 
revealing that diabetes cost the USA $20.4 billion in 1987, $90 billion 1994 and is 
estimated to cost $100 billion today (Meetoo et al., 2007). The cost of treating diabetes 
is certain to rise further, with current projections predicting that global increases in 
diabetes diagnosis will rise beyond 592 million people by 2035 (da Rocha Fernandes 
et al., 2016). 
The principal causal factors contributing to the increase in incidence of diabetes 
worldwide include relative over-nutrition and sedentary activity, both of which are a 
result of a global transition to a more modern westernised lifestyle (Zimmet, 1999). 
This lifestyle transition promotes the development of the predominant form of 
diabetes, type 2 diabetes mellitus (T2DM), which accounts for approximately 90% of 
all diabetes cases (Kharroubi and Darwish, 2015). According to the WHO there are 
two main types of diabetes: Type 1 DM (T1DM) and Type 2 DM (T2DM) (American 
Diabetes, 2016). Whilst there are clear overlapping features of both forms of diabetes, 
in particular the complications associated with both, there are distinct characteristics 
that exist between the two types. 
1.2.1 Type 1 diabetes (T1DM) 
T1DM accounts for approximately 10% of all diabetes cases (Daneman, 2006) and 
occurs as a result of selective autoimmune-mediated destruction of islet β-cells, 
consequently resulting in complete insulin deficiency (Morgan et al., 2014). Targeted 
destruction of β-cells is initiated by pancreatic infiltration of immune cells such as 
macrophages, T cells (CD8+ CD4+) and CD20+ B cells but the exact mechanisms by 
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which β-cells are specifically targeted remain unclear (Leete et al., 2016). What is 
clear is that β-cell destruction is progressive and does not occur in a synchronised 
fashion, a claim that was made following the observation of region-specific islet 
inflammation within the pancreases of recently diagnosed T1DM patients (Foulis and 
Stewart, 1984). As a result, early indications of T1DM development tend to go 
unnoticed until the onset of clinical symptoms become apparent following the 
destruction of 60-80% of β-cells (Notkins and Lernmark, 2001). 
T1DM is a disorder that is typically developed during childhood and early adult life 
and has been shown to be associated with genetic inheritance. Approximately 40 risk 
loci are associated with T1DM (Barrett et al., 2009), with the human leukocyte antigen 
(HLA) gene complex on chromosome 6p21 exhibiting the greatest correlation with 
T1DM development. The HLA complex is responsible for encoding proteins of the 
major histocompatibility complex (MHC), which fall into two classes, MHC1 and 
MHC2. MHC1 proteins present intracellular antigens, whereas MHC2 proteins 
present cell surface antigens and it is genetic abnormalities in the encoding of MHC2 
class antigens which has been shown to correlate with the progression of T1DM. The 
inheritance of particular HLA alleles account for almost half of the genetic risk 
associated with T1DM (Todd et al., 1987). Additional susceptibility loci include 
IDDM2 and CTL4A. The IDDM2 locus is located on chromosome 11p15, contains 
the insulin gene (INS) and has been shown to contribute approximately 10% towards 
T1DM susceptibility (Bennett et al., 1995). CLTA4 (cytotoxic T-lymphocyte-
associated protein 4) is located on chromosome 2q33 and encodes a molecule that 
down regulates T-cell activation, thus highlighting the protective role of CLT4A 
against autoimmunity (Kristiansen et al., 2000). 
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To compensate for the loss of endogenous insulin secretion, insulin replacement is 
used as mainstay therapy for the treatment of T1DM (Bacha and Klinepeter Bartz, 
2015). The main goals of insulin therapy are to maintain stable blood glucose levels 
and subsequently HbA1c levels to prevent the development of associated 
microvascular and macrovascular complications (American Diabetes, 2014). 
However, due to the requirement for tight regulation of blood glucose levels 
throughout the day, a range of recombinant insulin analogues have been developed 
with varying degrees of onset of action (Sanlioglu et al., 2013) e.g. fast-acting and 
long-acting insulin analogues.   
Fast-acting insulin analogues have been designed to be rapidly absorbed following 
subcutaneous injection (10-15 mins), achieve peak levels within 30-90 mins and have 
a duration of action of 4-6 hours (Sanlioglu et al., 2013). The overall result is a reduced 
delay of onset of action which allows for a flexible dosing schedule compared to that 
of regular insulin, which requires a longer waiting period prior to meal consumption 
(Sanlioglu et al., 2013). However, hypoglycaemia may be experienced with fast-acting 
insulin analogues if meals are not consumed within approximately 15mins of 
administration (Burge et al., 1997). Examples include, insulin-lispro (Humalog) 
(Zinman et al., 1997), insulin-aspart (Novolog) (Rys et al., 2011) and insulin-glulisine 
(Apidra) (Lih et al., 2010), which are developed by Eli Lilly, Novo Nordisk and 
Sanofi-Aventis respectively. 
Long-acting insulin analogues are designed to provide basal concentrations of insulin 
to control fasting hyperglycaemia and pre-prandial blood glucose levels throughout 
the day (Sanlioglu et al., 2013). The long duration of action is a consequence of 
formulation design whereby insulin is presented in the form of hexamers which slowly 
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dissociate to monomers, unlike fast-acting insulin which is presented as a monomeric 
formulation. Examples include insulin-glargine (Lantus) (Gillies et al., 2000), insulin-
detemir (Levemir) (Hermansen et al., 2006) and insulin-degludec (Tresiba) (Zinman 
et al., 2011) developed by Sanof-Aventis and Novo Nordisk respectively. For almost 
all T2DM patients starting insulin therapy, long-acting insulin is used alone or in 
combination with additional anti-diabetic therapies (Sanlioglu et al., 2013), the details 
of which are described in the following section. 
 
1.2.2 Type 2 diabetes 
T2DM is a non-communicable metabolic disorder that accounts for approximately 
90% of all diabetes cases. It is characterised by hyperglycaemia, which is a 
consequence of insufficient insulin secretion, insulin resistance in metabolically active 
tissues and inadequate suppression of glucagon production (Spellman, 2010). Reduced 
insulin secretion results in a reduction in the uptake of circulating blood glucose into 
metabolically active tissues, which is further exacerbated by insulin resistance, both 
of which collectively contribute to a hyperglycaemic state. The extent of glucose 
uptake reduction in T2DM was revealed by Groop et al who observed that glucose 
uptake in T2DM patients was reduced by 30% when compared to control patients 
(Groop et al., 1989). Furthermore, in the same study hepatic glucose production was 
shown to be significantly greater in T2DM patients compared to control subjects, 
highlighting the effects of inadequate suppression of glucagon production associated 
with T2DM (Groop et al., 1989). 
It has been well documented that an association between obesity and T2DM exists. 
Obesity is a state of low grade inflammation and is a key risk factor in the development 
Chapter 1 Introduction 
31 
 
of T2DM due to its association with insulin resistance and β-cell dysfunction (Boutens 
and Stienstra, 2016). Initially, the β-cells compensate for insulin resistance by 
upregulating insulin secretion and the extent of this upregulation determines whether 
or not the individual develops T2DM (Bergman, 2005). Eventually, however, the β-
cells are unable to meet the demand for insulin production to offset hyperglycaemia.  
In addition to promoting insulin resistance, the state of low grade inflammation 
associated with obesity promotes macrophage infiltration and subsequent release of 
inflammatory cytokines, which promote islet inflammation and β-cell apoptosis 
(Stienstra et al., 2007). This contributes to a reduction in β-cell mass that is associated 
with T2DM but the extent to which β-cell mass is reduced and its role in the etiology 
of T2DM is not fully understood (Ashcroft and Rorsman, 2012). Butler et al reported 
a 60% reduction β-cell mass in patients with T2DM (Butler et al., 2003), whereas a 
lower estimation of 39% has also been reported (Rahier et al., 2008). However, Menge 
et al revealed that glucose tolerance was only slightly affected following a partial 
pancreatectomy in human patients (Menge et al., 2008), suggesting that β-cell mass 
alone is not the principal factor involved in the development of T2DM. 
Genetic factors have also been implicated with T2DM incidence. One of the most 
important diabetes susceptibility genes is TCF7L2 (transcription factor-7-like-2) 
located on chromosome 10q, which increases diabetes risk by 45% (Rutter, 2014). 
TCF7L2 has been shown to be involved in Wnt signalling and it influences insulin 
secretion but it is unclear whether it is up- or downregulated in T2DM (Lyssenko et 
al., 2007). In addition, a polymorphism in SLC30A8, a highly expressed β-cell gene 
which codes for the ZnT8 zinc transporter, has been shown to increase T2DM 
susceptibility by 20% (Sladek et al., 2007). Variants of the KCNJ11 and ABCC8 
genes, which encode the Kir6.2 and SUR1 subunits of the ATP-sensitive K+ channel, 
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have been implicated in the development of neonatal diabetes (Bennett et al., 2010, 
Nessa et al., 2016). 
The primary aim of T2DM therapies is to maintain glucose homeostasis for as long as 
possible following diagnosis, thereby reducing the onset of associated complications 
(Kahn et al., 2014). There are numerous therapies with varying mechanisms of action 
that aim to reduce hyperglycaemia associated with T2DM, which are described below. 
Biguanides 
The first line therapy in treating T2DM is Metformin (Glucophage), which belongs to 
the biguanide class of compounds. The most prevalent effect of Metformin is a 
decrease in hepatic glucose production, whilst increased glucose uptake through 
increased GLUT4 expression and an inhibition of adipocyte lipolysis are the 
secondary effects of Metformin treatment (Bosi, 2009). The mechanism of action of 
Metformin centres on the activation of hepatic AMP-activated protein kinase resulting 
in the inhibition of acetly-coenzyme A carboxylase activity, which leads to reduced 
fatty acid synthesis, thus relieving the suppression of insulin receptor signalling and 
subsequent inhibition of hepatic gluconeogenesis (Fullerton et al., 2013). It has 
therefore essentially been classed as an insulin sensitiser. 
Sulphonylureas (SURs) and Glinides 
SURs and glinides promote insulin secretion by binding to the SUR1 receptor of β-
cells. This leads to closure of ATP-sensitive K+ channels (KATP) and the subsequent 
membrane depolarisation leads to opening of voltage-dependent calcium channels, 
Ca2+ influx and the subsequent triggering of insulin granule exocytosis (Seino et al., 
2012). Glinides typically have a quicker onset of action and a shorter half-life than 
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sulphonylureas and are taken more frequently to reduce postprandial surge in blood 
glucose concentration. The mechanism by which sulphonylureas and glinides act is 
not glucose-dependent, unlike some other therapies, and thus their use can lead to 
undesired hypoglycaemic events (Kelly et al., 2009). Furthermore, weight gain and 
increased risk of coronary heart disease have also been associated with sulphonylurea 
use (Seino et al., 2012). 
Thiazolidinediones (Glitazones) 
The thiazolidinedione (TZD) class of drugs, for example pioglitazone, function by 
activating the nuclear transcription factor peroxisome proliferator-activated receptor-
γ (PPARγ) to stimulate the transcription of anabolic genes such as GLUT4, fatty acid 
transporter and lipoprotein lipase (Dubois et al., 2002). The resulting effect is 
enhanced glucose and fatty acid uptake and reduced insulin resistance in adipose 
tissue, muscle and the liver (Hauner, 2002). However, adverse events such as weight 
gain (through adipocyte expansion), heart failure, bone fractures and bladder cancer 
have been associated with TZD use (Takada and Makishima, 2015). 
Sodium-glucose co-transporter-2 inhibitors (SGLT2) 
SGLT2 inhibitors function by inhibiting the SGLT2 transporter, which is involved in 
the reabsorption of glucose from the urine back into the circulation (Wright et al., 
2011). The resulting effect is lowering of the renal threshold for glucose excretion and 
subsequently increased excretion of glucose through the urine. This therapeutic 
approach reduces plasma glucose, body weight and blood pressure, but has been 
shown to increase the incidence of urinary tract infections by 40% (Vasilakou et al., 
2013) and promote unexplained increases in circulating LDL and HDL cholesterol 
(Lamos et al., 2013). 




The membrane bound intestinal alpha-glucosidase hydrolase enzymes are responsible 
for the hydrolysis of polysaccharides into monosaccharides, such as glucose, within 
the brush border of the small intestine (Tran et al., 2015). Inhibitors of α-glucosidase 
prevent this process thus delaying polysaccharide digestion and uptake of glucose 
from the lumen of the small intestine. The resulting effect is a reduction in postprandial 
glucose elevation (Kato and Node, 2014). Dose-dependent adverse events are 
predominantly gastrointestinal associated and include, flatulence, diarrhoea and 
abdominal discomfort (Van de Laar et al., 2005). 
GLP-1 mimetics 
GLP-1 mimetics, such as Exenatide and Liraglutide, are analogues of GLP-1, which 
is an incretin peptide secreted by intestinal L-cells following food intake (Holst, 1994). 
GLP-1 stimulates insulin secretion via activation of the β-cell GLP-1 receptors (GLP-
1R), which activates adenylate cyclase to promote increases in intracellular cAMP 
(Ma et al., 2014). GLP-1 has also been shown to preserve β-cell mass by stimulating 
β-cell proliferation, and it acts centrally to reduce appetite and promote weight loss 
(Buteau, 2008). Unlike sulphonylureas and glinides, which reduce blood glucose 
levels irrespective of circulating glucose levels, GLP-1 receptor agonists potentiate 
glucose-induced insulin secretion, thus reducing the possibility of hypoglycaemic 
events. However, like most therapies, adverse events exist such as nausea, vomiting 
(Prasad-Reddy and Isaacs, 2015) and pancreatitis has been involved in some 
individuals due to acinar cell inflammation (Filippatos et al., 2014). In addition, the 
method of administration requires daily injections which may result in injection site 
reactions (Prasad-Reddy and Isaacs, 2015). The identification of orally available 
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GLP1R agonists with reduced adverse events would be highly attractive and 
marketable. 
Dipeptidyl Peptidase 4 (DPP4) inhibitors 
DPP4 is a membrane bound exopeptidase glycoprotein, which is ubiquitously 
expressed on a variety of cells and is responsible for the N-terminal cleavage of a 
variety of peptides including growth factors, neuropeptides, cytokines and incretins 
(Rohrborn et al., 2015). Inhibitors of DPP4 induce 2- to 3-fold increases in endogenous 
levels of the incretin hormones, GLP-1 and GIP (Tran et al., 2015), which are involved 
in promoting postprandial release of insulin. Furthermore, DDP4 inhibitors have been 
shown to promote β-cell mass expansion and improve pancreatic insulin content (van 
Genugten et al., 2012). However, the effects of DPP4 are relatively modest and 
associations with acute pancreatitis with Sitagliptin and kidney dysfunction with 
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1.3 G-protein-coupled receptors 
1.3.1 Classification 
G-protein-coupled receptors (GPCRs) are a diverse super family of seven 
transmembrane bound proteins whose primary function is to initiate the activation of 
intracellular signalling pathways following stimulation by extracellular stimuli, which 
include photons, amines, lipids, ions, peptides and proteins (Bohme and Beck-
Sickinger, 2009). Due to the ubiquitous expression of GPCRs throughout the body, 
they have been implicated in the regulation of a variety of diverse physiological 
processes. 
In order for a protein to be classified as a GPCR it has to satisfy two main 
requirements. Firstly, the protein must contain seven stretches of amino acid sequence 
of approximately 25 to 35 consecutive residues that show a relatively high degree of 
hydrophobicity. These sequences represent the seven α-helices that form the 
transmembrane regions of the receptor. The second essential requirement is the ability 
to interact with a G-protein (Fredriksson et al., 2003). Details on GPCR structure are 
discussed in detail in section 1.3.2. 
GPCRs can be partitioned into two groups: odorant/sensory and non-odorant. The 
odorant receptors are typically localised to specific cell types and are responsible for 
detecting external stimuli such as odours, tastes and pheromones and regulate 
behaviours such as feeding and mating (Regard et al., 2008). Non-odorant GPCRs on 
the other hand are ubiquitously expressed in a variety of different tissues and interact 
with a diverse array of endogenous ligands that regulate numerous physiological 
processes (Regard et al., 2008). According to Bjarnadottir et al, the number of genes 
which encode for GPCRs in both the human and mouse genome totals 791 and 1697 
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respectively. Of the 791 GPCRs in the human genome, 400 are functional non-odorant 
GPCRs and the remaining 391 account for odorant GPCRs. As for the mouse, 495 of 
the 1697 genes are functional non-odorant GPCRs and the remaining odorant GPCRs 
(Bjarnadottir et al., 2006). Due to the large number of GPCRs in the genome and the 
multitude of physiological processes that GPCRs regulate, classification systems have 
been developed over the years to further understand relationships between structure, 
function, ligand preference and expression patterns. 
Attempts to classify GPCRs into groups have been based on various criteria, such as 
how a ligand binds to its receptor and structural features. The classical model of GPCR 
classification, the GPCRdb (G-protein-coupled receptor database), was developed by 
Kolakowski in 1994, which separates GPCRs into clans labelled A, B, C, D, E and F 
and then further into subclans using Roman numeral nomenclature (Kolakowski, 
1994). This system was developed to cover all vertebrate and invertebrate GPCRomes. 
However, the clans D and E, fungal pheromone and cAMP receptors respectively, are 
not relevant to the mammalian GPCRome in addition to clan A family IV which 
contains archaebacterial opsin receptors (Schioth and Fredriksson, 2005). 
Consequently, a classification system more relevant to the mammalian situation was 
developed by Fredriksson et al in 2002. This newer classification system was 
generated by analysing a large set of GPCR sequences in the human genome, 
performing sequence alignment to identify similarities and novel hits using BLAST, 
and grouping the different GPCR sequences using phylogenetic analysis. This 
approach resulted in the generation of the GRAFS mammalian classification system 
consisting of five main groups: Glutamate, Rhodopsin, Adhesion, Frizzled/Taste and 
Secretin. By using this method, a total of 802 GPCRs were identified in the human 
genome, accounting for approximately 2% of all human genes (Schioth and 
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Fredriksson, 2005). According to the GRAFS classification system, human GPCRs 
are categorised into the following families: Glutamate = 15 (2%); Rhodopsin = 701 
(87%); Adhesion = 24 (3%); Frizzled/Taste = 24 (3%); Secretin = 15 (2%); Other = 
23 (3%) (Fredriksson et al., 2003). 
 
1.3.2 Structure and function 
As previously mentioned, GPCRs are transmembrane bound proteins which initiate 
the activation of intracellular signalling pathways following activation by extracellular 
stimuli (Hur and Kim, 2002). Each GPCR contains an extracellular N-terminus, a 
cytoplasmic C-terminus and seven transmembrane forming hydrophobic α-helices 
connected by three inter-helical loops in each side of the membrane (See Figure 1.3.1) 
(Horn et al., 1998). 
 
Figure 1.3.1 GPCR structure (adapted from (Wettschureck and Offermanns, 2005). 
The diagram depicts the seven transmembrane spanning domains (purple), the 
extracellular N-terminus and the intracellular C-terminus. 
 
The N-terminus and extracellular loops are responsible for recognising extracellular 
ligands and modulating ligand access. The seven transmembrane region is responsible 
for ligand binding and transducing the extracellular signals by altering changes in 
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receptor conformation (Tuteja, 2009). Following a conformational alteration in 
receptor structure, the intracellular regions are then able to interact with intracellular 
effector molecules such as G-proteins, β-arrestins, G-protein receptor kinases (GRKs) 
and other downstream signalling molecules (Zhang et al., 2015). 
The ability of a receptor to bind to a G-protein is one of the requirements for a receptor 
to be classed as a GPCR (Fredriksson et al., 2003). G-proteins are intracellular 
heterotrimeric proteins composed of α, β and γ subunits with a nucleotide binding 
pocket located on the α-subunit (Jastrzebska, 2013). In the absence of a suitable 
agonist the GPCR remains in the inactive/resting state (R), with the G-protein complex 
bound to GDP. Upon binding of an agonist to the receptor, the receptor undergoes a 
conformational change, in particular transmembrane helices III and VI (Lohse et al., 
2014), which results in the rapid exchange of GDP with GTP for the nucleotide 
binding site on the α-subunit. This exchange forces the receptor into the active or R* 
state. Binding of GTP results in the destabilisation of the heterotrimeric complex and 
the dissociation of the Gα from the βγ subunit (Jastrzebska, 2013). This dissociation 
allows the Gα-subunit to interact with various effector molecules to initiate 
downstream signalling events depending on the specific Gα-subunit involved (See 
Figure 1.3.2). Following effector and subsequent pathway activation, GTP is 
converted back to GDP by the intrinsic GTPase activity of the α-subunit, which in turn 
results in the reassembly of the heterotrimeric G-protein complex and the return of the 
GPCR back to the inactive/resting state (R) (Tuteja, 2009). 




Figure 1.3.2 G-protein interaction following GPCR activation (Wettschureck and 
Offermanns, 2005). Schematic diagram illustrating the GPCR activation cycle. Ag = 
agonist, RGS = Regulator of G-protein signalling. 
 
The determining factor in which pathway and subsequent effector molecules are 
activated following receptor activation depends on the class of Gα-subunit that is 
associated with the receptor. In humans there are 21 Gα subunits encoded by 16 genes, 
6 Gβ subunits (35kDa) and 12 Gγ subunits (8-10kDa) (Moreira, 2014). Heterotrimeric 
G-proteins are typically grouped into four main classes: Gαs (includes Gαs and Gαolf); 
Gαi (includes Gαt, Gαi1, Gαi2, Gαi3, Gαo1, Gαo2 and Gαζ); Gαq/11 (includes Gαq, 
Gα11, Gα14, Gα15 and Gα16); Gα12 (includes Gα12 and Gα13) (Moreira, 2014). 
GPCRs that couple through Gαs activate the membrane bound adenlyate cyclase 
enzyme which converts intracellular ATP to the second messenger 3’,5’-cyclic AMP. 
Conversely, Gαi coupled receptors inhibit adenylate cyclase activity thus reducing the 
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generation of intracellular cAMP from ATP. Gαq coupled receptors activate 
phospholipase C which hydrolyses PIP2 to generate diacyclglycerol and inositol 1,4,5 
triphosphate, resulting in the mobilisation of calcium from intracellular stores within 
the endoplasmic reticulum. Finally, Gα12/13 coupled receptors activate the Rho 
GTPase which is involved in regulating actin cytoskeletal remodelling (Amisten et al., 
2013).  
In addition to Gα-subunit-mediated activation of particular signalling cascades, 
GPCRs also have the ability to modify intracellular signalling through Gα-subunit-
independent mechanisms such as via the βγ-subunit and β-arrestin. Studies have 
shown that the βγ-subunit of G-protein complexes has the ability to inhibit calcium 
channels, in particular the binding of the βγ-subunit to the α1 subunit of Cav2 channels 
(Currie, 2010), and also activate inward rectifying K+ channels (Dascal, 2001). 
Arrestins are cytosolic proteins that are typically involved in switching off GPCR 
activity following ligand binding (Drake et al., 2006). This process involves two steps, 
the first step being the phosphorylation of a ligand activated receptor by GRKs or 
second messenger protein kinases. This is then followed by the recruitment of the β-
arrestin to the receptor, which results in steric hindrance of further receptor activation 
and the subsequent initiation of receptor internalisation (Rankovic et al., 2016). In 
addition to their ability to switch off signalling pathways, arrestins have also been 
shown to activate signalling effectors such as the mitogen-activated protein kinases 
ERK1/2, JNK and p38 as well as Akt (DeWire et al., 2007). 
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1.3.3 GPCRs as drug targets 
GPCRs are expressed in various tissue types and are involved in the regulation of 
many biological processes by controlling a multitude of intracellular signalling 
cascades. This heterogenous nature of GPCRs has made them an attractive target for 
therapeutic agents (Garland, 2013). An analysis of the DrugBank database in 2013 
revealed that of the 1448 small molecules, 131 biologics and 84 nutraceuticals on the 
market, 437 (26%) act through GPCRs (Garland, 2013). They also represent the largest 
number of target class that has achieved market approval since 1982, approximately 
17% of all approvals. Furthermore, 6 of the 20 drugs with the highest global sales in 
2010 targeted GPCRs (Rask-Andersen et al., 2011). 
The success of exploiting the vast potential of GPCRs in the treatment of diseases is 
dependent on the availability of research tools required to evaluate their suitability as 
drugable targets. The development of gene expression technologies, such as RNA 
sequencing, RNA microarray and qPCR, have contributed to the understanding of 
GPCR expression within specific tissues. Furthermore, tissue expression analysis has 
allowed for the identification of GPCR targets for therapeutic exploitation in disease 
states, the assessment of target suitability with regards to off target tissue expression, 
whilst also contributing to the deorphanisation of orphan GPCRs based on co-
expression analysis of both ligand and receptor e.g. the identification of the RDC7 and 
RDC8 receptors as the adenosine A1 (ADORA1) and A2A (ADORA2A) receptors 
(Tang et al., 2012). GPCR structural data from X-ray crystallography and STAR 
technology (Robertson et al., 2011) have promoted the understanding of ligand 
receptor interactions and when used in combination with in-silico computational 
modelling can be employed to predict potential drug candidate molecules with suitable 
drug-like moieties from an array of commercially available compound or biologic 
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libraries (Garland, 2013). Moreover, an array of in vitro assay technologies are 
available for the functional assessment of drug candidates such as, calcium, cAMP, β-
arrestin, GTPγS and impedance-based assays. Further assessment of ligand function 
in vivo can be performed using transgenic animal models following receptor knock 
down or overexpression. The utilisation of such technologies can be used to accelerate 
target identification, target validation, ligand hit finding, lead optimisation and ligand 
functional assessment from the early stages of exploratory research through to 
translational development, thus making GPCRs an attractive tractable target class for 
therapeutic exploitation. 
 
1.3.4 GPCRs as drug targets for Type 2 diabetes mellitus 
One therapeutic approach for treating T2DM centres on promoting insulin secretion 
in order to compensate for β-cell dysfunction, which is characterised by a decrease in 
insulin secretion in response to glucose and reduced β-cell mass (Oh da and Olefsky, 
2016). However, the ability of a therapeutic target to promote insulin secretion needs 
to be taken with caution as unnecessary increases in insulin secretion can result in 
unwanted hypoglycaemia. This type of scenario is dependent on the mechanisms 
associated with function and therefore, exploiting targets whose associated 
mechanisms selectively potentiate glucose-induced insulin secretion are more 
attractive than those that do not e.g. sulphonylureas or insulin therapies (International 
Hypoglycaemia Study, 2015). One such target class that has been shown to selectively 
potentiate glucose-induced insulin secretion are GPCRs, in particular GPCRs that 
couple through the Gαs and Gαq signalling pathways (see section 1.1.4.2). The 
increase in intracellular cAMP levels through Gαs activation alone is not enough to 
promote insulin secretion, as cAMP is a poor beta cell secretagogue, but potentiation 
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of glucose-induced insulin secretion is observed if cytoplasmic calcium is elevated 
downstream of the glucose-dependent pathway (Tengholm, 2012). Additionally, 
glucose-dependent stimulation of insulin release is also associated with Gq-coupled 
GPCRs, which promote PKC activation and release of calcium from intracellular 
stores. 
While promoting insulin secretion, as described above, is the main cornerstone of 
T2DM therapies, the additional issue of declining β-cell mass with progressive disease 
state, which in turn exacerbates insulin secretory dysfunction, is also important.  This 
can be overcome therapeutically by either enhancing β-cell proliferation, preventing 
β-cell apoptosis and/or stimulating β-cell neogenesis. The potential involvement of 
GPCRs in promoting β-cell mass is exemplified by the role of the GLP-1 receptor. 
GLP-1 receptor activation promotes β-cell proliferation by activating PI3K and its 
subsequent downstream effectors Akt, PKCζ and p38 MAPK (Buteau et al., 1999), 
and it also reduces apoptosis in vitro by preventing peroxide-mediated oxidative stress 
in a cAMP- and P13K-dependent manner. Additionally, GLP-1 receptor signalling has 
been shown to reduce ER stress (i.e. overproduction of misfolded proteins that 
contribute to reduced β-cell survival) through the activation of PKA and translation of 
AFT4 (Tsunekawa et al., 2007). 
However, despite the aim of promoting insulin secretion and maintaining β-cell mass, 
the association of obesity with T2DM means that there is also an increasing need to 
target body weight to reduce insulin resistance. This had led to an additional focus on 
targets that regulate appetite, energy homeostasis and prevent chronic tissue 
inflammation (Reimann and Gribble, 2016). Whilst this thesis focusses on GPCRs 
expressed on islets, which are more likely to be targets for regulating islet hormone 
secretion and β-cell mass, it is also important to acknowledge the role of GPCRs 
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expressed in alternative tissues to get a holistic view of targeting GPCRs in T2DM. 
The GPCR targets discussed below cover all aspects of T2DM pathology from insulin 
secretion, β-cell mass, insulin resistance and appetite regulation. 
Glucagon-like peptide 1 receptor (GLP1R) 
The GLP-1 receptor is the most well established β-cell GPCR target whose 
mechanisms and subsequent role as a T2DM target have been extensively explored. 
In brief, the GLP-1 receptor exerts anti-diabetic effects through four mechanisms: 1) 
potentiating glucose-induced insulin secretion through the activation of the Gαs 
signalling pathway, 2) promoting β-cell proliferation and preventing apoptosis 
(Buteau et al., 2003), 3) inhibiting glucagon secretion (Holst, 2007) and 4) promoting 
weight loss (Baynes, 2010). As a result of the numerous highly beneficial effects of 
targeting the GLP-1 receptor for T2DM, a variety of GLP-1 receptor agonists have 
been developed and approved for clinical use such as Exenatide, Liraglutide, 
Lixisenatide, Albiglutide and Dulaglutide (Oh da and Olefsky, 2016). 
Free fatty acid receptor 1 (FFAR1 or GPR40) 
FFAR1 is a Gαq-coupled GPCR that is expressed on β-cells and enteroendocrine cells. 
Its activation potentiates second-phase insulin secretion (Crespin et al., 1973) and it 
has also been implicated in promoting GLP-1 secretion (Edfalk et al., 2008). Thus, 
activation of FFAR1 can promote insulin secretion either directly through activation 
on β-cells or indirectly through increased GLP-1 release from enteroendocrine cells. 
Despite clinical interest in this target, a successful drug candidate has yet to be 
discovered and only a few potential candidates are currently in clinical trials: TAK-
875 (Takeda) discontinued at Phase III, AMG-837 (Amgen) discontinued at Phase I, 
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LY2881835 (Eli Lilly) discontinued at Phase I, JTT-851 (Japan tobacco) currently in 
Phase II, P11187 (Piramal) currently in Phase I (Oh da and Olefsky, 2016). 
Glucose-dependent insulinotropic receptor (GPR119) 
Like FFAR1, GPR119 is expressed on both β-cells and gastrointestinal 
enteroendocrine cells and it potentiates glucose-induced insulin secretion through 
Gαs-coupled signalling. It also promotes release of GLP-1 and GIP (Chu et al., 2008) 
in rodent animal models. In contrast to FFAR1, no GPR119 agonists have progressed 
to later stage clinical trials, the reason of which is attributed to a lack of efficacy in 
humans (Katz et al., 2012). This apparent species difference highlights the importance 
of using appropriate translational models in early stage research in order to predict 
human outcome, an area which is addressed within this thesis. 
Free fatty acid receptor 4 (FFAR4 or GPR120) 
FFAR4 is expressed on mouse δ-cells (Stone et al., 2014) and mouse gut endocrine 
cells (Iwasaki et al., 2015) but not on mouse β-cells. The principal transduction 
pathway associated with FFAR4 receptor activation is Gαq, which is the pathway 
responsible for promoting GLP-1 secretion from L-cells, but it has also been shown to 
couple through Gαi to inhibit ghrelin and somatostatin release (Reimann and Gribble, 
2016). Interestingly, FFAR4 has been suggested to mediate the anti-inflammatory and 
insulin-sensitising effects of ω3-FAs, such as DHA and EPA, the effects of which 
were not observed in Ffar4-KO mice (Oh et al., 2010). However, an area of concern 
is the differential expression of splice variants between species, where humans express 
both FFAR4L (long) and FFAR4S (short) whereas other species only express 
FFAR4S. Stimulation of FFAR4L leads to β-arrestin pathway activation but does not 
lead to G-protein-dependent calcium signalling whereas FFAR4S does (Watson et al., 
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2012). This discrepancy could lead to complications when assessing function in 
translation models, which could be an explanation for the absence of clinical projects 
involving FFAR4 receptor agonists. 
 
Despite the appeal of exploiting GPCRs as therapeutic targets for T2DM, the clinical 
assessment of therapeutic agents that target GPCRs for T2DM has been limited to the 
receptors highlighted above. Furthermore, clinical success is restricted to the GLP-1 
receptor. Such findings are surprising considering that human islets express 293 
GPCRs (Amisten et al., 2013). However, despite this large pool of potentially novel 
targets, the role of most GPCRs in islet function is poorly characterised. A contributing 
factor which may impede the understanding of GPCR-mediated regulation of islet 
function is the availability of human tissue required for functional assessment. As a 
consequence, surrogate tissue, in particular mouse islet tissue, is required to predict 
the human setting. However, as mentioned previously (section 1.1.1), differences in 
islet architecture in addition to gene expression (Dai et al., 2012) have been reported, 
thus questioning the suitability of using mouse islets in predicting human islet 
function. To date, the quantitative assessment of GPCR expression differences 
between human and mouse islets has not been performed. Such comparisons would 
provide further insight into the suitability of using mouse islets as surrogate tissue for 
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1.4 Islet-expressed GPCR peptide ligands 
Previous studies have revealed that approximately 30% of all GPCRs expressed on 
human islets are activated by peptide ligands and that approximately 50% of all 
peptide ligands are expressed within islets (Amisten et al., 2013). Such islet GPCR 
peptide ligands include the ‘classic’ examples of glucagon and somatostatin, but 
additional peptides such as peptide YY (PYY) (Persaud and Bewick, 2014), kisspeptin 
(KISS1) (Hauge-Evans et al., 2006), urocortin3 (UCN3) (van der Meulen et al., 2015) 
and ghrelin (GHRL) (Dezaki and Yada, 2012) are also expressed within islets and 
exhibit roles in islet function. Identifying GPCR peptide ligands that play a role in 
regulating islet function can provide insight into therapeutic opportunities for the 
treatment of T2DM, an example of which is the development of GLP-1 mimetics. The 
roles and mechanisms of action of ‘classic’ and ‘non-classic’ intraislet expressed 
GPCR peptide ligands are described below. 
Glucagon (GCG) 
Glucagon (GCG) is a 29 amino acid peptide that is secreted from islet α-cells and is 
responsible for opposing the actions of insulin by stimulating hepatic glucose 
synthesis and glucose mobilisation (Quesada et al., 2008). Glucagon is a derivative of 
proglucagon, a 160 amino acid precursor polypeptide encoded by the GCG gene, 
which is converted to glucagon by neuroendocrine convertase 2 expressed in α-cells. 
In contrast, neuroendocrine convertase enzyme 1, within enteroendocrine cells, is 
responsible for the conversion of proglucagon into glicentin, oxyntomodulin, GLP-1 
and GLP-2 (Campbell and Drucker, 2015). Glucagon functions through the Gαs-
coupled glucagon receptor (GCGR), which when activated promotes the activation of 
membrane bound adenylate cyclases and subsequent intracellular cAMP generation. 
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The glucagon receptor is expressed on liver, brain, heart, kidney, adipose and 
gastrointestinal cells in addition to the β-cells, where its activation promotes insulin 
secretion (Kawai et al., 1995). 
Somatostatin (SST) 
Somatostatin (SST) is a peptide hormone that is expressed within the hypothalamus, 
gastrointestinal tract and also by the δ-cells of the endocrine pancreas. Two active 
forms with lengths of 14 and 28 amino acids exist (SST-14 and SST-28 respectively), 
both of which exert their function through G-protein-coupled receptors, of which there 
are five isoforms (SSTR1-5) (Kailey et al., 2012). All five somatostatin receptors 
couple via Gαi proteins which when activated inhibit membrane bound adenylate 
cyclases, thus contributing to the general inhibitory actions of somatostatin. SST-14 is 
the predominant form expressed by the δ-cells within islets, and it is released in 
response to glucose and amino acids (Ipp et al., 1977). Following its release, SST-14 
potently inhibits glucagon and insulin release from α- and β-cells respectively in both 
humans and rodents, but conflictions regarding which receptor subtypes are involved 
in somatostatin function exist. Exploring which receptors facilitate SST regulation of 
islet function is complicated further by reported differences in receptor involvement 
between human and rodent species. In the mouse, the effects of somatostatin on α- and 
β-cells are predominantly mediated by SSTR2 and SSTR5 respectively (Strowski et 
al., 2000), whereas in humans islets conflicting evidence surrounding the involvement 
of SSTR2 and SSTR5 on β-cell function has been reported (Brunicardi et al., 2003) 
(Zambre et al., 1999). 
 
 




Ghrelin (GHRL) has been implicated in a variety of physiological processes ranging 
from the promotion of growth-hormone release, appetite regulation and adiposity 
(Dezaki and Yada, 2012). GHRL cells of the stomach are primarily responsible for the 
production of circulating levels of ghrelin (Ariyasu et al., 2001) but expression of 
GHRL and its receptor, growth-hormone secretagogue receptor (GHSR), has also been 
reported in islets, in particular the α-cells (Date et al., 2002) and β-cells (Volante et 
al., 2002). Activation of the ghrelin receptor by ghrelin inhibits glucose-induced 
insulin secretion through the attenuation of intracellular cAMP production and PKA 
activation in β-cells, and subsequently it has been postulated that the ghrelin-GHSR 
system could be targeted for the treatment of T2DM (Dezaki and Yada, 2012). 
Urocortin3 (UCN3) 
Urocortin3 (UCN3) is a peptide hormone that is abundantly expressed within β-cells 
of both mouse and human islets, but its expression has also been observed within α-
cells of human islets (Li et al., 2003). Interestingly, UCN3 expression is down 
regulated in β-cells of diabetic mouse models and in human diabetic islets (van der 
Meulen et al., 2015), suggesting it may play a role in the pathophysiology of T2DM. 
UCN3 promotes both insulin and glucagon secretion, yet increased plasma glucose 
and increased glucose tolerance observed in these studies contradict the insulinotropic 
actions of UCN3 (Li et al., 2003) (Li et al., 2007), thus suggesting additional function. 
It has recently been reported that UCN3 is co-released with insulin and potentiates 
glucose-stimulated somatostatin secretion via its cognate receptor, the CRF2 receptor 
(CRHR2), on δ-cells (van der Meulen et al., 2015). These observations suggest that 
the paracrine actions of UCN3 activates a negative feedback loop that promotes 
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somatostatin release to reduce further insulin secretion once plasma glucose levels 
have normalised. 
Peptide YY (PYY) 
The gut hormone PYY is expressed in mouse islets, in particular in α- and PP cells 
(Bottcher et al., 1989), and it has received interest due to its modulation of fuel 
homeostasis through its central effects on appetite regulation. It also plays a role in 
islet physiology by modulating β-cell mass, a key feature in the pathophysiology of 
T2DM, by exhibiting pro-proliferative and anti-apoptotic effects on mouse β-cells 
through the activation of Y1 (NPY1R) receptors (Persaud and Bewick, 2014). 
However, intravenous administration of PYY in mice has been shown to inhibit insulin 
release in mice (Bottcher et al., 1989), whilst PYY knockout mice are 
hyperinsulinaemic (Boey et al., 2006), suggesting that while PYY based therapies 
could treat T2DM, the reduction in insulin secretion may well counteract the beneficial 
effects of enhanced β-cell mass. Further studies are required to explore whether such 
observations are translatable to the human setting and to fully understand the 
involvement of other Y-receptors in PYY-mediated islet function. 
Kisspeptin (KISS1) 
The kisspeptin peptides (KISS1) are a family of peptides encoded by the KISS1 gene 
that function through GPR54 (Muir et al., 2001) and are typically involved in 
controlling the onset of puberty (Messager et al., 2005). Both the KISS1 and GPR54 
genes are expressed within the pancreas and further studies have revealed the 
expression of both genes within both mouse and human islets, in particular the α- and 
β-cells (Hauge-Evans et al., 2006). Conflicting results exist regarding the role of 
kisspeptins in islet function, with reports suggesting an inhibitory effect on insulin 
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secretion from mouse islets below 11.1mM glucose (Vikman and Ahren, 2009), 
whereas a reversible potentiation of glucose-stimulated (20mM) insulin secretion from 
pig, mouse and human islets has also been reported (Bowe et al., 2012), which is 
thought to be mediated by elevations in intracellular calcium (Bowe et al., 2009). 
Chemokine (CXC-motif) ligand 14 (CXCL14) 
CXCL14, also termed breast and kidney-expressed chemokine (BRAK), is an orphan 
chemokine ligand that belongs to the CXC-class chemokine family. Abundant 
expression of CXCL14 mRNA is observed in the lungs, kidneys, brain, skin, small 
intestine and taste buds (Hara and Tanegashima, 2012), while co-localisation with 
somatostatin in the δ-cells of mouse islets has also recently been demonstrated (Suzuki 
and Yamamoto, 2015). 
Due to its ubiquitous expression, CXCL14 has been implicated in the involvement of 
numerous biological processes, including immune cell trafficking, tumour 
suppression, tumour proliferation, anti-microbial defence and feeding behaviour (Hara 
and Tanegashima, 2012). Interestingly, CXCL14 has been suggested to participate in 
the regulation of rodent glucose homeostasis. Studies in mice have shown that a high 
fat diet markedly upregulates CXCL14 in the serum and white adipose tissue 
(Takahashi et al., 2007), whilst CXCL14 knock out mice are protected from HFD-
induced obesity (Tanegashima et al., 2010), have improved insulin sensitivity and are 
protected from HFD-induced hyperinsulinemia and hyperglycaemia (Nara et al., 
2007). CXCL14 has also been shown to be implicated in modifying insulin-dependent 
glucose uptake in peripheral tissues, albeit with differing effects, with attenuation 
observed in monocytes (Hara and Nakayama, 2009) but enhancement observed in 
adipocytes (Takahashi et al., 2007). 
Chapter 1 Introduction 
53 
 
The association of CXCL14 with glucose homeostasis, coupled with its expression 
within δ-cells suggests that it may play a role in regulating islet function, but, to date, 
such studies have not been performed. Furthermore, preliminary studies implying a 
potential role of CXCL14 in islet function have been limited to mouse models and thus 
the translational relevance of such findings in a human setting are unclear.  
Complicating matters further, with regards to revealing the mechanism of action of 
CXCL14, is the orphan status of CXCL14, i.e. the receptor responsible for its function 
has not been identified. Typically, chemokines bind to GPCRs of their own chemokine 
class (Kufareva et al., 2015). Despite this class-specific interaction between 
chemokine ligands and receptors, a receptor has yet to be identified for CXCL14. It 
has been proposed that CXCR4 is responsible for mediating CXCL14 function as 
determined by its ability to bind with high affinity to wild-type and stable CXCR4-
overexpressing THP-1 cells in radioligand binding experiments (Tanegashima et al., 
2013). In the same study, CXCL14 was also shown to inhibit CXCL12-mediated 
chemotaxis of THP-1 cells, a process which is facilitated by CXCR4. Conversely, an 
alternative report revealed conflicting evidence regarding CXCL14-CXCR4 
interactions by revealing that CXCL14 did not alter CXCL12-induced CXCR4 
phosphorylation, G-protein mediated calcium mobilisation or CXCR4 internalisation 
in CXCR4 transfected HEK293 and Jurkat T cells (Otte et al., 2014). Current 
inconsistencies in the literature regarding the involvement of CXCR4, or any other 
receptor for that matter, in CXCL14-mediated function means CXCL14 retains its 
orphan ligand status. Whether CXCL14 does in fact bind to a GPCR is also debateable, 
as CXCL14 homologs in all vertebrates differ structurally from all other chemokines 
by possessing an uncharacteristically short amino-terminus of only two amino acids 
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located before the first disulphide bridge, a region which is typically required for 
triggering GPCR activation (Benarafa and Wolf, 2015). 
 
As discussed in the previous section (1.3.4), understanding the role of GPCRs in 
human islet function is restricted by the limited availability of human islets required 
for functional assessment, resulting in a reliance on surrogate tissue. This issue also 
extends to islet-expressed peptides that function through GPCRs and whose function 
is yet to be determined. Typically rodent islets, in particular mouse islets, are used to 
fill the void created by a lack of human tissue, but as previously mentioned (section 
1.1.1), concerns over the suitability of using rodent islets to predict the human setting 
exist due to architectural and gene expression differences. This thesis aims to address 
such concerns by comparing the mRNA expression profiles of GPCRs (GPCRomes) 
and GPCR peptide ligands (Secretomes) of human and mouse islets in an attempt to 
assess the suitability of utilising mouse islets as surrogate tissue for studies exploring 
the role of GPCRs and GPCR peptide ligands in human islet function. In addition, this 
thesis also aims to utilise the GPCRome and Secretome data to assess the role of 
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1.5 Thesis aims 
 Determine the mRNA expression profiles of GPCRs in human and mouse 
islets, compare species differences and assess the suitability of using mouse 
islets for human islet GPCR studies. 
 Determine the mRNA expression profiles of GPCR peptide ligands in human 
and mouse islets, compare species differences and assess the suitability of 
using mouse islets for predicting the role of islet GPCR peptide ligands in 
human islet function. 
 Explore the effects of CXCL14 on islet function, identify the mechanisms 
involved in CXCL14-mediated effects and, using the GPCRome and 
Secretome data, assess which GPCRs may be responsible for CXCL14 action. 
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2.1 Cell culture of pancreatic β-cell lines 
The use of primary β-cells in research is limited by the availability of pancreatic 
endocrine tissue in addition to technical limitations ranging from the isolation of islets, 
the cell sorting of islet cell populations and the preservation of the innate 
characteristics of a β-cell (Skelin et al., 2010). In addition, pressures to develop animal 
free approaches in accordance with the principles of the 3Rs (replacement, reduction, 
refinement) (Daneshian et al., 2011) has encouraged researchers to seek alternatives. 
The development of explant derived cell lines with induced proliferation enables the 
propagation of uniform cells with similar physiological characteristics to the parent 
tissue, thus avoiding some of the technical issues associated with primary cell culture. 
Another advantage of using cell lines is the consistency and reproducibility of results 
obtained from clonal cells, a problem associated with primary cell usage due cellular 
and hormonal heterogeneity among cellular sources. However, there are disadvantages 
with using cell lines, such as the change of characteristics over time with continuous 
culturing, abnormal chromosomal content due to their tumour origin, genetic 
mutations, altered protein expression, modified metabolism and disruption of cell to 
cell interaction (Skelin et al., 2010). Despite these concerns, β-cell lines have still been 
developed and utilise to cautiously predict β-cell function. 
MIN6 cells 
MIN6 cells originate from an insulinoma of a transgenic C57BL/6 mouse harbouring 
the insulin promoter-SV40 T antigen hybrid gene (Miyazaki et al., 1990). They exhibit 
many similar characteristics as primary β-cells, such as GLUT2 expression, 
glucokinase expression, show glucose-dependent insulin secretion in earlier passages 
and contain a relatively high insulin content (10% of primary β-cells) (Roderigo-Milne 
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et al., 2002). However, the loss of glucose-induced insulin secretion can be observed 
in later passages, which may possibly be due to an outgrowth of cells with a poor 
response to glucose or a reduced expression of genes responsible for glucose-induced 
insulin secretion (Miyazaki et al., 1990). 
INS-1 cells 
INS-1 cells are X-ray induced rat insulinoma derived cells that also display many of 
the important characteristics of primary β-cells, such as high insulin content (20% of 
native cells), express GLUT2 and glucokinase and respond to glucose within the 
physiological range. In addition, glucose-stimulated insulin secretion is maintained 
over many passages highlighting the robustness of this cell line, in particular the 
INS1E clone, in comparison to other lines. However, in order for INS-1 cells to 
propagate and maintain the functional characteristics of β-cells, 2-mercaptoethanol is 
required within the culture media which can be toxic and denature proteins (Skelin et 
al., 2010). 
Endoc-βH1 cells 
Endoc-βH1 cells are a human pancreatic β-cell line derived from human foetal 
pancreatic buds. Briefly, human foetal pancreatic ducts were transduced with a lenti-
viral vector expressing SV40LT under the control of the rat insulin promoter and then 
transplanted into SCID (severe combined immunodeficiency) mice to allow for the 
expansion of the transformed β-cells. Following in vivo propagation, resulting 
insulinomas were removed and transduced with human telomerase reverse 
transcriptase (hTERT) to promote immortalisation of the cells, before again being 
transplanted into SCID mice to propagate. The resulting tissue was harvested, cultured 
in vitro and shown to maintain significant insulin content (10% of native cells) whilst 
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being able to secrete insulin in response to glucose for over 80 passages (Weir and 
Bonner-Weir, 2011). 
2.1.1 Culture of MIN6 cells 
Adherent MIN6 cells were grown as monolayers in tissue culture treated filter capped 
Nunc flasks within a humidified 37oC incubator containing a 5% CO2, 95% air 
atmosphere. The cells were maintained in culture media comprised of DMEM 
(containing 25mM glucose) supplemented with 10% FBS, 2mM L-glutamine and 
100U/ml penicillin/100µg/ml streptomycin. 
MIN6 cells were grown up to 70-80% confluency before subculturing or for 
experimental use. Subculturing of cells was achieved by aspirating the culture media, 
washing the cells with PBS (37oC) to remove residual serum containing media and 
treating with 0.1% trypsin/0.02% EDTA solution for 3-5 minutes at 37oC. Following 
the detachment of cells with trypsin/EDTA treatment, serum containing growth media 
was added to inhibit trypsin activity. The cells were pelleted at 200 x g for 3 mins, the 
supernatant removed and the cells resuspended in a suitable volume of growth media. 
The cells were counted as described in section (2.1.4). The cells were either seeded 
out into tissue culture flasks for further subculturing or into plates for experimentation. 
2.1.2 Culture of INS-1 cells 
Adherent INS-1 cells were grown as monolayers in tissue culture treated filter capped 
Nunc flasks within a humidified 37oC incubator containing a 5% CO2, 95% air 
atmosphere. The cells were maintained in culture media comprised of RPMI 
(containing 11.1mM glucose) supplemented with 10% FBS, 10mM HEPES, 1mM 
pyruvate, 100U/ml penicillin/100µg/ml streptomycin and 50µM 2-Mercaptoethanol. 
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INS-1 cells were grown up to 90% confluency before subculturing or used for 
experimentation. Subculturing of cells was achieved by aspirating the culture media, 
washing the cells with PBS (37oC) to remove residual serum containing media and 
treating them with 0.1% trypsin/0.02% EDTA solution for 3-5 minutes at 37oC. 
Following the detachment of cells with trypsin/EDTA treatment, serum containing 
growth media was added to inhibit trypsin activity. The cells were pelleted at 200 x g 
for 3mins, the supernatant removed and the cells resuspended in a suitable volume of 
growth media. The cells were counted as described in section (2.1.4) and either seeded 
out into tissue culture flasks for further subculturing or into plates for experimentation. 
2.1.3 Culture of Endoc-βH1 cells 
The adherent Endoc-βH1 cell line was provided, under MTA to Prof Shanta Persaud, 
by Dr. Phillipe Ravassard of ICM Biotechnology and Biotherapy, Paris, France. 
Endoc-βH1 cells were grown up in monolayers in pre-coated F25cm2 TPP flasks in 
culture media comprised of DMEM (5.5mM glucose), 2% BSA fraction V, 50µM 2-
Mercaptoethanol, 10mM nicotinamide, 100U/ml penicillin/100µg/ml streptomycin, 
6.7ng/ml of sodium selenite and 5.5µg/ml of transferrin. Prior to cell plating or 
subculturing, plasticware was pre-coated with coating media comprised of 4oC chilled 
DMEM (25mM glucose), 100U/ml penicillin/100µg/ml streptomycin, 2µg/ml of 
fibronectin and 1% ECM. Due to the perishable nature of the coating media 
constituents it was imperative that the medium was only prepared on day of use and 
kept at 4oC. In order to coat an F25cm2 flask, 2.5ml of coating medium was added to 
an empty flask and placed in a 37oC incubator for a minimum of 1hr or a maximum of 
24 hours. Following incubation, the coating medium was removed immediately before 
seeding of cells. 
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Subculturing of cells in F25cm2 flasks was achieved by removing the medium from 
the cultured cells, rinsing the cells with 3ml of pre-warmed (37oC) 1X D-PBS followed 
by the addition of 1ml of 0.1% trypsin/0.02% EDTA solution. The flask was placed 
into a 37oC incubator for 3 mins to allow for cell detachment before 1ml of neutralising 
medium (80% 1X D-PBS, 20% heat inactivated FBS) was added to deactivate the 
trypsin. Detached cells were transferred to a sterile 15ml Falcon tube, pelleted at 700 
x g for 5mins, the supernatant removed and then the cells were resuspended in 5ml of 
growth medium. The cells were counted as described in section (2.1.4). Following cell 
counting, cells were seeded at a density of 70,000-75,000 cells/cm2 in the pre-coated 
flasks. The flasks were placed into a humidified 37oC incubator containing a 5% CO2, 
95% air atmosphere. 
2.1.4 Cell counting 
Cell counting was performed using Invitrogen’s Countess Automated Cell Counter. 
Briefly, cell suspensions were generated prior to counting as described in the cell 
culture sections above. 10µl of 0.4% Trypan blue solution was added to a 0.6ml 
Eppendorf tube followed by 10µl of cell suspension. The cells and dye were gently 
mixed before 10µl was added to a chamber port of a cell counting chamber slide and 
the cells were counted. Dead cells with disrupted cell membranes show up as blue due 
to dye uptake, whereas live cells will appear with bright centres. 




Figure 2.1.1 Cell viability representation using the Countess Automated Cell 
Counter. 
Total cell count, live cell count, dead cell count and percent viability readings were 
generated. 
2.1.5 Freezing down/thawing of cells 
In order to maintain a stock of cell lines for long term storage, cells are cryo-preserved 
in liquid nitrogen at -196oC. Briefly, adherent cells were trypsinised, resuspended in 
fully complemented growth media, pelleted and resuspended in a volume of 
cryopreservant (90% fully complemented growth media, 10% DMSO) at a seeding 
density of 1-3 x 106 cells/ml. 1ml of cell suspension was dispensed into a 2ml cryovial, 
placed into a Nalgene Mr. Frosty cryo freezing container containing 250ml of 
isopropyl alcohol and stored for 24 hours at -80oC. The presence of isopropyl alcohol 
during the freezing process ensures the cells are steadily frozen down at a rate of 
approximately 1oC/min, thus improving cell survival. 
The retrieval of cell lines from liquid nitrogen was achieved by thawing vials of cells 
in a 37oC water bath before quickly transferring to a 50ml Falcon tube containing 30ml 
of fully complemented media. The cells were then pelleted at 200 x g for 3 mins, the 
supernatant removed and the cells resuspended and transferred to a suitably sized 
culture flask. 
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2.2 Islet isolation 
2.2.1 Isolation of human islets of Langerhans 
Human islets were isolated from heart beating donors at the Islet Transplantation Units 
at King’s College Hospital using the Edmonton protocol (Ryan et al., 2001). After 
islets had been transferred from King’s College Hospital to the Guy’s campus they 
were handpicked and transferred to 9cm non-tissue culture treated dishes containing 
CMRL culture media and maintained at 37oC, 5% CO2 for at least 24 hours to allow 
for recovery. 
2.2.2 Isolation of mouse islets of Langerhans 
Mouse islet isolation was performed using the collagenase digestion method for both 
the outbred ICR/CD1 strain and the inbred C57/BL6 strain. Adult males between the 
ages of 8-12 week old were used. 
2.2.2.1 Surgery 
Prior to surgery a 1mg/ml collagenase solution was prepared in ice cold MEM and 
kept on ice. Mice were terminated by the cervical dislocation method and the 
abdominal cavity was surgically exposed. Under a dissecting microscope the ampulla 
of Vater was clamped and 2.5ml of ice cold collagenase solution was carefully injected 
through the common bile duct. The perfused pancreas was then surgically removed 
and placed into a 50ml Falcon tube on ice. 
2.2.2.2 Digestion of the pancreas 
Prior to starting, wash media comprised of MEM, 10% NCS, 2mM L-glutamine and 
100U/ml penicillin/100µg/ml streptomycin was prepared and placed on ice. 
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The 50ml Falcon tubes containing pancreatic material were placed into a 37oC water 
bath for 10mins to allow for collagenase digestion of pancreatic tissue to occur. 
Following incubation, 25ml of wash media was added to the tubes to deactivate 
collagenase and halt unwanted digestion of islets. The tubes were shaken vigorously 
to encourage pancreatic tissue separation and centrifuged at 300 x g for 1.15 mins at 
10oC. The supernatant was carefully removed and 25ml of fresh wash media was 
added, tubes vortexed and centrifuged again. This process was repeated a further two 
times. After the last wash the resuspended pancreatic tissue was sieved into a funnel 
and collected in new un-skirted 50ml Falcon tubes. The tubes were centrifuged at 340 
x g for 1.5 mins at 10oC. Following centrifugation, the supernatant was removed and 
tubes inverted onto paper towel to ensure removal of remaining residue. The pellet 
was resuspended in 15ml of histopaque and vortexed. 10ml of wash media was gently 
added to the tube so that an interface between media and histopaque was formed. The 
sample was then centrifuged at 3510 x g for 24 mins at 10oC. Following centrifugation, 
islets were removed from the interface and placed into a new un-skirted 50ml Falcon 
tube. The tube was topped up with wash media to the 50ml mark and centrifuged at 
300 x g for 1.15 mins at 10oC. Following centrifugation, islets were left to settle for 
3mins before 25ml of media was removed from the top, 25ml of fresh media added 
and islets centrifuged again. This process was repeated 2 more times before the wash 
steps were repeated with 10ml volumes of replacement media for another three spins. 
After the final centrifugation step, islets were resuspended in10ml of wash media and 
added to a 9cm non-tissue culture treated dish. Islets were handpicked into 9cm dishes 
containing culture media comprised of RPMI supplemented with 10%FBS, 2mM L-
glutamine and 100U/ml penicillin/100µg/ml streptomycin and placed into a 
humidified 37oC incubator containing a 5% CO2, 95% air atmosphere. 
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2.3 Gene expression analysis 
2.3.1 Total RNA extraction 
Total RNA extraction was achieved using a modified version of the TRIzol RNA 
extraction method. The benefit of this method is that protein and genomic DNA can 
be extracted alongside total RNA. RNA isolated using this method is then further 
purified and concentrated using an RNA MiniElute Cleanup kit (Qiagen). The RNeasy 
MinElute Cleanup Kit columns remove contaminating residual salts and phenol as 
well as RNAs shorter than 200 base pairs, such as 5.8S rRNA, 5S rRNA, and tRNAs, 
which together comprise 15–20% of the total RNA, resulting in an enrichment of 
mRNAs. 
Gene expression analysis was performed on both cell lines and islets of Langerhans. 
For cell lines, media was removed from a confluent 6 well containing the cell line of 
interest (approximately 1x106 cells/well) and 1ml of TRIzol added. TRIzol was left 
for 5mins to dissolve cellular material and the sample was transferred to -80oC for 
storage. For mouse and human islets of Langerhans, each biological replicate 
contained approximately 150-250 islets. Islets were pelleted at 0.2 x g for 3 mins, the 
supernatant was completely removed and 1ml of TRIzol was added. The samples were 
left at room temperature for 5 mins before being stored at -80oC. 
Prior to starting the RNA extraction procedure, isopropanol was chilled at -20oC and 
a centrifuge was pre-chilled to 4oC. TRIzol samples were removed from storage, 
thawed and left at room temperature for 5 mins. 200µl of chloroform was then added 
to each sample to create a biphasic mixture where polar single stranded RNA strands 
migrate to the aqueous phase whilst protein and non-polar double stranded DNA 
remain in the organic phase (protein) or interphase (DNA). The tubes were manually 
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shaken 50 times before being centrifuged at 12000 x g for 15 mins at 4oC. During this 
stage, 0.5µl of 20µg/µl ultra-pure glycogen was added to fresh 1.5ml RNase free tubes. 
Glycogen is a highly branched carbohydrate which binds to and promotes RNA pellet 
precipitation. Following centrifugation, the aqueous phase was transferred to the 
glycogen containing tubes using an RNase free filter tip. 500µl of pre-chilled 
isopropanol was added to each tube containing the glycogen aqueous phase mix. The 
sample was mixed by inverting and was stored at -80oC for 1 hour or -20oC overnight. 
Next, the samples were centrifuged again at 12,000 x g for 15 mins at 4oC to pellet the 
RNA. The supernatant was carefully aspirated and 1ml of freshly prepared 75% 
ethanol was added to the tube. Samples were then centrifuged at 7,500 x g for 10mins 
at 4oC. The presence of ethanol promotes precipitation allowing for the visualisation 
of a white RNA pellet. The supernatant was again carefully and completely aspirated 
and the pellets dried in a heating block set to 37oC for 1-3 mins. The RNA pellet was 
then dissolved in 100µl of RNase free water, vortexed and stored at -80oC until it was 
concentrated and purified using the RNEasy MiniElute Cleanup kit (Qiagen). 
2.3.2 RNA concentration and purification 
Further concentration and purification of total RNA was achieved using Qiagen’s 
RNeasy MiniElute Cleanup kit. No more than 45µg of total RNA in 100µl was added 
to each column. For each two RNA samples, 1.5ml Eppendorf tubes containing either 
800µl of RLT buffer (1% 2-mercaptoethanol), 600µl of 100% ethanol, 1.1ml of RPE 
buffer or 1.1ml of 80% ethanol were prepared. 
Each RNA sample was rapidly defrosted and thoroughly vortexed to ensure that the 
RNA pellet was completely dissolved in the 100µl of water added at the end of the 
TRizol purification protocol. 350µl of RLT buffer was then added to each of the 100µl 
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of RNA sample and vortexed. 250µl of 100% ethanol was then added and mixed by 
pipetting. The sample was transferred to a MinElute column, placed in a collection 
tube and centrifuged at 9500 x g for 15 seconds. The flow through was discarded and 
the column placed into a fresh collection tube. 500µl of RPE buffer was added to the 
spin column and centrifuged at 9500 x g for 15 seconds. The flow through was 
decanted from the collection tube, the column and collection tube reassembled and 
500µl of 80% ethanol was added to the column. The sample was centrifuged at 9500 
x g for 2mins and the collection tube and contents were discarded. The column was 
placed in a new collection tube with the lid open and spun at 20,000 x g for 5mins to 
dry the membrane. The collection tube and contents were again discarded and column 
placed in new collection tube. 14µl of RNase free water was added to the centre of the 
column membrane and the spin column was centrifuged at 20,000 x g for 1min to elute 
the RNA. A total elution volume of approximately 12µl was obtained. The RNA 
concentration was quantified using a Nanodrop instrument and the remaining sample 
was stored at -80oC. 
2.3.3 RNA quantification 
Total RNA was quantified using the NanoDrop 2000 spectrophotometer, which is able 
to detect the concentration and purity of RNA in a 1µl sample. Since nucleotides 
absorb at 260nm, the concentration of RNA is determined by measuring absorbance 
at A260nm. Additional ratio readings at 260/280nm and 260/230nm are determined to 
assess protein, carbohydrate and phenol contamination within the sample. A pure 
sample of RNA is accepted if the determined 260/280nm ratio is ~2.0 and the 
260/230nm measurement is 2.0-2.2. RNA samples classed as pure were stored at -
80oC until required for mRNA purification. 
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2.3.4 cDNA synthesis 
Complementary DNA synthesis is the process in which mRNA is transcribed into 
cDNA by the action of a reverse transcriptase such as the TaqMan Reverse 
Transcriptase which is a recombinant Murine Leukaemia Vurus reverse transcriptase 
(MuLVRT). Reverse transcription of RNA to cDNA was performed using the TaqMan 
Reverse Transcription kit. 
A reverse transcription master mix was generated as indicated below and placed on 
ice. 
Table 2.3.1 Reverse transcription master mix preparation. 
Reagent Volume/reaction (µl) 
10X TaqMan RT-buffer 2.50 
25mM MgCl2 5.50 
10mM dNTP 5.00 
Random hexamers 1.25 
RNase inhibitor 0.50 
MultiScribe transcriptase 0.65 
  
Mater mix/tube 15.40 
RNA/tube (60-2000ng) 9.60 
 
PCR tubes containing master mix and RNA were placed into a thermal cycler and run 
under the following settings. 
Table 2.3.2. Thermal cycler settings for PCR 
Temperature (oC) Time (mins) Cycles 
25 10 1 
48 30 1 
95 5 1 
4 eternity 1 
 
Following thermal cycling, the cDNA samples were stored at -20oC until required for 
qPCR gene expression analysis. 
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2.3.5 Quantitative real time polymerase chain reaction 
Quantitative real-time polymerase chain reaction (qPCR) is a technique employed to 
quantify gene expression. It combines the conventional polymerase chain reaction 
technique with either non-specific fluorescent dyes that bind to double stranded DNA, 
for example SYBR green, or sequence specific DNA fluorescently labelled probes as 
is the case with TaqMan probes. The combined effect is the fluorescent quantitative 
measurement of amplified genes of interest relative to the expression of a suitable 
housekeeping gene. The Qiagen SYBR green method was employed for the 
assessment of gene expression analysis. 
2.3.5.1 Housekeeping gene normalisation 
Due to the fact the concentration of cDNA material cannot be determined by current 
methods, the expression of genes of interest cannot be quantified per unit of cDNA. 
Therefore, gene expression is quantified relative to the mRNA expression of a 
housekeeping gene expression. The quantity of cDNA used for gene expression 
analysis is initially calculated by determining the Ct value of the chosen housekeeping 
gene for the cDNA stock. A subsequent dilution of the cDNA stock is then performed 
to achieve a desired housekeeping gene Ct value to allow for reliable detection of 
genes of interest. For the purpose of this study the housekeeping gene GAPDH was 
used and a target Ct value of 18 to 20 for this gene was chosen. 
cDNA stocks, Qiagen QuantiTect primer qPCR assays and Qiagen QuantiFast SYBR 
green mastermix aliquots were all thawed on ice. cDNA stock was diluted tenfold in 
molecular biology grade water for initial housekeeping gene expression assessment. 
5X working substocks of primers were prepared from 10X stocks by diluting in 
molecular biology grade water. The following reaction mix was prepared for each 
cDNA sample per well. 
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Table 2.3.3. qPCR reaction mix preparation per well. 
Reagent Volume (µl) 
SYBR green 5 
Diluted cDNA 1 
Water 2 
 
8µl of reaction mix was added to each well of a 96 well Roche Light Cycler plate and 
then centrifuged at 1000rpm for 1 min to promote collection of sample at the base of 
the well. 2µl of 5X primer was then added to each well, the plate sealed with adhesive 
film and then centrifuged again using the same settings. The plate was then read using 
the LightCycler 480 RT-PCR System (Roche) using the following settings. 













Pre-incubation 95 None 5mins 4.4  1 None 
Amplification 95 None 10secs 4.4  40  
60 Single 30secs 2.2  
Melting Curve 95 None 10secs 4.4  1  
60 Single 30secs 2.2  
40 None 30secs 2.2 5 
Cooling 40 None 30secs 2.2   None 
 
Following the plate read, data was extracted using the LightCycler 480 software v1.5. 
The required volume of cDNA substock required for future gene analysis screens was 
determined using the following equation, where rCt = required housekeeping gene Ct 
value and aCt = actual Ct value of housekeeping gene of tenfold diluted cDNA. 
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2.3.5.2 Gene expression profiling 
Following the exclusion of all odorant GPCRs, the poorly characterised bitter taste 
receptor family (TAS2Rs) and GPCRs where no available mouse orthologue existed, 
the relative quantification of 335 functional GPCRs from a potential ~800 within the 
human genome were screened in human islets, ICR mouse islets and C57 mouse islets. 
145 GPCR peptide ligand genes were also screened in human islets, ICR mouse islets 
and C57 mouse islets. 
Preliminary screening of gene expression was performed in ‘single shot’ mode using 
pooled cDNA from biological replicates. Following the exclusion of the negative hits 
and those with poor melt curve statuses, the qPCR products of the remaining positive 
hits were run on an agarose gel (section 2.3.6) to assess true amplification of the 
desired gene and exclude false positive hits. Genes that were known to be expressed 
from the scientific literature, but whose amplicon bands were incorrect, were re-run 
with redesigned primers. Genes whose calculated Ct value were ≥30, which had a 
correct amplicon band size in the gel analysis were labelled as trace expressing genes. 
Lastly, genes whose amplicon bands were correct and had a Ct value <30 were 
quantified further by determining expression within each biological replicate. 
2.3.5.3 Primer efficiency determination 
The amount of amplified cDNA replicated throughout the qPCR thermal cycling 
process is dependent on intrinsic factors such as the ability of the primer to bind to its 
specific template region and the ability of the polymerase to amplify the template 
region of interest. The combination of these factors is referred to as the primer 
efficiency. In theory, if a primer efficiency value of 100% is observed then a doubling 
of the amplified product should be observed after each cycle. However, this is often 
not the case and primers will tend to exhibit slightly different primer efficiency values. 
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Therefore, in order to correctly compare the expression levels of different genes using 
qPCR, a primer efficiency value for each primer pair is required. This is achieved by 
running a cDNA titration experiment and determining the slope of a Ct (cycle 
threshold) vs log cDNA plot. 
Primers selected for primer efficiency analysis have to not only indicate expression 
within the target tissue of interest but also have to show high enough level of 
expression (Ct<25) so that reliable detection can be determined over the full cDNA 
titration range. The assay was performed by titrating stock cDNA by performing a 5 
point, 1 in 2 serial dilution in molecular biology grade water. 3µl/well of cDNA was 
added to Roche LightCycler 480 compatible 96 well plate, followed by 5µl of 2X 
SYBR green mastermix and 2µl of primer. The plate was run using a Roche LC480 
instrument using the same programme as described in Table 2.3.4. Ct values were 
plotted against Log cDNA dilution and the slope determined. The slope value was then 
converted to a primer efficiency value using the following equation: 
 
Figure 2.3.1 Primer efficiency calculation equation 
 
2.3.5.4 Data reduction 
Gene expression relative to GAPDH was determined using the ∆∆Ct method (Pfaffl, 
2001), where E = primer efficiency value; gioCt = Ct value of the gene of interest; hCt 
= Ct value of the housekeeping gene. 




Figure 2.3.2 Equation for determining relative gene expression 
 
2.3.6 Agarose gel electrophoresis 
In order to determine whether the amplified qPCR product is genuine, the product was 
run on an agarose electrophoresis gel and the amplicon band length was compared to 
the predicted length supplied by the manufacturer. 
Briefly, a 2% agarose gel solution was prepared by dissolving 3g of agarose into 150ml 
of 1X bionic buffer in a microwave. Once dissolved, 7.5µl of 10mg/ml ethidium 
bromide was added and poured out into a pre-prepared cast. 2µl of 6X Orange DNA 
loading dye was added to each well of the qPCR plate containing amplified qPCR 
product and the plate centrifuged at 200 x g for 1 minute. 12µl/well of dye/qPCR 
product mix or 7µl/well of OrangeRuler 50bp DNA ladder was added the agarose gel. 
The gel was then run at 150V for approximately 40 minutes and bands visualised under 
UV light using a Genius transilluminator. 
 
2.4 Measurement of insulin secretion 
The assessment of insulin secretion from cell lines and islets was performed using 
static incubation measurements. The static method involves incubating islets or cells 
with ligands of interest in a ‘closed system’ i.e. media is neither removed nor replaced 
during incubation. In contrast to the dynamic perifusion method, static measurements 
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improves the chance of observing autocrine and paracrine effects of ligand treatment 
that may not be observed by the perifusion method. 
2.4.1 Static incubation using islets 
Cultured handpicked islets were transferred to a 15ml Falcon tube containing Gey and 
Gey physiological salt solution supplemented with 2mM glucose and centrifuged at 
200 x g for 5 mins. The supernatant was removed and 10ml of fresh 2mM glucose Gey 
and Gey was added to the tube and the islets were incubated in humidified incubator 
at 37oC for 1 hour. During incubation, 500µl of ligand treatment in Gey and Gey buffer 
was prepared in 1.5ml Eppendorf tubes and placed on ice. Following incubation the 
supernatant was removed from the islets, 15ml of 2mM glucose Gey and Gey was 
added and the islets centrifuged again at 200 x g for 5 mins. The supernatant was 
removed, the islets resuspended in 15ml of 2mM glucose Gey and Gey buffer and the 
contents of the tube transferred to a 9cm non-treated Petri dish. Islets were then 
handpicked under microscope into the prepared 1.5ml Eppendorf tubes and placed 
back on ice. All tubes were then placed in a water bath at 37oC for 1 hour. The tubes 
were then centrifuged at 200 x g for 1 min to pellet islets and 250µl of supernatant was 
carefully harvested and stored at -20oC until required for insulin content assessment 
by radioimmunoassay. 
Table 2.4.1 Preparation of 1 x Gey and Gey buffer (per 2L, pH8.4) 
Reagent Mass (g) Final Concentration (mM) 
NaCl 26 111 
KCl 1.48 5 
NaHCO3 9.08 27 
MgCl2.6H2O 0.84 1 
KH2PO4 0.12 0.22 
MgSO4.7H2O 0.28 0.28 
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Table 2.4.2 preparation of 20mM glucose Gey and Gey buffer. 
Reagent Amount required Final concentration 
G&G buffer 500ml 1X 
dH2O 500ml - 
D-glucose 3.6g 20mM 
CaCl2 2ml (of 1M stock) 2mM 
BSA 500mg 0.5mg/ml 
 
2.4.2 Static incubation using MIN6 cells 
25,000 MIN6 cells per well were plated out in fully complemented growth media in 
96 well culture plates and incubated for 24 hours in a humidified 37oC incubator 
containing 5% CO2. The following day the media was replaced with growth media 
containing low glucose (1g/L) and incubated again for 24 hours. The next day media 
was removed and 200µl of 2mM glucose Gey and Gey buffer added to each well and 
the plate incubated at 37oC for 2 hours. Following incubation, media was removed 
from the cell plate by tapping and 200µl of ligand buffer was added per well. The plate 
was incubated for 1 hour in a humidified 37oC incubator with 5% CO2. After 
incubation the plate was spun at 200 x g for 1 minute to pellet floating cells from the 
supernatant and 100µl of supernatant was transferred to an empty 96 well plate. 
Samples were stored at -20oC until required for insulin content assessment by 
radioimmunoassay. 
2.4.3 Static incubation using INS-1 cells 
15,000 INS-1 cells per well were plated out in fully complemented growth media in 
96 well culture plates and incubated for 24 hours in a humidified 37oC incubator 
containing 5% CO2. The following day the cells were washed with 2.8mM glucose 
SAB buffer and 150µl/well of fresh 2.8mM glucose SAB buffer was added to the plate. 
The cells were incubated at in a 37oC incubator for 2 hours. During incubation ligand 
treatment was made up in SAB buffer and placed on ice. Following incubation, media 
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was removed from the cell plate and 200µl of ligand buffer was added per well. The 
plate was incubated for 1 hour in a humidified 37oC incubator with 5% CO2. After 
incubation the plate was spun at 200 x g for 1 minute to pellet floating cells from the 
supernatant and 100µl of supernatant was transferred to an empty 96 well plate. 
Samples were stored at -20oC until required for insulin content assessment by 
radioimmunoassay. 
Table 2.4.3 Preparation of 10X SAB buffer. 
Reagent g/500ml Final concentration 
NaCl 33.32 1.14M 
KCl 1.73 47mM 
KH2PO4 0.82 12mM 
MgSO4 0.70 11.6mM 
 
Table 2.4.4 Preparation of 1X SAB buffer. 
Reagent Amount/100ml Final concentration 
10X SAB 90 1X 
dH2O 10 - 
HEPES 2ml (of 1M stock) 20mM 
NaHCO3 0.214g 25.5mM 
CaCl2 0.25ml (of 1M stock) 2.5mM 
BSA 0.2g 0.2% 
 
2.4.4 Radioimmunoassay 
The insulin radioimmunoassay (RIA) is a competition binding assay which allows for 
the accurate detection of low concentrations of insulin within a sample. There are three 
main components of the assay; the insulin antibody (Ab), the radiolabelled insulin 
(Ag*) and unlabelled insulin (Ag). The assay is based on the competitive and 
reversible binding of unlabelled insulin and radiolabelled insulin for an anti-insulin 
antibody binding site:  
Ab + Ag + Ag* ↔ Ab:Ag + Ab:Ag + Ag + Ag* 
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The assay is performed by incubating a fixed concentration of antibody with 125I-
insulin and non-radiolabelled insulin (either samples or standards) at 4oC for 48 hours. 
Following incubation, the antibody:antigen bound complex is then separated from free 
antigen by precipitation and insulin content of the sample quantified by the 
displacement of radioactive antigen. Insulin content is determined by extrapolating 
sample cpm counts from standard curve cpm counts. 
Prior to starting, samples for testing were thawed out at room temperature and both 
borate buffer and 30% PEG solutions were prepared as described below. 
Table 2.4.5. Borate buffer preparation. 
Reagent Required conc. Amount for 2L 
Boric Acid 133mM 16.5g 
EDTA 10mM 7.4g 
NaOH 67.5mM 5.4g 
BSA 1g/L 2g 
 





Sample conditions were assayed in duplicate and diluted 5X in 80µl of borate buffer, 
whilst standard curve samples and reference samples (total, NSB and maximum 
binding) were performed in triplicate. A nine point insulin standard curve was 
prepared by performing a one in two serial dilution in borate buffer of a 10ng/ml stock 
and 100µl transferred to each standard tube. Antibody stock was diluted tenfold in 
borate buffer and 100µl added to each tube with the exception of NSB and total tubes. 
Insulin tracer (125I-insulin) was prepared in borate buffer at a concentration giving 
10,000cpm. 100µl of tracer was added to each tube, tubes covered with Parafilm and 
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incubated at 4oC for 48 hours. A summary table of reagent addition for each condition 
can be found below. 
Table 2.4.7. Summary table of test condition preparations for RIA 
Condition Buffer Antibody Tracer Standard Sample 
Totals   100µl   
NSB 200µl  100µl   
Max 100µl 100µl 100µl   
Standards  100µl 100µl 100µl  
Samples  100µl 100µl  100µl 
 
Following the 48 hour incubation period, a 15% PEG precipitation buffer was prepared 
as follows. 
Table 2.4.8. Preparation of RIA precipitation solution 
Reagent Amount/500ml 





With the exception of the total condition, 1ml of precipitation solution was added to 
each tube and then centrifuged at 1500 x g for 15 mins at 4oC using a Jouan Cool Spin 
centrifuge. Following centrifugation, the supernatant was carefully aspirated leaving 
a pellet containing antibody:antigen bound complexes. Radioactive content was 




Chapter 2 - Methods 
79 
 
2.5 Measurement of apoptosis 
Apoptosis is an energy dependent process that involves the activation of a group of 
cysteine proteases called “caspases” which mediate a multitude of apoptotic events 
such as DNA fragmentation, degradation of cytoskeletal and nuclear proteins, 
expression of ligands for phagocytic receptors and uptake by phagocytic cells (Elmore, 
2007). Cellular apoptosis was assessed using Promega’s Caspase-Glo 3/7 assay. The 
assay is based on a luminescent readout which is directly proportional to the activity 
of the apoptotic enzymes, caspase-3/7, within the cell. 
In brief, 100µl of cells per well were plated out in white 96 well plates for 24hours 
before the cells were challenged with 50µl of ligand treatment in the absence or 
presence of 50µl of cytokines (1U/µl TNFα, 1U/µl IFNγ, 0.01U/µl IL1β) for 18hours 
at 37oC, 5% CO2. Following ligand/cytokine challenge, 75µl of media was removed 
and cells were lysed by the addition of 25µl of Caspase-Glo 3/7 reagent containing a 
lysing agent, proluminescent caspase-3/7 DEVD-aminolucoferin substrate and a 
proprietary thermostable luciferase. Lysis of the cell releases intracellular endogenous 
caspase-3/7 enzymes which convert the pro-aminoluciferin substrate into free 
aminoluciferin, which is then metabolised by the luciferase in the presence of ATP 
and O2 to generate a luminescent signal. Luminescent signal was captured on a Veritas 
luminometer. 
 




Figure 2.5.1. Caspase-3/7 assay principle. 
 
 
2.6 Measurement of cell proliferation 
Cell proliferation was indirectly assessed by measuring 5-bromo2’-deoxyuridine 
(BrdU) incorporation into newly synthesised genomic DNA of replicated cells. The 
extent of BrdU uptake was then quantified by combining ELISA and 
chemiluminescence technologies. 
Briefly, cells were plated out in 96 well plates and incubated overnight in fully 
complemented growth media. The next day, cell media was changed to serum free 
media containing 2mM glucose, to ensure that the cells reached a quiescent state prior 
to ligand treatment, and the cells once again incubated overnight. Following overnight 
incubation, the cells were treated with ligand in the presence or absence of serum and 
incubated at 37oC for 2 days. On day five, the cell media was spiked with 10µl of 
1:100 BrdU labelling solution and incubated for 4 hours at 37oC before the cell media 
was removed. 200µl of FixDenat solution was then added to each well and the plate 
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incubated for 30 mins at room temperature. The contents of the wells was aspirated, 
100µl/well of anti-BrdU-POD working solution added and the plate incubated for 90 
mins at room temperature. Following the incubation, the cells were washed three times 
with 200µl/well of wash solution before 100µl/well of substrate solution was added. 
The plate was then incubated at room temperature until blue staining developed. 
25µl/well of 1M H2SO4 was then added to halt the intensity of further staining and the 
absorbance was read at 450nm. 
 
2.7 Measurement of intracellular cAMP 
The effects of test ligands on intracellular cAMP levels was measured using Cisbio’s 
HTRF cAMP assay. An HTRF assay is an assay which utilises the combination of 
FRET technology and time resolved (TR) fluorescence. FRET is the process by which 
a fluorescent signal is generated following energy transfer from an excited fluorophore 
donor molecule to an acceptor fluorophore molecule when in close proximity to each 
other. A fluorescent measurement is recorded over a time to create a fluorescent 
spectrum also known as a time resolved fluorescent readout. The incorporation of a 
dual emission readout minimises the background interference of media and buffer 
quenching and allows for normalisation of readout signal to cell number. 
The cAMP HTRF assay is based on the competition between endogenously produced 
cAMP with a donor fluorophore (d2) conjugated cAMP molecule for an acceptor 
fluorophore (cryptate) conjugated anti-cAMP antibody. Production of endogenous 
intracellular cAMP results in the competitive displacement of d2-cAMP from the anti-
cAMP antibody resulting in a decrease in FRET signal. The introduction of a cAMP 
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standard curves allows for the direct measurement of intracellular cAMP production 
by extrapolating FRET values from the standard curve. 
 
Figure 2.7.1. cAMP HTRF assay principle 
In brief, MIN6 cells were detached from a T75 flask using 5ml of enzyme free cell 
dissociation buffer. Enzyme free dissociation buffer was used rather than trypsin so 
that cell surface receptors would not be digested during the detachment process. 
Following detachment, 5ml of full complemented growth media was added to the cell 
suspension and centrifuged at 200 x g for 3 mins. The supernatant was removed and 
the cell pellet resuspended in a volume non-complemented DMEM to create the 
required cell density per well per 5µl. 5µl/well of cells were plated out in a white 384 
well round bottomed plate followed by 5µl of ligand treatment prepared in HBSS 
supplemented with 10mM HEPES, 0.2% BSA and 2mM IBMX with a pH of 7.4 (pH 
adjusted with HCl). The plate was incubated at room temperature for 1 hour. 
Following incubation 5µl of d2-cAMP prepared in lysis buffer was added to each well 
followed by the addition of 5µl/well of cryptate-Ab prepared in lysis buffer. The plate 
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was again incubated at room temperature for 1 hour before being read on a Pherastar 
FS plate reader (BMG LabTech) under the following settings (Table 2.7.1). 
Table 2.7.1. Pherastar HTRF plate read settings 
Parameter Setting 
Delay time 100µs 
Integration time 100µs 
No. flashes 50 
 
2.7.1.1 Data reduction 
The dual emission readout allows for the normalisation of the 665nm wavelength to 
background fluorescence at 620nm. This allows for the correction of signal 
interference caused by the potential quenching of media, quenching by coloured 
compounds and variations in cell number. Ratio values for each well are calculated as 




2.8 ATP assay 
Intracellular ATP levels were measured using Promega’s CellTiter-Glo Luminescent 
Cell Viability assay. This particular assay is typically used to assess cell viability 
following chronic ligand treatment but for the purposes of the experiments described 
in this thesis the procedure was modified to assess acute ligand treatment. 
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The principle of the CellTiter-Glo assay is based on the conversion of luciferin into 
oxyluciferin, AMP, PPi, CO2 and light by Ultra-Glo Luciferase which requires both 
Mg2+, O2 and ATP. The reliance of luciferase enzyme activity on ATP means 
luminescent output is altered by intracellular ATP levels. Therefore, an indirect 
quantification of intracellular ATP levels can be determined following extrapolation 
from a standard curve. 
 
Figure 2.8.1 CellTiter-Glo Cell Viability assay principle. 
 
For the purpose of studies assessing the effects of acute ligand treatment on 
intracellular ATP levels, MIN6 cells were used. Cells were plated out in white walled, 
clear bottomed 96 well plates and incubated overnight in a humidified incubator at 
37oC supplemented with 5% CO2. The following day, the media was changed to low 
glucose media to allow cells to reach a more glucose responsive state the following 
day. The next day media was removed from the plate and replaced with 50µl/well of 
ligand made up in Gey and Gey buffer. The plate was then incubated for 1 hour at 
37oC. Following incubation, 50µl/well of CellTiter-Glo reagent was added to the plate, 
the contents mixed on a plate shaker for 1 minute and the plate incubated at room 
temperature for 10 mins. The plate was then read on a Veritas luminometer using the 
pre-installed CellTiter protocol. 
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2.9 Glucose uptake assay 
One of the main functions of β-cells is to sense increases in circulating glucose 
concentrations and subsequently secrete insulin in response. Insulin secretion from β-
cells is mediated by glucose uptake via the GLUT2 and subsequent phosphorylation 
by glucokinase (Thorens, 2001). 
In order to assess the effects of exogenous CXCL14 on glucose uptake in the MIN6 
cell line a glucose uptake assay from Promega was developed. Glucose uptake and 
glucokinase activity is indirectly assessed by replacing glucose within the assay buffer 
with 2DG and measuring the accumulation of the cell impermeable metabolite 
2DG6P, a process catalysed by intracellular glucokinase. After incubation with 2DG 
in the presence of test ligand, the cells are lysed with STOP buffer to terminate uptake 
and destroy endogenous levels of NADPH within the cells. A high pH buffer solution 
(Go buffer) is added to neutralise the acid and a detection reagent is added that includes 
NAD+, G6PDH, a reductase, pro-luciferin, and luciferase. The result is the generation 
of NADPH from 2DG6P, luciferin from NADPH and luminescence from the 
metabolism of luciferin by luciferase. The luminescent signal is proportional to the 
accumulation of 2DG6P. 
 
Figure 2.9.1 Promega glucose uptake assay principle. 
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2.10 β-arrestin assays 
β-arrestin technology exploits the mechanism of intracellular β-arrestin recruitment at 
agonist-activated receptors, allowing for the functional measurement of ligand-
receptor interactions irrespective of the G-protein-coupled pathways involved. The 
experiments described in this thesis utilise the PathHunter β-arrestin assays developed 
by DiscoveRx. Briefy, PathHunter technology involves fusing GPCRs with ProLink 
enzymes that are co-expressed in cell lines expressing a fusion protein of β-arrestin 
and an N-terminal deletion mutant of β-galactosidase. Activation of the GPCR results 
in recruitment of the fusion β-arresin protein to the ProLinked-tagged GPCR forcing 
the complementation of the two enzyme fragments resulting in the formation of an 
active β-galactosidase enzyme. The active form of the β-galactosidase enzyme 
catalyses the conversion of a chemiluminescent detection reagent into a luminescent 
signal which is directly proportional to receptor activation. 
 
Figure 2.10.1 PathHunter β-arrestin assay principle. 
 
The β-arrestin assays were performed as follows. A frozen vial containing 1.25 x 106 
of PathHunter eXpress β-arrestin GPCR U2OS cells in 0.1ml of cryopreservant was 
thawed out in a water bath at 37oC. 0.5ml of pre-warmed CP (cell plating) reagent was 
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then added to the vial and the contents transferred to a 15ml Falcon tube containing 
11.5ml of pre-warmed CP reagent. 100µl/well of cell suspension (10,000 cells/well) 
was then plated out into a white walled, clear bottomed 96 well plate and the cells 
were cultured for 48 hours in a 37oC humidified incubator supplemented with 5% CO2. 
48 hours later, the media was carefully removed from the plate and 50µl/well of 
vehicle (ligand diluent in assay buffer) or 2X antagonist prepared in assay buffer 
(HBSS, 10mM HEPES, 0.1% BSA) was added to each well. Immediately after, 
50µl/well of 2X agonist prepared in assay buffer was added and the plate was 
incubated at 37oC for 90 mins. During incubation, 5.5ml of detection reagent was 
prepared by adding 1.25ml of substrate reagent 1 and 0.25ml of substrate reagent 2 to 
4.75ml of cell assay buffer (all supplied within the kit). After the 90 minute incubation, 
55µl of detection reagent was added to each well and the plate was incubated at room 
temperature for 60 mins. Luminescence was captured on a Veritas luminometer.
Chapter 3 – GPCRome comparison 
88 
 

















G protein-coupled receptors (GPCRs) are a diverse super family of seven 
transmembrane bound proteins whose primary function is to initiate the activation of 
intracellular signalling pathways following stimulation by extracellular stimuli, which 
include photons, amines, lipids, ions, peptides and proteins (Kroeze et al., 2003). Due 
to the ubiquitous expression of GPCRs throughout various tissues, they are implicated 
in the regulation of a variety of diverse physiological processes (Moller et al., 2001), 
such as the regulation of the secretion of the blood glucose controlling hormones 
insulin, glucagon and somatostatin from islets (Amisten et al., 2013). As a result, 
GPCRs are being identified as therapeutic targets for the treatment of T2DM (Reimann 
and Gribble, 2016). 
To date, the success of GPCRs as targets for the treatment of T2DM is limited to the 
GLP-1 receptor (GLP1R), which mediates the function of the GLP-1 peptide to 
regulate insulin and glucagon secretion from the pancreas. Drugs that target the 
GLP1R have been shown to enhance glucose-stimulated insulin release, reduce 
elevated levels of glucagon, inhibit gastric emptying and suppress appetite, but 
adverse effects such as pancreatitis, nausea, vomiting and gastrointestinal complaints 
are associated with such therapeutics (Trujillo and Nuffer, 2014). In addition, current 
GLP1R agonist therapeutics require injectable dosing thus negatively impacting 
patient compliance (Tomkin, 2014). As a result, there are continuing efforts to identify 
alternative GPCR targets for the treatment of diabetes. 
According to Amisten et al (Amisten et al., 2013), human islets express 293 non-
odorant GPCRs, but despite this large pool of potential targets only 2 GPCR targets, 
other than GLP1R, are currently under clinical investigation, GPR119 and GPR40 
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(FFAR1) (Reimann and Gribble, 2016). Part of the issue contributing the limited 
success of targeting GPCRs for T2DM is the poor functional characterisation of the 
majority of islet expressed GPCRs. This issue is further exacerbated by the limited 
availability of human islets required to study GPCR function, and as a result rodent 
islets, particularly mouse islets, are relied upon as translational models. 
Whilst the issue of islet availability is resolved by using rodent models, the suitability 
of rodent islets as translational models to predict human islet function is unclear. 
Differences in the proportion of islet endocrine cell populations (Steiner et al., 2010) 
and islet architecture between human and mouse islets have been documented 
(Cabrera et al., 2006), and the fact that the mouse genome contains a total of 1697 
GPCRs whereas the human genome contains approximately 791 GPCRs (Bjarnadottir 
et al., 2006) gives rise to questions regarding the suitability of using mouse islets for 
human islet GPCR studies.  
The experiments described in this chapter aim to compare human and mouse islet 
GPCR mRNA expression profiles (GPCRomes). Mouse islets from both the outbred 
ICR mouse strain and the inbred C57/BL6 (C57) mouse strain are compared to human 
islets with the aim of identifying similarities and differences in GPCR mRNA 
expression between the two species and to determine the suitability of using mouse 
islets as translational models for the study of human islet GPCRs. 
 
 




 Quantify the mRNA expression of 376 human non-olfactory GPCRs in human 
islets and their orthologue counterparts in mouse islets. 
 Compare the GPCR mRNA expression profiles of human and mouse islets and 
highlight species differences and similarities. 
 Determine the suitability of using mouse islets as translational models to assess 
















3.3.1 Gene expression analysis 
Human and mouse islet GPCRomes were determined by qPCR using Qiagen’s 
QuantiTect primers and QuantiFast SYBR green mastermix. 376 human non-odorant 
GPCRs and 335 mouse orthologues were included in this study. 41 human GPCRs had 
no known mouse orthologues. The human bitter taste receptors were excluded from 
the inter-species comparative analysis due to the poor annotation of mouse orthologue 
bitter taste receptors. 
 
3.3.1.1 Isolation of human and mouse islets for GPCR mRNA quantification 
As described in section 2.2.1, human islets were obtained from four heart beating 
donors (2 male, 2 female) at the Islet Transplantation Units at King’s College London 
using a revised version (Huang et al., 2004) of the Edmonton protocol. The donors 
were between the ages of 43-59, were non-diabetic and had a BMI of 22-33kg/m2. 
Mouse islets were isolated in-house as described in section 2.2.2. Two strains of mice 
were used for the purpose of this study, the outbred ICR strain and the inbred C57/BL6 
(C57) strain, so that strain differences as well as species differences could be 
compared. All islets were obtained from adult male mice aged 8-12 weeks. 
Following the isolation of human and mouse islets, approximately 200 islets per 
biological replicate were handpicked and added to 1ml of TRIzol for 5mins before 
being stored at -80oC awaiting RNA extraction and cDNA generation. 
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3.3.1.2 cDNA generation 
Quantitative real time polymerase chain reaction was performed using the two step 
approach which requires the generation of cDNA prior to performing the qPCR 
reaction. Firstly, total RNA was extracted from previously TRIzol harvested tissue as 
described in detail in section 2.3.1 and quantified as described in section 2.3.3. 
Following quantification, mRNA was purified from the total RNA sample using 
Qiagen’s RNeasy MiniElute Cleanup kit (section 2.3.2). Finally, cDNA was reversed 
transcribed from purified mRNA using the TaqMan Reverse Transcription kit (section 
2.3.4). 
 
3.3.1.3 Quantitative real time polymerase chain reaction 
qPCR was performed using Qiagen’s QuantiTect primers, QuantiFast SYBR green 
master mix and the Roche LightCycler 480 under the settings described in section 
2.3.5. Gene expression was represented as expression relative to GAPDH expression 












3.4.1 Confirmation of islet endocrine cell presence 
In order to confirm the presence of α-, β-, δ-, PP- and ε- endocrine cell populations 
within the islet groups, mRNA quantification of glucagon (GCG), insulin (INS), 
somatostatin (SST), pancreatic polypeptide (PPY) and ghrelin (GHRL) was performed 
(Figure 3.4.1). All aforementioned peptides were expressed at the mRNA level within 
each islet population, thus confirming the presence of the endocrine cell populations 
within each islet group. 
 
Figure 3.4.1 mRNA confirmation of endocrine cell presence within islet groups. 
The presence of α-, β-, δ-, PP- and ε-cells endocrine cells were confirmed by the 
detection of GCG, INS, SST, PPY and GHRL mRNA expression respectively. Data 
expressed as mean + SEM relative to GAPDH expression, from four biological 
replicates. 
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3.4.2 GPCR mRNA expression analysis in human and mouse islets 
Expression of 376 human GPCR mRNAs and 335 mouse orthologous counterparts 
relative to the house keeping gene GAPDH in both human and mouse islets has been 
organised alphabetically into receptor families as illustrated below.
Chapter 3 – GPCRome comparison 
96 
 
Chapter 3 – GPCRome comparison 
97 
 

















































Chapter 3 – GPCRome comparison 
104 
 
Chapter 3 – GPCRome comparison 
105 
 


















































Chapter 3 – GPCRome comparison 
114 
 
Chapter 3 – GPCRome comparison 
115 
 

































Chapter 3 – GPCRome comparison 
122 
 
Chapter 3 – GPCRome comparison 
123 
 











Figure 3.4.2 Column plots of GPCR mRNA expression in human and mouse 
islets. Receptor mRNA expression data are grouped within GPCR subfamilies and 
arranged in alphabetical order. Data are expressed as mean + SEM relative to GAPDH 
expression, from four biological replicates for all islet groups. T = trace expression, A 
= absent expression. 
qPCR analyses revealed that of the 376 human GPCR mRNAs screened for expression 
in human islets, 221 (59%) were expressed and quantified, 63 (17%) were present at 
non-quantifiable trace levels and 92 (24%) were absent (Figure 3.4.3). 




Figure 3.4.3 Proportional analysis of GPCR mRNA expression in human islets 
 
Figure 3.4.4 Proportional analysis of GPCR mRNA expression in ICR mouse 
islets 
 
Figure 3.4.5 Proportional analysis of GPCR mRNA expression in C57 mouse 
islets 
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Of the 335 mouse GPCR orthologues screened for expression in ICR mouse islets, 
167 (50%) were expressed and quantified, 114 (34%) were expressed at non-
quantifiable trace levels and 54 (16%) were absent (Figure 3.4.4). This compares 
similarly with the C57 mouse islets where 163 (49%) were expressed and quantified, 
67 (20%) expressed at non-quantifiable levels and 105 (31%) that were not detected 
(Figure 3.4.5). 
The mRNA expression data for each islet group were re-plotted as dot plots and 
tabulated to create a rank order of GPCR expression. This revealed that within human 
islets, the top ten highest expressed GPCRs were GPR56, CASR, GPR119, LPNH1, 
FFAR1 (GPR40), ELTD1, GLP1R, GPRC5B, HTR1F and GPRC5C (Figure 3.4.6). 
The top ten highest expressed GPCRs in ICR mouse islets were revealed as Gpr56, 
Glp1r, Cckar, Gpr158, Gabbr2, Galr1, Ffar1 (Gpr40), Gprc5c, Fzd3 and Calcrl (Figure 
3.4.7). Within C57 mouse islets Glp1r, Gpr56, Gpr158, Cckar, Gabbr2, Ffar1 (Gpr40), 
Gipr, Gprc5c, Galr1 and Galr3 were ranked as the top ten highest expressed GPCRs 
(Figure 3.4.8). 
Table 3.4.1 Rank order of the top highest expressed GPCRs in human and mouse 
islets. GPCRs ranked in order of expression with expression compared to the total 
GPCR expression within each islet group. 
Rank 
















1 GPR56 13.9 Gpr56 18.7 Glp1r 21.0 
2 CASR 10.5 Glp1R 16.6 Gpr56 20.1 
3 GPR119 6.2 Cckar 6.6 Gpr158 9.0 
4 LPHN1 5.6 Gpr158 4.2 Cckar 3.9 
5 FFAR1 4.5 Gabbr2 2.5 Gabbr2 3.0 
6 ELTD1 3.0 Galr1 2.4 Ffar1 2.6 
7 GLP1R 2.3 Ffar1 2.3 Gipr 2.6 
8 GPRC5B 2.2 Gprc5c 2.2 Gprc5c 1.9 
9 HTR1F 2.2 Fzd3 1.8 Galr1 1.7 
10 GPRC5C 2.0 Calcrl 1.7 Galr3 1.7 
 





Figure 3.4.6 A dot plot representing the mRNA expression of 376 GPCRs in 
human islets. Data expressed as mean expression relative to GAPDH from four 
biological replicates. 
 





Figure 3.4.7 A dot plot representing the mRNA expression of 335 mouse 
orthologue GPCRs in ICR mouse islets. Data expressed as mean expression relative 
to Gapdh from four biological replicates. 
 
 





Figure 3.4.8 A dot plot representing the mRNA expression of 335 mouse 
orthologue GPCRs in C57 mouse islets. Data expressed as mean expression relative 
to Gapdh from four biological replicates. 
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3.4.3 A comparison of human and mouse islet GPCR expression profiles 
A comparison of orthologue GPCR expression between the islets groups was 
performed using regression analysis and quantified by defining a coefficient of 
determination (r2). In order to incorporate the absent and trace expressed GPCRs, 
which could not be reliably quantified relative to the housekeeping gene GAPDH, into 
the r2 calculation, the trace and absent expressed GPCRs were assigned an expression 
value of 0.00001 and 0.000001 relative to GAPDH respectively. 
A comparison of GPCR expression between human islets and mouse ICR islets 
revealed a reasonable degree of similarity with an r2 value of 0.360 determined (Figure 
3.4.9). Similarly, an r2 value of 0.304 was determined when comparing GPCR 
expression between human and C57 mouse islets (Figure 3.4.10). A high degree of 
similarity was observed between both the inbred and outbred mouse strains as 
indicated by an r2 value of 0.946 (Figure 3.4.11). 
Further analysis of the GPCR expression profiles within human and mouse islets 
revealed that of the 335 GPCR orthologues screened, 190 GPCRs were commonly 
expressed in human and both strains of mouse islets (Figure 3.4.12), a list of which 
can be found in Table 3.4.2. Species and mouse strain specific differences in GPCR 
expression were also observed within the islet groups, with 26, 24 and 3 GPCRs 
exclusively expressed within human, ICR and C57 islets respectively (Table 3.4.3). 






Figure 3.4.9 Regression analysis of orthologue GPCR expression between human 
and ICR mouse islets. A coefficient of determination (r2) of 0.360 was determined. 
Data expressed as mean expression relative to GAPDH from four biological replicates. 






Figure 3.4.10 Regression analysis of orthologue GPCR expression between 
human and C57 mouse islets. A coefficient of determination (r2) of 0.304 was 
determined. Data expressed as mean expression relative to GAPDH from four 
biological replicates. 






Figure 3.4.11 Regression analysis of orthologue GPCR expression between ICR 
and C57 mouse islets. A coefficient of determination (r2) of 0.946 was determined. 
Data expressed as mean expression relative to GAPDH from four biological replicates. 
 






Figure 3.4.12 Venn diagram of orthologue GPCR expression in human and 
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Table 3.4.2 A table of 190 commonly expressed GPCRs in human and mouse 
islets. Data arranged in rank order of expression within human islets. 
Rank  Rank  Rank  Rank  
1 GPR56 49 LPHN2 97 CYSLTR1 145 GPR98 
2 CASR 50 FZD3 98 PRLHR 146 ACKR1 
3 GPR119 51 GPR39 99 CCRL2 147 ADORA2B 
4 LPHN1 52 GIPR 100 CX3CR1 148 GPR182 
5 FFAR1 53 C5AR1 101 BDKRB2 149 FZD9 
6 ELTD1 54 GPR75 102 GPR22 150 GPR132 
7 GLP1R 55 CHRM3 103 GPRC5A 151 TACR3 
8 GPRC5B 56 ADORA1 104 GPR157 152 HCRTR1 
9 GPRC5C 57 FZD4 105 SMO 153 GPR64 
10 ADORA2A 58 LPAR2 106 FZD7 154 GPR152 
11 GPR4 59 GPER 107 OPN3 155 NPBWR1 
12 EDNRA 60 GPR158 108 F2RL2 156 S1PR3 
13 GPR142 61 FPR3 109 BAI3 157 ADORA3 
14 FZD6 62 S1PR1 110 P2RY6 158 GPR85 
15 SCTR 63 F2RL3 111 P2RY12 159 CELSR1 
16 ADRA2A 64 CRHR2 112 GPR153 160 GPRC6A 
17 GPR19 65 TBXA2R 113 GPBAR1 161 CRHR1 
18 VIPR1 66 GPR162 114 LPAR5 162 GPR45 
19 FZD1 67 GPR37 115 FFAR3 163 GPR87 
20 GPR124 68 CXCR7 116 P2RY2 164 APLNR 
21 AVPR1B 69 AGTR1 117 KISS1R 165 CHRM2 
22 CCKAR 70 DRD2 118 GPR133 166 OPRL1 
23 EDNRB 71 ADRB1 119 GALR1 167 ADCYAP1R1 
24 CXCR4 72 GPR123 120 LGR5 168 GPR62 
25 GPR27 73 GPR52 121 LPAR4 169 CCR10 
26 GPR135 74 CELSR3 122 CHRM4 170 CHRM1 
27 ADRA2C 75 GPR146 123 GPR21 171 GPR151 
28 GHSR 76 PTGFR 124 GPR173 172 GPR150 
29 F2R 77 GPR179 125 FFAR2 173 XCR1 
30 GPR126 78 GPR34 126 PTH1R 174 FZD2 
31 F2RL1 79 AVPR1A 127 LPAR3 175 CCR3 
32 SSTR2 80 GPR160 128 NPY1R 176 HTR1B 
33 SSTR1 81 P2RY14 129 SSTR4 177 GPR37L1 
34 GPR125 82 ADRB2 130 S1PR2 178 ADRA1D 
35 P2RY1 83 C3AR1 131 PTGER1 179 BAI1 
36 BRS3 84 P2RY13 132 MRGPRE 180 BAI2 
37 GCGR 85 GPR183 133 FZD8 181 CCR1 
38 LPAR1 86 PTAFR 134 GABBR2 182 CCR4 
39 GPR116 87 CCKBR 135 GRPR 183 CXCR5 
40 GABBR1 88 SUCNR1 136 NPFFR2 184 GPR26 
41 CALCRL 89 BDKRB1 137 NMBR 185 GRM7 
42 PTGER4 90 CNR1 138 ADRA2B 186 HTR1A 
43 FZD5 91 GPR3 139 GRM8 187 LGR6 
44 GPR44 92 VIPR2 140 CMKLR1 188 MCHR1 
45 GPR120 93 CELSR2 141 OXTR 189 TACR1 
46 LGR4 94 CD97 142 TAS1R3 190 UTS2R 
47 GPR161 95 S1PR5 143 TAAR1   
48 PTGER3 96 PTGIR 144 LTB4R   
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Table 3.4.3 A table of tissue specific GPCR expression in human and mouse islets. 
Data depicted represents orthologue GPCRs expressed at trace (italics) levels and 
above and arranged in rank order of expression level. 
Expression rank Human islets ICR islets C57 islets 
1 HTR1F Oprk1 Gpr65 
2 GRM4 Gpr101 Npffr1 
3 GPR63 Ackr2 Taar2 
4 OPRM1 Adrb3  
5 CXCR6 Chrm5  
6 GPR113 Ccxr11  
7 GPR143 Drd3  
8 GPRC5D Fpr1  
9 GPR68 Gpr111  
10 GNRHR Gpr141  
11 GPR82 Gpr17  
12 DRD4 Gpr174  
13 PTGER2 Gpr18  
14 GPR115 Grm5  
15 MTNR1B Hrh2  
16 NMUR1 Htr2b  
17 PTH2R Mc2r  
18 NPY5R Mc3r  
19 CALCR Mrgprx2  
20 GPR1 Npy2r  
21 GPR83 Ntsr2  
22 MRGPRD P2ry10  
23 NMUR2 Prokr1  
24 PPYR1 Tshr  
25 PTGDR   











In order to highlight GPCRs that have been proposed to be of interest as therapeutic 
targets for the treatment of T2DM and to assess the suitability of using mouse islets to 
study such targets, a regression analysis plot comparing GPCR mRNA expression 
between human and ICR mouse islets was generated (Figure 3.4.13). These data 
indicate that of the 284 GPCRs that are expressed within human islets at trace level 
and above, only 1 GPCR (GLP1R), which is also highly expressed within mouse islets, 
has had clinical success. Only 2 other GPCRs, FFAR1 and GPR119, have undergone 
clinical investigation and like in human islets are also expressed highly in mouse islets. 
The data provided here allow the identification of 14 GPCRs that have suitable 
characteristics as potential targets for T2DM therapy and are highlighted by red dots 
in Figure 3.4.13: GPR56, GIPR, GPR120, GCGR, GPRC5B, CNR1, FFAR3, FFAR2, 
KISS1R, GPR75, NPY1R, GPBAR1, GPR55 and CNR2. It is interesting to note that 
these potential GPCR targets are expressed in both mouse and human islets at similar 
levels (r2 = 0.531). Table 3.4.4 summarises the functional relevance of the 14 GPCRs 
as targets for T2DM. 






Figure 3.4.13 Identification of GPCR targets of interest for the treatment of 
T2DM. Green dots indicate clinically successful targets, blue dots indicate GPCRs 
currently under clinical investigation and red dots are GPCRs proposed to have clinical 
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Table 3.4.4 A table GPCR targets with potential therapeutic benefit for T2DM. 












↑ insulin Unpublished 
data 
GIPR GIP α, β and σ cells, 
adipose tissue 
↑ insulin, 
↑ glucagon,  





Long-chain NEFA Enteroendocrine 
cells, β- and σ-
cells 
↑ GLP-1,  
↑ GIP,  
↓somatostatin, 
↓ ghrelin 
(Stone et al., 
2014) 
GCGR Glucagon, oxyntomodulin β-cells, liver, 
adipose, brain 
↑ insulin,  
↑ energy 




GPRC5B Unknown High expression 
in islets, adipose 











CNS, β-cells ↑ insulin (Li et al., 
2010) 
FFAR3 Short chain fatty acids β-cells, spleen, 
lymph node, bone 
marrow, adipose 
tissue 
↓ insulin (Tang et al., 
2015) 
FFAR2 Short chain fatty acids β-cells, 
monocytes, 
adipose tissue 









↑ insulin (Bowe et al., 
2012) 
GPR75 CCL5 α- and β-cells, 
brain 





(Liu et al., 
2013) 










GPBAR1 Bile acids Enteroendocrine 
cells, adipose 
tissue 
↑ GLP-1,  
↑ energy 
expenditure 
(Duan et al., 
2015) 















↑ insulin (Li et al., 
2010) 
 




G-protein coupled receptors play an important role in regulating islet function by 
mediating the actions of various stimuli such as nutrients, bile acids, gut hormones and 
neurotransmitters (Reimann and Gribble, 2016) and as a result have been targeted by 
therapeutics for the treatment of T2DM. However, despite the expression of nearly 
300 GPCRs within islets (Amisten et al., 2013), only the GLP-1 receptor (GLP1R) has 
been clinically successful, whilst only two other GPCRs have undergone clinical 
assessment, FFAR1 and GLP119 (Oh da and Olefsky, 2016). Part of the reason for 
this limited success could be due to the restricted availability of human islets required 
to assess GPCR-mediated islet function, thus subsequently resulting in the reliance on 
cell lines and animal tissue to predict human islet physiology. The most common tissue 
used for predicting human islet function are mouse islets, but studies have identified 
gene expression differences between mouse and human islets (Kutlu et al., 2009), (Dai 
et al., 2012), (Benner et al., 2014), which raises questions as to the suitability of using 
mouse islets in predicting the human islet setting. 
The experiments described within this chapter were designed to compare the GPCR 
mRNA expression profiles between human islets and islets isolated from two strains 
of mice to assess the suitability of using mouse islets as surrogate models for human 
islet GPCR studies. Due to the large volume of data that is included within this chapter, 
results will be discussed in sections with respect to the aims of the study; 1) Reveal 
the GPCR expression profiles within human and mouse islets, 2) Compare the GPCR 
expression profiles between mouse and human islets and 3) Assess the suitability of 
using mouse islets to assess the function of newly identified GPCR targets for the 
treatment of T2DM. 
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Reveal the human and mouse islet GPCRomes 
Gene expression analysis revealed that a high proportion of total non-odorant GPCRs 
are expressed within the islets of Langerhans in both human and mouse islets. Of the 
376 GPCRs assessed for expression within human islets, 284 GPCR mRNAs (75%) 
were shown to be expressed by human islets, whereas of the 335 mouse orthologue 
GPCR genes screened in mouse islets, 281 (84%) GPCRs were identified in ICR 
mouse islets and 230 (67%) were expressed in C57 mouse islets. It is well documented 
that GPCRs play an important role in regulating biological processes by mediating the 
activation of intracellular signalling pathways following stimulation by extracellular 
stimuli, and thus the revelation that both human and mouse islets express a high 
proportion non-odorant GPCRs highlights the complexity and variety of ways by 
which islet function is regulated. For example, islet function is regulated by neural 
input from the CNS, by gastrointestinal peptides, bile acids and also circulating 
nutrients, fatty acids and amino acids, all of which have the ability to regulate islet 
function through GPCR-mediated mechanisms (Reimann and Gribble, 2016). It is 
therefore unsurprising that a large number and variety of GPCRs are required to 
respond to this diverse array of physiological inputs.  
However, what is particularly interesting is that whilst islets express a high percentage 
of non-odorant GPCRs that are available within the genome, the number of potential 
intracellular signalling pathways through which GPCRs couple is limited. Whilst the 
abundance of islet receptor expression compared to the limited number of pathways 
that could potentially be activated may seem excessive, it does highlight the variety of 
scenarios in which islets may be stimulated in order to maintain the primary function 
of regulating glucose homeostasis. For example, not only do islets respond to inputs 
during food intake, but also in situations of stress, pregnancy and during development. 
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Furthermore, the islet is a multicellular micro-organ comprised of a variety of different 
cell populations, such as the endocrine α-, β-, δ-cells, and cells of the intra-islet 
vasculature. Each cell population is responsible for mediating numerous unique 
functions that are regulated by specific GPCR mechanisms, thus contributing to the 
variety and abundance of receptor expression observed within the islet. 
 
Compare GPCRomes between human and mouse islets 
In addition to revealing the GPCR expression profiles within human and mouse islets, 
a principle aim of this chapter was to compare GPCR mRNA expression profiles 
between species. Before undertaking such studies, it was postulated that a certain 
degree of difference in GPCR gene expression would be observed between mouse and 
human islets due to the already documented differences in the number of non-odorant 
GPCRs that exists in the mouse compared to the human genome, 495 compared to 400 
respectively (Bjarnadottir et al., 2006). In addition, it has been revealed that the islet 
architecture also differs between the species, with mouse islets being comprised of β-
cells that are arranged in a central core surrounded by a mantle of α-cells and δ-cells, 
whereas the arrangement of such cells within human islets is less defined and found 
to be more interspersed with each other (Cabrera et al., 2006). Furthermore, the 
proportions of endocrine cells that reside within islets also differs between the two 
species. The proportion of α-, β-, δ-cells within the human islet is approximately 40, 
50, 10% respectively, whereas in mouse islets the proportions are approximately 15-
20, 60-80, 10% respectively (Steiner et al., 2010). However, whilst it can be postulated 
that differences in islet GPCR gene expression may exist between species, a 
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quantitative assessment of such GPCR expression differences between species, as well 
as between islets from different mouse strains, has not been revealed. 
For the purpose of comparing and quantifying the GPCR mRNA expression between 
islet groups, regression analysis was performed. A comparison of the GPCR 
expression profiles between the two mouse strains revealed a high degree of similarity, 
with an r2 value of 0.946 (Figure 3.4.11), despite C57 mice expressing 52 fewer 
GPCRs than their outbred counterpart (Figure 3.4.5). A comparison of the GPCR 
expression profiles between human islets and islets from the ICR and C57 mouse 
strains revealed a greater degree of difference, with r2 values of 0.360 and 0.304 
determined respectively (Figure 3.4.10, Figure 3.4.11). This observation was further 
emphasised by the revelation that human islets express 26 GPCRs that are not 
expressed by either mouse strains (Table 3.4.3). The observation that the degree of 
similarity in overall GPCR expression in human islets is more similar to that of the 
ICR strain than the C57 strain is likely to be due to the fact that human and ICR mouse 
islets share 227 commonly expressed GPCRs whereas human islets only share 197 
with C57 mouse islets. An additional contributing factor is likely to be the degree of 
genetic variability between the two mouse strains, as one would presume that a greater 
degree of gene expression variability is likely to be observed within the outbred ICR 
strain. This degree of genetic variability between biological replicates of the ICR strain 
could result in a greater degree of inconsistency in expression compared to the C57 
strain, thus preferentially skewing the data in favour of using ICR islets as suitable 
surrogate models for human islet studies. Furthermore, the use of outbred models is 
likely to introduce a degree of genetic variability consistent with the human situation 
and thus more translationally relevant. 
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With regards to species- and mouse strain-specific receptor expression, 26 orthologue 
GPCRs were shown to be specifically expressed in human islets, 24 specifically 
expressed in ICR mouse islets and 3 in C57 mouse islets (Figure 3.4.12). Of the 26 
GPCRs that are exclusively expressed in human islets, HTR1F was identified as the 
most abundantly expressed. In recent years, serotonin has received interest with 
regards to the functional adaptation of β-cells during pregnancy, in particular the 
ability of mouse β-cells to secrete serotonin during pregnancy (Goyvaerts et al., 2016), 
(Ohara-Imaizumi et al., 2013). However, the use of mouse islets to predict the 
functional effects of serotonin in human islets ought to consider the disparity in 
expression of the HTR1F receptor between human and mouse islets, as the full 
functional effects of serotonin may not be revealed when using mouse islets should 
the HTR1F receptor modulate islet function. In addition to HTR1F, further examples 
of GPCRs that are exclusively expressed in human islets include DRD4, GRM4, 
GPR143 and OPRM1. Besides the effects of receptor expression exclusivity, a degree 
of enrichment of GPCR expression within human islets compared to mouse islets may 
also have contributed to the low correlation values determined by regression analysis. 
Examples of receptors with enriched expression in human islets include BRS3, FPR3, 
FZD1, SCTR and OPRD1. Interestingly though, whilst BRS3 mRNA expression is 
enriched in human islets by a factor of >500, functional studies have demonstrated 
that pharmacological agonism of BRS3 promotes glucose-induced insulin secretion 
from both isolated mouse and human islets (Feng et al., 2011). These findings suggest 
that while mRNA expression is an indicator of receptor involvement in tissue function, 
follow up functional studies are still required to fully confirm such predictions. 
Further to human islet-specific expression, examples of mouse islet-specific GPCR 
expression was also observed and include, Galr2, Galr3 and Crhr1. Galr2, Galr3 were 
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shown to be exclusively expressed within mouse islets whereas, Crhr1 was shown to 
be enriched in mouse islets. Increased plasma levels of galanin and reduced galanin 
receptor expression have been reported in T2DM, and this state of galanin resistance 
has been shown to positively correlate with insulin resistance (Fang et al., 2016). 
However, the difference in galanin receptor mRNA expression between mouse and 
human islets may require the use of a more suitable surrogate model in order to fully 
understand the involvement of galanin in the pathophysiology of T2DM in humans. 
The corticotropin-releasing hormone (CRH) system has also received attention with 
regards to islet function following the revelation that UCN3 is expressed by β-cells 
and activates a negative feedback loop that promotes somatostatin release to inhibit 
glucose-induced insulin secretion upon normalisation of blood glucose (van der 
Meulen et al., 2015). Additionally, CRH promotes glucose-induced insulin secretion 
and proliferation of rat β-cells through the activation of the CRH1 receptor (Huising 
et al., 2010). However, only trace level expression of the CRH1 receptor was observed 
in human islets suggesting that CRH-mediated increases in glucose-stimulated insulin 
secretion via the CRH1 receptor in rat islets may not be observed in human islets. 
Differences in GPCR mRNA expression were also observed between the mouse 
strains. Of particular interest is the SSTR3 receptor, which was revealed to be 
exclusively expressed in the islets of the C57 mouse strain. Evidence of disparities in 
somatostatin receptor subtype expression between rodent species have been reported 
previously. Interestingly however, in the same study, both absence and presence of the 
SSTR3 receptor was observed between islets of individual mice from the same 
population of C57 mice (Ludvigsen et al., 2004). Reasons for such differences are 
unlikely to be due to genetic background due to the fact that such intra-species 
differences are observed in the genetically stable inbred C57 strain, thus suggesting 
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that SSTR3 receptor expression may be regulated. The regulation of SSTR3 
expression has previously been reported in neuronal cilia, whereby agonist treatment 
with somatostatin decreases SSTR3 expression via a β-arrestin-dependent mechanism 
(Green et al., 2016). Interestingly, the expression of SSTR3 is suggested to be 
restricted to the primary cilia within islets (Iwanaga et al., 2011) and therefore, like 
within neuronal cilia, its expression may also be regulated by somatostatin. This 
dynamic expression of SSTR3 may account for the expression differences observed 
between islets. Based on our findings and published studies, understanding the role of 
the poorly characterised SSTR3 in islet function may be impeded not only by inter-
species variabilities but also intra-species variabilities in SSTR3 islet expression. 
Whilst exclusivity in GPCR expression was observed between islet groups, a large 
proportion of GPCR mRNAs were commonly expressed by both human islets and 
both strains of mouse islets, 190 (57%) in total (Figure 3.4.12). Of the 190 commonly 
expressed GPCRs, genes encoding the ‘classic’ T2DM receptor targets GLP1R, 
FFAR1 and GPR119 were shown to be highly expressed, highlighting the suitability 
of using mouse islets to further evaluate the pharmacological properties of novel 
therapeutics for these receptors. In addition to the ‘classic’ T2DM receptors, a number 
of proposed novel targets were also shown to be commonly expressed as indicated in 
(Table 3.4.4). These receptors will be discussed further in the following section. 
 
The suitability of using mouse islets as surrogate models to assess the function of 
novel T2DM GPCR targets in human islet function 
The final aim of this chapter was to assess the suitability of using mouse islets to 
further explore the role of potential T2DM GPCR targets in human islet function. The 
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expression levels of 14 GPCR targets (Table 3.4.4) were compared in human and ICR 
mouse islets using a correlation plot (Figure 3.4.13). The data revealed a coefficient 
of determination of r2 = 0.531, signifying a reasonable degree of similarity in 
expression between both human and mouse islets, suggesting that mouse islets may 
well be suited to predict the function of such GPCRs in human islets. However, it is 
important to note that expression comparisons should be performed for each GPCR to 
give a true indication of whether mouse islets are suitable for the prediction of GPCR 
function for the particular target of interest, as global regression analysis of multiple 
targets can mask the suitability of using mouse islets for specific targets of interest. It 
is also possible that although mRNA expression within the whole islet may be similar 
between species, differences in cell specific expression between islets of different 
species may exist, which may be of importance when assessing the suitability of 
assessing the functional role of GPCRs when using translation models. 
Summary and future perspectives 
In summary, the experiments and analyses described in this chapter reveal 1) the 
mRNA expression profiles of most non-odorant GPCRs in human and mouse islets, 
2) compare GPCR expression profiles to highlight similarities and differences in 
GPCR expression between human and mouse islets and 3) assess whether mouse islets 
are suitable for assessing the function of novel GPCR targets in human islets based on 
expression levels. 
The data generated in this chapter provides a comprehensive insight into the suitability 
of using mouse islets as surrogate tissue for human islet GPCR studies based on 
mRNA expression. However, there are limitations to this form of assessment that need 
to be considered. Firstly, the data presented does not include non-orthologue receptors 
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which may be present but were not screened. The mouse genome contains 95 extra 
non-odorant GPCRs which were not quantified and thus the degree of tissue-specific 
differences are likely to be underestimated. Furthermore, GPCR expression 
comparisons were based on mRNA expression and not protein, and thus does not take 
into account whether actual functional protein is expressed. Factors such as whether 
the actual protein is synthesised, undergoes post-translational modification, localises 
to the plasma membrane or whether cellular machinery required for protein function 
is present, cannot be determined by mRNA expression analysis. In addition, gene 
expression analysis is performed on whole islets which are comprised of multiple cells 
types and thus further analysis, such as single cell PCR, FACS purification of 
endocrine cell populations or immunohistochemistry is required to determine the cells 
in which the GPCRs are expressed. An added complication to performing such 
comparative analyses with whole islets is that the cell population proportions differ 
between both human and mouse islets. For example, the proportion of β-cells in human 
islets is less than that observed in mouse islets and therefore the expression levels of 
GPCRs by the β-cells of human islets are automatically likely to show reduced 
expression compared to mouse islets.  
Thus, whilst there are limitations to this form of analysis, the data generated provide 
a substantial amount of information that can be utilised as a foundation for further 
enhancing our knowledge of the role of GPCRs in human islet function using mouse 
islets as translational models.
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G-protein coupled receptors are important regulators of islet function and they do so 
by mediating the actions of a variety of ligand classes, such as neurotransmitters, 
nutrients, bile acids, divalent cations and peptide ligands (Reimann and Gribble, 
2016). Previous studies have revealed that approximately 30% of all GPCRs expressed 
on human islets are activated by peptide ligands and that approximately 50% of all 
peptide ligands are expressed within islets (Amisten et al., 2013). Such intra-islet 
GPCR peptide ligands include the ‘classic’ examples of glucagon and somatostatin 
but additional peptides such as PYY (Persaud and Bewick, 2014), KISS1 (Hauge-
Evans et al., 2006), and UCN3 (van der Meulen et al., 2015) have also been shown to 
be expressed and exhibit a role in islet function. 
Since the emergence of gene expression analysis techniques such as RNA sequencing, 
microarray and qPCR, increasing information has been gathered on tissue specific 
gene expression and such data have been utilised to identify genes encoding proteins 
which may play key roles in tissue function. However, understanding the function of 
such proteins in human tissues is highly dependent on tissue availability, and in the 
event of limited supply of human tissue, surrogate tissue from model animals is 
required. However, differences in islet gene expression (Dai et al., 2012) and islet 
architecture (Cabrera et al., 2006) between human and rodent islets have been 
documented, thus questioning the suitability of such translational models. 
The experiments described in this chapter aim to compare the mRNA expression 
profiles of GPCR-peptide ligands (‘Secretomes’) in human islets with those of islets 
from the outbred ICR and the inbred C57/BL/6 (C57) mouse strains in order to assess 
whether mouse islets can be used as a suitable translational model to evaluate GPCR 
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peptide ligand function in human islets. In addition, the data generated within this 
chapter will form the basis for novel exploratory projects aimed at assessing the role 




















 Quantify the mRNA expression of GPCR peptide ligands in human islets and 
their orthologue counterparts in islets isolated from the outbred ICR and the 
inbred C57/BL6 mouse strains. 
 Compare the GPCR peptide ligand expression profiles of human and mouse 
islets and highlight species differences and similarities. 
 Identify GPCR peptide ligands of interest for future projects aimed at assessing 
















4.3.1 Gene expression analysis 
Human and mouse islet ‘Secretomes’ were determined by qPCR using Qiagen’s 
QuantiTect primers and QuantiFast SYBR green mastermix. 159 GPCR peptide 
ligands and 145 mouse orthologues were screened for expression. The mRNA 
expression of 14 genes could not be determined due to primer unavailability or because 
mouse orthologues of human GPCR peptide ligand genes do not exist. 
4.3.1.1 Isolation of human and mouse islets for mRNA quantification 
As described in section 2.2.1, human islets were isolated from pancreases retrieved 
from four heart beating donors (2 male, 2 female) at the Islet Transplantation Units at 
King’s College London, using a revised version of (Huang et al., 2004) the Edmonton 
protocol. The donors were between the ages of 43-59, were non-diabetic and had a 
BMI of 22-33kg/m2. 
Mouse islets were isolated in-house from male adult ICR and C57/BL6 mice aged 8-
12 weeks as described in section 2.2.2. Approximately 200 isolated mouse and human 
islets per biological replicate were handpicked, dissolved in 1ml of TRIzol for 5mins 
before being stored at -80oC awaiting RNA extraction and cDNA generation. 
4.3.1.2 cDNA generation 
Quantitative real time polymerase chain reaction (qPCR) was performed using the two 
step approach which requires the generation of cDNA prior to performing the qPCR. 
Firstly, total RNA was extracted from previously TRIzol harvested tissue as described 
in detail in section 2.3.1 and further purified and concentrated using Qiagen’s RNeasy 
MiniElute Cleanup kit (section 2.3.2). The purified mRNA was then quantified as 
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described in section 2.3.3 and reversed transcribed into cDNA using the TaqMan 
Reverse Transcription kit (section 2.3.4). 
 
4.3.1.3 Quantitative real time polymerase chain reaction 
qPCR was performed using Qiagen’s QuantiTect primers, Quantifast SYBR green 
master mix and the Roche LightCycler 480 using the settings described in section 
2.3.5. GPCR peptide ligand expression data are represented as expression relative to 














4.4.1 mRNA expression analysis of GPCR peptide ligands in human and mouse 
islets 
The mRNA expression of 159 human GPCR peptide ligands and their mouse 
orthologous counterparts (145 in total) relative to the house keeping gene GAPDH in 
both human and mouse islets was quantified. Expression of islet peptide ligand family 
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Figure 4.4.1 Column plots of GPCR peptide ligand mRNA expression in human 
and mouse islets. Expression data are grouped into peptide families and arranged in 
alphabetical order. Data are expressed as mean + SEM relative to the mRNA 
expression of GAPDH, from four biological replicates for each islet group. T = trace 
expression, A = absent expression. 
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Analysis of GPCR peptide ligand mRNA expression revealed that of the 159 genes 
screened in human islets, 85 (53%) genes were expressed and quantified, 43 (27%) 
were present at non-quantifiable trace levels (i.e <0.001% of the mRNA expression of 
GAPDH) and 31 (20%) were absent (Figure 4.4.2). Of the 145 mouse GPCR peptide 
ligand orthologues screened for expression in ICR mouse islets, 61 (42%) were 
expressed and quantified, 48 (33%) were expressed at trace level and 36 (25%) were 
absent (Figure 4.4.3). In C57 mouse islets, 61 (42%) peptide ligands were expressed 
and quantified, 25 (17%) were expressed at trace level whilst 59 (41%) were absent 
(Figure 4.4.4). 
To highlight the rank order of GPCR peptide ligand expression, mRNA expression dot 
plots were generated for each islet group. Within human islets, the top ten highest 
expressed GPCR peptide ligands were GCG, SST, IAPP, C1QL1, NPY, IL8, GHRL, 
AGT, PPY and UCN3 (Figure 4.4.5). In ICR mouse islets, the ten highest expressed 
peptide ligands were Iapp, Gcg, Sst, Ppy, Pyy, Ucn3, Pdyn, Rspo4, Npy and Col4a 
(Figure 4.4.6), whereas in C57 mouse islets the ten highest expressing peptide ligands 
were Iapp, Gcg, Ppy, Sst, Pyy, Ucn3, Rspo4, Pdyn, Wnt4 and Col4a (Figure 4.4.7). A 
summary of this information can be found in Table 4.4.1. 
 




Figure 4.4.2 Proportional analysis of GPCR peptide ligand mRNA expression in 
human islets. 
 
Figure 4.4.3 Proportional analysis of orthologue GPCR peptide ligand mRNA 
expression in ICR mouse islets. 
 
Figure 4.4.4 Proportional analysis of orthologue GPCR peptide ligand mRNA 
expression in C57 mouse islets. 
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Table 4.4.1 Rank order of the top ten highest expressed orthologue GPCR peptide 
ligand mRNAs in human and mouse islets. % total indicates expression as a percent 
of total GPCR peptide ligand expression relative to GAPDH mRNA. 
 Human ICR C57 












1 GCG 71.28 Iapp 41.42 Iapp 48.73 
2 SST 21.28 Gcg 21.78 Gcg 25.05 
3 IAPP 1.47 Sst 14.46 Ppy 10.04 
4 C1QL1 0.92 Ppy 14.40 Sst 8.38 
5 NPY 0.57 Pyy 5.89 Pyy 6.51 
6 IL8 0.43 Ucn3 0.49 Ucn3 0.55 
7 GHRL 0.31 Pdyn 0.31 Rspo4 0.23 
8 AGT 0.24 Rspo4 0.20 Pdyn 0.09 
9 PPY 0.23 Npy 0.17 Wnt4 0.06 









Figure 4.4.5 A dot plot representing the mRNA expression of 159 GPCR peptide 
ligands in human islets. Data are expressed as mean expression relative to GAPDH 
from four biological replicates. 





Figure 4.4.6 A dot plot representing the mRNA expression of 145 orthologue 
GPCR peptide ligands in ICR mouse islets. Data are expressed as mean expression 
relative to Gapdh from four biological replicates. 





Figure 4.4.7 A dot plot representing the mRNA expression of 145 orthologue 
GPCR peptide ligands in C57 mouse islets. Data are expressed as mean expression 
relative to Gapdh from four biological replicates. 
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4.4.2 A comparison of GPCR peptide ligand expression profiles between human 
and mouse islets. 
A comparison of orthologue GPCR peptide ligand mRNA expression profiles between 
the islets groups was performed using regression analysis and quantified by defining 
a coefficient of determination (r2). In order to incorporate the absent and trace 
expressed peptides, which could not be reliably quantified relative to the house 
keeping gene GAPDH, into the r2 calculation, the trace and absent expressed peptides 
were assigned expression values of 0.00001 and 0.000001 relative to GAPDH 
respectively. 
A linear regression comparison of GPCR peptide ligand expression between human 
and the mouse ICR islets revealed a low degree of similarity with an r2 value of 0.245 
(Figure 4.4.8). Similarly, an r2 value of 0.225 was determined when comparing GPCR 
peptide ligand expression between human and C57 mouse islets (Figure 4.4.9). A high 
degree of similarity in GPCR peptide ligand expression was observed between the 
inbred and outbred mouse strains as indicated by an r2 value of 0.968 (Figure 4.4.10). 
In order to further quantify the extent of orthologue GPCR peptide ligand expression 
overlap, as well as highlight distinct expression differences between the islet groups, 
Venn analysis was performed (Figure 4.4.11). Of the 145 GPCR peptide ligand 
orthologues screened, 71 GPCR ligands expressed above trace levels were commonly 
expressed in human islets and both strains of mouse islets, a list of which can be found 
in Table 4.4.2. Species and strain specific GPCR peptide ligand mRNA expression 
was also observed within the islet groups with 20, 10 and 2 ligands only expressed 
within human, ICR and C57 islets respectively (Table 4.4.3). 






Figure 4.4.8 Regression analysis of GPCR peptide ligand mRNA expression 
between human and ICR mouse islets. A coefficient of determination (r2) of 0.245 
was determined. Data are expressed as mean expression relative to GAPDH from four 
biological replicates. 






Figure 4.4.9 Regression analysis of GPCR peptide ligand mRNA expression 
between human and C57 mouse islets. A coefficient of determination (r2) of 0.225 
was determined. Data are expressed as mean expression relative to GAPDH from four 
biological replicates. 






Figure 4.4.10 Regression analysis of GPCR peptide ligand mRNA expression 
between ICR mouse islets and C57 mouse islets. A coefficient of determination (r2) 
of 0.968 was determined. Data are expressed as mean expression relative to GAPDH 
from four biological replicates. 
 




Figure 4.4.11 Venn diagram of orthologue GPCR peptide ligand mRNA 
expression in human and mouse islets. The data depicts GPCR peptide ligand 
orthologues expressed at trace level and above. 
 
Table 4.4.2 Commonly expressed GPCR peptide ligand mRNAs in human and 
mouse islets. Data are arranged in rank order of expression within human islets. 
Rank  Rank  Rank  
1 GCG 26 TAC1 51 CXCL10 
2 SST 27 WNT5A 52 VIP 
3 IAPP 28 UCN 53 SCT 
4 C1QL1 29 GAL 54 PYY 
5 NPY 30 PTHLH 55 RSPO4 
6 GHRL 31 CCL28 56 CX3CL1 
7 AGT 32 NPFF 57 COL4A5 
8 PPY 33 NMB 58 PENK 
9 UCN3 34 CARTPT 59 INSL5 
10 C3 35 GNRH1 60 GRP 
11 C4A 36 NPW 61 CALCA 
12 CD55 37 CCL3 62 CCL19 
13 COL3A1 38 CXCL13 63 CCL21 
14 EDN3 39 APLN 64 CXCL4 
15 THY1 40 INSL3 65 PPBP 
16 COL4A1 41 C1QL3 66 EDN2 
17 RARRES2 42 CXCL5 67 PNOC 
18 CXCL16 43 CXCL14 68 AVP 
19 ADCYAP1 44 QRFP 69 CXCL9 
20 WNT4 45 C1QL2 70 GAST 
21 CXCL12 46 CCL5 71 PTH2 
22 COL4A2 47 KISS1   
23 CCL11 48 CCK   
24 ANXA1 49 TAC3   
25 WNT9A 50 WNT11   
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Table 4.4.3 Species- and strain-specific GPCR peptide ligand mRNA expression 
in human and mouse islets. Data depicted include othologue GPCR peptide ligands 
expressed at trace level (italics) and above. 
Rank Human islets ICR islets C57 islets 
1 CRH Ccl17 Hcrt 
2 CCL26 Rspo2 Wnt6 
3 WNT3 C1ql4  
4 CXCL3 Ccl1  
5 RLN1 Galp  
6 COL4A4 Nps  
7 CCL7 Npvf  
8 RSPO3 Tshb  
9 WNT2 Wnt1  
10 LHB Wnt10b  
11 TRH   
12 COL4A6   
13 KNG1   
14 NTS   
15 OXT   
16 PROK2   
17 RSPO1   
18 WNT16   
19 WNT3A   













G-protein-coupled receptors are responsible for regulating islet function by mediating 
the actions of a variety of ligands, which include intra-islet peptides, such as PACAP 
and VIP, and peptides delivered via the systemic circulation following secretion from 
alternative tissues, such as incretins (Ahren, 2000). Due to the importance of peptide 
ligand-mediated GPCR signalling in the regulation of islet function, exploration into 
the role of peptide ligands, in particular incretins, has received much attention with 
regards to identifying novel therapeutic approaches to improve islet function in T2DM 
(Gribble, 2012). The classic example of such an approach is the development of GLP-
1 peptide mimetics, which enhance glucose-stimulated insulin release, reduce elevated 
levels of glucagon, promote β-cell proliferation, reduce β-cell apoptosis, inhibit gastric 
emptying and suppress appetite (Drucker, 2015). However, despite the success of the 
GLP-1 mimetics in the treatment of T2DM, it is the only peptide-GPCR-mediated 
approach that has proven to be clinically successful. Therefore, efforts to identify the 
role of GPCR peptide ligands in islet function and to exploit such novel peptide-
GPCR-mediated mechanisms as potential therapies for T2DM are under investigation 
(Irwin and Flatt, 2015). 
Examples of intra-islet expressed GPCR peptide ligands that are under investigation 
include urocortin-3 (UCN3), ghrelin (GHRL), peptide tyrosine tyrosine (PYY) and 
kisspeptin (KISS1). Urocortin-3 has recently been shown to be abundantly expressed 
in β-cells, is co-released with insulin and causes a reduction in glucose-induced insulin 
secretion by promoting somatostatin release from δ-cells. It is thought that the 
paracrine effects of urocortin-3 activate a negative feedback loop that promotes 
somatostatin release to inhibit glucose-induced insulin secretion (van der Meulen et 
al., 2015). Ghrelin is another peptide ligand that inhibits glucose-induced insulin 
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secretion through a GPCR-mediated mechanism by attenuating intracellular cAMP 
production and PKA activation in β-cells (Dezaki and Yada, 2012). Finally, the gut 
hormone PYY has been shown to be expressed in mouse islets, in particular in α- and 
PP cells (Bottcher et al., 1989), and has received interest due to its regulation of 
appetite, inhibition of glucose-stimulated insulin secretion, whilst exhibiting pro-
proliferative and anti-apoptotic effects on mouse β-cells mediated through the 
activation of NPY1R receptors (Persaud and Bewick, 2014). However, some of the 
studies investigating the role of the aforementioned peptides in islet function have only 
been performed in animal models and thus a knowledge gap exists in the role of such 
peptides in human islet function. 
Understanding the role of GPCR peptide ligands in human islet function is restricted 
by the limited availability of human islets, thus resulting in the reliance on using 
animal islets to predict the human situation. However, it is well documented that 
mouse islets, the typical surrogate tissue, exhibit a different islet architecture (Cabrera 
et al., 2006) and contain different proportions of endocrine cells (Steiner et al., 2010). 
Furthermore, species differences in human and mouse islet gene expression have been 
well documented (Kutlu et al., 2009) (Dai et al., 2012) (Benner et al., 2014), a claim 
that can be supported by the GPCR expression results obtained in the previous chapter. 
Such reported dissimilarities raise questions over the suitability of utilising mouse 
islets as surrogate models for assessing human islet function. 
The aims of the experiments described in this chapter were to 1) quantify the mRNA 
expression of GPCR peptide ligands in human islets and the islets of outbred ICR and 
inbred C57 mouse strains, 2) compare the mRNA expression profiles to assess the 
suitability of using mouse islets as surrogate models for human islet GPCR peptide 
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ligand studies and 3) identify islet expressed GPCR peptide ligands whose role in islet 
function is yet to be determined and thus should be investigated. 
 
Quantify human and mouse islet GPCR peptide ligand mRNA expression profiles 
Gene expression analysis revealed that a high proportion of GPCR peptide ligands are 
expressed by both human and mouse islets. Of the 159 GPCR peptide ligands screened 
for expression in human islets, 128 (81%) were shown to be expressed, whilst of the 
145 mouse orthologues screened, 109 (75%) and 86 (59%) were shown to be 
expressed in ICR and C57 mouse islets respectively. This extent of abundant 
expression is expected of endocrine cells whose primary function is to secrete a 
multitude of factors which regulate not only processes within the islet 
microenvironment but also the processes of other tissues through delivery via the 
systemic circulation (Brereton et al., 2015). Interestingly, the number of peptide 
mRNAs expressed by C57 mouse islets was less compared to ICR mouse islets, a trend 
that was observed also with GPCR expression (Figure 3.4.4, Figure 3.4.5), as 
discussed in the previous chapter. This trend is likely to be attributed to the greater 
genetic variability of the outbred ICR strain compared to the more homogeneous 
inbred C57 mouse strain, where expression between biological replicates is more 
consistent. 
High expression of the classic intra-islet GPCR peptide ligands, SST, GCG, IAPP, 
was observed for all of the islet groups along with intra-islet peptide ligands PPY, 
UCN3, NPY and GHRL (Figure 4.4.5, Figure 4.4.6, Figure 4.4.7), thus confirming the 
suitability of our approach in reliably revealing GPCR peptide ligand mRNA 
expression. However, while the expression values of these ‘classic’ islet peptides was 
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revealed to be similar between islet groups, it did not conclusively confirm whether 
mouse islets are suitable for assessing the function of the numerous additional peptides 
expressed in human islets. Therefore, comparative analyses were performed to reveal 
the similarities and differences in GPCR peptide ligand mRNA expression between 
human and mouse islets. 
 
Comparison of islet GPCR peptide ligand expression profiles 
For the purpose of comparing and quantifying the GPCR peptide ligand mRNA 
expression profiles between islet groups, regression analysis was performed. As 
previously observed with GPCR expression (Figure 3.4.11), a remarkable degree of 
similarity in islet GPCR peptide ligand gene expression was observed between both 
mouse strains, r2 = 0.968. Conversely, linear regression analysis revealed that there 
was weaker correlation between GPCR peptide gene expression in human and mouse 
islets, with r2 values of 0.245 and 0.225 determined versus the ICR mouse strain and 
C57 strain respectively. A factor that could influence such dissimilarities could be the 
differences in islet endocrine cell proportions between human and rodent species 
(Steiner et al., 2010), whereby β-cell specific peptide ligands are likely to be perceived 
to be expressed at lower levels in human compared to mouse islets due to the higher 
proportion of β-cells within mouse islets. It is interesting to note that, similarly with 
GPCR expression, ICR mouse islets appear to resemble human islets more than the 
C57 counterpart, which as mentioned previously is likely to be due the similarity in 
genetic variability of biological replicate samples for both human and outbred ICR 
mice, unlike the inbred C57 mouse strain. Whilst a degree of genetic variability may 
result in inconsistent results between biological replicates when using ICR mouse 
Chapter 4 – Secretome comparison 
187 
 
islets, the fact that this degree of variability is also likely to be observed between 
human islet samples, suggests that ICR mice may well be a more suitable translational 
murine model system for human islets than islets from C57 mice. 
Despite the fact that a large degree of overlap in gene expression was observed 
between the three islet groups, species- and strain-specific expression was also 
observed (Table 4.4.3). Examples of human islet-specific or human islet-enriched 
peptide mRNAs include CRH, UCN, C1QL1 and ADCYAP1. Corticotrophin-
releasing factor (CRH) was shown to be exclusively expressed within human islets 
and is ranked #21 with regards to expression of the 128 peptide ligands expressed in 
human islets. The receptors responsible for CRH function are CRHR1 and CRHR2 
(Fekete and Zorrilla, 2007), both of which are expressed by human islets and also by 
both strains of mouse islets (Figure 3.4.2). CRH has been shown to promote glucose-
induced insulin secretion in isolated rat β-cells through the activation of the CRH1 
receptor and subsequent generation of increased intracellular cAMP. In the same 
study, CRH also promoted proliferation of primary rat neonatal β-cells through 
ERK1/2 phosphorylation, a mechanism which was further promoted under elevated 
glucose conditions (Huising et al., 2010). Another study revealed that intravenous 
infusion of CRH through the superior mesenteric artery increased whole pancreatic 
and islet blood flow in rat but in contrast did not influence insulin secretion (Carlsson 
et al., 1995). Whilst it appears that CRH may promote glucose-induced insulin 
secretion, β-cell mass and islet blood flow in rodent models, the lack of endogenous 
islet expression of CRH in mouse islets suggests that such effects could only be 
mediated through systemic delivery of CRH, rather than by local activation as may be 
the case with human islets. Furthermore, the CRH1 receptor is only expressed at trace 
levels in human islets but it is expressed approximately 250 times more in mouse islets 
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(Figure 3.4.2), suggesting that the observed effects of CRH in islet function in rodents 
may not in fact translate to humans. It is also interesting to note that urocortin1 
(UCN1), another CRH1 ligand, is also predominantly expressed in human islets. Such 
results indicate that mouse islets may not be suitable for assessing the role of CRH1 
ligands, CRH and UCN, in human islets. 
Examples of mouse islet-specific or mouse islet-enriched peptide ligand mRNA 
expression include Pyy, Vip, Ccl3, Grp, Penk and Pdyn. PYY mRNA was shown to 
be expressed at very low levels in human islets but was expressed at levels 
approximately 26,000 times higher in islets from both mouse strains, and it was ranked 
as the fifth highest expressed peptide ligand in mouse islets from a total of 145 peptide 
ligands screened. The role of PYY in islet function has been explored in mouse models 
and it has been demonstrated to promote cell proliferation and protect from cytokine-
induced apoptosis in mouse β-cells (Persaud and Bewick, 2014). With regards to 
insulin secretion, PYY inhibits glucose- and carbachol induced insulin secretion from 
mouse islets (Bottcher et al., 1989), but has no effect on glucose-induced insulin 
secretion in humans following i.v administration (Ahren and Larsson, 1996), thus 
clearly highlighting a species-specific effect. Interestingly though, the expression 
profiles of the receptors for PYY between human and mouse islets are similar (Figure 
3.4.2). Whilst PYY appears to exhibit effects on islet function in mouse models, the 
absence of effect in humans in addition to the discrepancy in expression of PYY 
between mouse and human islets questions the relevance of studying PYY as an 
intraislet regulator of human islet function. 
It is clear that consistencies in GPCR peptide ligand mRNA expression exist between 
human and mouse islets, as exemplified by the highly expressed SST, GCG, IAPP, 
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UCN3, PPY, NPY and GHRL peptides, but a certain degree of specificity is also 
observed between species e.g. CRH and PYY in particular. Whilst similarities in 
peptide expression may be observed within the islets of different species, the 
expression profiles of the receptors responsible for function also needs to be taken into 
consideration before an assumption on using mouse islets to predict human islet 
function can be declared. For example, whilst SST is highly expressed within human, 
ICR and C57 islets, the SST receptor family mRNA expression profiles differ between 
human and ICR mouse islets; where SSTR3 is absent and SSTR1 is only expressed at 
trace levels in ICR mice (Figure 3.4.2). In this scenario it would be more appropriate 
to use islets from C57 mice as a translational model to study SST signalling that would 
be relevant to the situation in human islets. A further complication is the fact that islets 
are made up of several different cell types. It is therefore possible that even though the 
expression of a particular gene may be found at similar levels in human and mouse 
islets, the cell type-specific expression may be different in the two species, which may 
have significant consequences for the functional role of specific GPCRs or GPCR 
peptide ligands. 
 
Identify peptides for further islet function studies 
Complement component 1, q subcomponent-like 1 (C1QL1) 
CIQL1 is the fourth highest expressed GPCR peptide ligand mRNA in human islets 
(Figure 4.4.5), accounting for 0.92% of total ligand expression (Table 4.4.1). While 
the mRNA expression of CIQL1 in human islets is approximately 260 times greater 
in human islets compared to mouse islets, its cognate receptor, BAI3 (Bolliger et al., 
2011), is expressed in both human and mouse islets (Figure 3.4.2), suggesting that 
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mouse islets could be utilised to assess C1QL1 function. To date, no studies assessing 
the role of C1QL1 on islet function have been performed, but the high expression of 
this ligand in human islets makes it a potentially interesting candidate for further 
studies. 
Endothelin-3 (EDN3) 
Endothelin-3 (EDN3) is the 14th, 18th and 19th most abundantly expressed peptide 
ligand in human islets, ICR mouse islets and C57 mouse islets respectively (Figure 
4.4.5, Figure 4.4.6 and Figure 4.4.7). The endothelin peptide family (endothelin-1, -2 
and -3, encoded by genes EDN1, EDN2 and EDN3) are vasoactive peptides that are 
released from vascular endothelium and function via the endothelin-A (EDNA) and 
endothelin-B (ENDB) receptors. Increased serum protein levels of endothelin-1 are 
observed in diabetes patients (Takahashi et al., 1990) and whilst endothelin-1 has been 
shown to promote insulin release from isolated rat and mouse islets via the endothelin-
A receptor (De Carlo et al., 2000), (Gregersen et al., 2000), it has consequently been 
shown to exacerbate cardiovascular complications in T2DM and contribute to elevated 
blood pressure through vasoconstriction (Ergul, 2011). Unlike endothelin-1, 
endothelin-3 acts only on the endothelin-B receptor, which is primarily involved in 
promoting vasodilation and thus opposes the vasoconstrictive effects of endothelin-1. 
Studies assessing the role of endothelin-3 in islet function are limited, but due to the 
relationship between the endothelin system and cardiovascular effects in T2DM, 
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Chemokine-ligand (CXC-motif)-14 (CXCL14) 
CXCL14 is a chemokine ligand belonging the CXC-class of chemokines. CXCL14 is 
currently being investigated by several research groups for its role in regulating 
metabolism. Studies in mice have demonstrated that a high fat diet markedly 
upregulates CXCL14 serum protein concentration and its expression in white adipose 
tissue (Takahashi et al., 2007), whilst CXCL14 knockout mice are protected from 
HFD-induced obesity (Tanegashima et al., 2010), have improved insulin sensitivity 
and are protected from HFD-induced hyperinsulinemia and hyperglycaemia (Nara et 
al., 2007). CXCL14 has also been implicated in modifying insulin-dependent glucose 
uptake, albeit with differing effects, with attenuation of glucose uptake observed in 
monocytes (Hara and Nakayama, 2009), yet enhancement of glucose uptake is 
observed in adipocytes (Takahashi et al., 2007). According to the data revealed within 
this chapter, CXCL14 mRNA is expressed within both human and mouse islets, an 
observation that is consistent with results obtained by Suzuki et al who revealed by 
immunohistochemistry that CXCL14 is expressed within the secretory vesicles of δ-
cells and not within α-, β- or PP cells (Suzuki and Yamamoto, 2015). It has therefore 
been postulated that CXCL14 may be co-released with somatostatin to modulate 
insulin secretion in a paracrine fashion (Suzuki and Yamamoto, 2015). However, the 
role of CXCL14 on islet function has not yet been assessed. The association of 
CXCL14 with metabolism and the demonstration that CXCL14 is expressed within 
islets makes it an attractive candidate for further investigation. The effects of CXCL14 
on islet function will be explored in the following chapter. 
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Summary and future perspectives 
The experiments performed within this chapter quantified and compared the mRNA 
expression profiles of 145 orthologue GPCR peptide ligands in human islets and in 
two strains of mouse islets. The expression profiles between ICR and C57 mice were 
remarkably similar despite C57 mice expressing 23 fewer GPCR peptide ligands. 
Human islets appear to be more similar to ICR mouse islets than to C57 islets, which 
is likely to be due to similarities in genetic variability, but the overall degree of 
expression similarity between human and mouse islets was low. Whilst similarities in 
peptide ligand expression was observed, with 71 (49%) peptide ligand genes expressed 
in both human and mouse islets, a degree of tissue-specific expression was also 
observed: human islets = 20, ICR = 10, C57 = 2 specific peptide ligands. In particular, 
the abundantly expressed CRH mRNA was shown to be expressed only in human 
islets, whilst PYY mRNA was expressed approximately 26,000 more abundantly in 
mouse islets compared to human islets. 
The use of mouse islets as a translational model for predicting human islet GPCR 
peptide ligand function appears to be ligand-specific and needs to take into account 
not only the expression levels of the peptide ligand of interest but also the expression 
profile of the receptors responsible for mediating the function of the peptide. 
Furthermore, additional studies would need to be performed to elucidate the 
localisation of GPCR peptide ligand mRNA expression within islets due to the fact 
that the studies performed within this chapter reveal whole islet expression and not 
cell-specific expression, and it will also be necessary to confirm expression of the 
peptides themselves rather than just the mRNAs encoding them. Nevertheless, the 
results described provide detailed information into the expression profiles of 145 
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GPCR peptide ligand mRNAs in both human and mouse islets and, furthermore, they 
highlight the suitability of using mouse islets for assessing the function of GPCR 
peptide ligands in the human setting. 
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Analysis of the human and mouse islet ‘Secretome’ data generated in chapter 4 of this 
thesis revealed the expression of the CXC-family chemokine CXCL14 in both human 
and mouse islets. In recent years, CXCL14 has received interest from research groups 
studying its role in cancer, immunology and metabolism, but progress in 
understanding the mechanisms by which CXCL14 functions has been hindered by the 
orphan status of this chemokine, as no known receptor has been identified. 
Typically, chemokines bind to receptors of their own class, of which there are four (C, 
CC, CXC, C3XC), and within each class some chemokines bind to many receptors 
and multiple receptors may bind to many chemokines (Kufareva et al., 2015). 
However, despite this class specific interaction between chemokine ligands and 
receptors, a receptor has yet to be identified for CXCL14. It has been proposed that 
CXCR4 is responsible for CXCL14 mediated function as determined by its ability to 
bind with high affinity to wild-type and stable CXCR4-overexpressing THP-1 cells in 
radioligand binding experiments (Tanegashima et al., 2013). In the same study, 
CXCL14 was also shown to inhibit CXCL12-mediated chemotaxis of THP-1 cells, a 
process which is facilitated by CXCR4. Conversely, a conflicting report demonstrated 
that CXCL14 did not alter CXCL12-induced CXCR4 phosphorylation, G-protein-
mediated calcium mobilisation or CXCR4 internalisation in CXCR4 transfected 
HEK293 and Jurkat T cells, suggesting that CXCL14 is not a ligand for the CXCR4 
receptor (Otte et al., 2014). As it stands, inconsistencies in the literature regarding the 
involvement of CXCR4, or any other receptor for that matter, in CXCL14 mediated 
function means CXCL14 will continue to maintain its orphan ligand status. 
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CXCL14 is currently being investigated by several research groups for its role in 
regulating metabolism. There is accumulating evidence demonstrating that obesity 
results in a state of low-grade chronic inflammation that promotes the release of pro-
inflammatory cytokines, lipids and chemokines from adipose tissue, which 
consequently contributes to metabolic comorbidities such as type 2 diabetes mellitus 
(Xu et al., 2015). CXCL14 is a secreted chemokine that is expressed and secreted by 
the adipose tissue and contributes to inflammatory processes by recruiting monocytes 
to the site of inflammation. Studies in mice have demonstrated that a high fat diet 
markedly upregulates CXCL14 serum protein concentration and its expression in 
white adipose tissue (Takahashi et al., 2007), whilst CXCL14 knockout mice are 
protected from HFD-induced obesity (Tanegashima et al., 2010), have improved 
insulin sensitivity and are protected from HFD-induced hyperinsulinemia and 
hyperglycaemia (Nara et al., 2007). CXCL14 has also been shown to be implicated in 
modifying insulin-dependent glucose uptake, albeit with differing effects, with 
attenuation of glucose uptake observed in myocytes (Hara and Nakayama, 2009), 
whilst enhancement of glucose uptake is observed in adipocytes (Takahashi et al., 
2007). 
The association of CXCL14 with obesity, its subsequent effects on glucose 
homeostasis and its expression within the islets of Langerhans, as identified in the 
Secretome data (Figure 4.4.1), makes it an interesting target to study in relation to type 
2 diabetes. Whilst most studies have focused on the role of CXCL14 on the regulation 
of glucose homeostasis in vivo, a direct effect of CXCL14 on islet function has yet to 
be explored. The experiments described in this chapter aim to explore the role of 
CXCL14 on islet and β-cell function and the underlying mechanisms mediating these 
effects, and to attempt to identify the GPCR/s through which it acts. 




 Quantify CXCL14 mRNA expression in islets, β-cell lines and adipose tissue. 
 Explore the effects of exogenous CXCL14 on islet and β-cell function. 
 Identify the intracellular mechanisms involved in CXCL14-mediated effects 
on islets and β-cells. 
 Using the islet GPCRome and Secretome data in Chapters 3 and 4, explore 

















5.3.1 Gene expression analysis 
mRNA was harvested from human islets, ICR mouse islets, MIN6 cells, Endoc-BH1 
cells, mouse brown adipose tissue (BAT) and mouse gluteal white adipose tissue 
(GWAT) and reverse transcribed into cDNA as previously described (Sections 2.3.1, 
2.3.3, 2.3.2 and 2.3.4). qPCR was performed using Qiagen’s QuantiTect primer 
assays, Quantifast SYBR green master mix and the Roche LightCycler 480 under the 
settings described in section 2.3.5. Data were represented as expression relative to the 
expression of the housekeeping gene GAPDH. Confirmation of correct amplicon 
product was determined by agarose gel electrophoresis as described in section 2.3.6. 
 
5.3.2 Static insulin secretion studies 
The effects of acute CXCL14 exposure on insulin secretion from islets, MIN6 cells 
and INS-1 cells were carried out as described in section 2.4. In brief, islets, harvested 
as described in section 2.2, or monolayers of MIN6 cells and INS-1 cells were 
incubated with CXCL14 for 1 hour at 37oC in physiological buffer supplemented with 
glucose. Following incubation, supernatant was retrieved and insulin content was 
determined by radioimmunoassay (Section 2.4.4). 
 
5.3.3 Apoptosis protocol 
Pro- or anti-apoptotic properties of CXCL14 were assessed by treating monolayers of 
MIN6 cells (25,000 cells/well) and INS-1 cells (15,000 cells/well) with exogenous 
CXCL14 in the absence or presence of pro-inflammatory cytokines (Section 2.5). 
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Enzymatic activity of the apoptotic enzymes Caspase 3 and 7 were determined using 
Promega’s Capsase-Glo 3/7 assay. 
 
5.3.4 Proliferation protocol 
The proliferative effects of CXCL14 were assessed in MIN6 cells and INS-1 cells 
using a BrdU colorimetric ELISA as described in section 2.6. In brief, 20,000 MIN6 
cells/well or 15,000 INS-1 cells/well were cultured in 96 well plates overnight in a 
humidified 37oC incubator containing a 5% CO2, 95% air atmosphere. The following 
day, the medium was changed to serum free medium supplemented with 2mM glucose 
and incubated overnight again to ensure the cells reached a quiescent state prior to 
experimentation. The following day, the medium was changed once more to medium 
containing either 0, 1, 2, 10, 20 or 40ng/ml of CXCL14 in the presence or absence of 
10% serum. The cells were cultured for 48 hours at 37oC before BrdU incorporation 
in newly synthesised cells was measured using the BrdU ELISA kit. 
 
5.3.5 Intracellular cAMP assessment 
In order to assess whether CXCL14 signals through agonism of Gαi-coupled receptors 
or inverse agonism of Gαs-coupled receptors, a cAMP assay using Cisbio’s HTRF 
technology was developed. In brief, MIN6 cells were plated out in suspension in low 
volume 384 well white plates following flask detachment using enzyme-free 
dissociation buffer. CXCL14-mediated Gαi-coupling and Gαs-coupling was 
determined by treating MIN6 cells with exogenous CXCL14 in the presence or 
absence of forskolin respectively for a 1 hour incubation period in HBSS assay buffer 
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supplemented with IBMX. The plate was read on a BMG Pherastar and intracellular 
cAMP levels determined by extrapolating FRET values off of a standard curve. 
5.3.5.1 Z factor calculation (Z’) 
To assess assay robustness, a Z’ value was determined using the following calculation, 
where δ = standard deviation and μ = means of the positive (p) and negative (n) 
controls (Zhang et al., 1999). 
 
Z’ Interpretation 
1 Ideal assay 
Between 0.5 and 1 Excellent assay 
Between 0 and 0.5 Marginal assay 
0 No assay 
 
 
5.3.6 Glucose uptake assessment 
The effects of exogenous CXCL14 on glucose uptake in MIN6 cells were determined 
using the Promega glucose uptake kit as described in section 2.9. In brief, 30,000 
MIN6 cells/well/100µl were plated out in fully complemented cell culture medium (as 
described in section 2.1.1) and cultured overnight in a humidified 37oC incubator 
containing a 5% CO2, 95% air atmosphere. The following day, the growth medium 
was replaced with fully complemented low glucose culture medium (no glucose 
DMEM supplemented with 2mM glucose, 10% FBS, 2mM L-glutamine and 100U/ml 
penicillin/100µg/ml streptomycin), in order to promote at state of quiescence prior to 
experimentation, before the cells were then incubated overnight in a humidified 37oC 
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incubator containing a 5% CO2, 95% air atmosphere. Following overnight incubation, 
the cell medium was removed from the plate and the cells were washed with 
200µl/well of PBS. 50µl/well of treatment (CXCL14 or vehicle) was then added to 
each well of the plate and the cells were then incubated for 1 hour at 37oC. 5µl of 10X 
2DG solution prepared in PBS was added to each well and the cell plate was again 
incubated for 1 hour at 37oC. Following incubation, 25µl of Stop buffer was added to 
each well in order to terminate glucose uptake and destroy intracellular NADPH. 
25µl/well of Go buffer was added to the plate followed by 100µl of 2DG6P detection 
reagent and the plate was then incubated for 1 hour at room temperature. 
Luminescence was measured using a Veritas luminometer plate reader. 
 
5.3.7 Intracellular ATP assessment 
5.3.7.1 MIN6 cells 
The effects of CXCL14 on intracellular ATP levels within MIN6 cells were 
determined using the CellTiter-Glo Viability kit as described in section 2.8. 
Briefly, MIN6 (25,000 cells/well) cells were plated out in white walled, clear bottom 
plates and cultured overnight in a humidified 37oC incubator containing a 5% CO2, 
95% air atmosphere. The following day, the medium was changed to low glucose 
medium (2mM glucose) with the aim of reducing glucose-induced basal intracellular 
ATP generation and thus increase the assay window. The next day, the medium was 
removed and the cells were incubated with 50µl/well of exogenous CXCL14 prepared 
in Gey and Gey buffer for 1 hour at 37oC. 50µl/well of CellTiter-Glo reagent was 
added to each well and the plate was then incubated for 10 mins at room temperature 
before luminescence was measured using a Veritas Luminometer. 




The effects of exogenous CXCL14 on intracellular ATP levels within ICR mouse 
islets were determined using the CellTiter-Glo 3D Viability kit. 
Briefly, mouse islets were harvested as described in Section 2.2.2 and cultured 
overnight in RPMI medium (11.1mM glucose) supplemented with 10% FBS, 2mM L-
glutamine and 100U/ml penicillin/100µg/ml streptomycin in a humidified 37oC 
incubator containing a 5% CO2, 95% air atmosphere. The following day, the islets 
were transferred to Gey & Gey physiological solution containing 2mM glucose and 
incubated for 2 hours within a humidified 37oC incubator containing a 5% CO2, 95% 
air atmosphere. The islets were then washed and 3 islets/well/25µl were handpicked 
under a microscope into a white 96 well plate and treated with 25µl of 2X treatment 
buffer in the presence of 2 or 20mM glucose for 1 hour at 37oC. 50µl of luciferase 
reagent was added to each well and the plate was then incubated for 30mins at room 
temperature before the luminescent signal was measured. 
 
5.3.8 β-Arrestin recruitment assays 
The assessment of CXCL14 function at the CXCR4 and CXCR7 receptors was 
assessed using mouse CXCR4 and CXCR7 β-arrestin assay kits supplied by 
DiscoverX. Function of CXCL14 at these receptors was assessed in both agonist and 
antagonist mode, with CXCL12 used as the natural ligand and competing ligand to 
assess CXCL14 antagonism at both receptors. Detailed methodology can be found in 
section 2.10. 
Briefly, 10,000 PathHunter cells/well were plated out and cultured for 48 hours in a 
humidified incubator at 37oC supplemented with 5% CO2. On the day of ligand 
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treatment, ligands were prepared at 2X concentration in assay buffer (HBSS, 10mM 
HEPES, 0.1% BSA, pH7.4 with NaOH). Agonism was assessed by adding 50µl/well 
of vehicle (antagonist diluent in assay buffer) followed by 50µl/well of 2X 
concentrated ligand in assay buffer. Antagonism was assessed by adding 50µl/well of 
2X ligand (CXCL14), followed by 50µl of 2X agonist (CXCL12). The plate was 
incubated at 37oC for 90 mins before 55µl/well of detection reagent was added. The 
plate was then incubated at room temperature for 60 mins and the luminescence signal 















5.4.1 CXCL14 mRNA expression 
qPCR analysis revealed the expression of CXCL14 mRNA in human islets, mouse 
islets, brown (BAT) and white (GWAT) adipose tissue but not in the Endoc-βH1 and 
MIN6 β-cell lines (Figure 5.4.1). Validation of the specificity of the qPCR product 
was confirmed by agarose gel electrophoresis (Figure 5.4.2). 
 
Figure 5.4.1. CXCL14 mRNA expression analysis in islets, β-cell lines and adipose 
tissue. Data expressed as mean + SEM relative to GAPDH mRNA expression, n=4. 
A = absent expression. 
 
Figure 5.4.2. Agarose gel image of CXCL14 qPCR products. Wells are arranged in 
the following order from left to right: 50bp ladder, Endoc-βH1, human islet, MIN6, 
mouse islet, BAT, GWAT and 50bp ladder. Correct amplicon sizes for human (74bp) 
and mouse (76bp) samples were detected. 
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5.4.2 Exploring the effects of exogenous CXCL14 on islet function 
5.4.2.1 The effects of CXCL14 on insulin secretion from MIN6 cells 
The effects of exogenous CXCL14 on insulin secretion from MIN6 cells were assessed 
in order to identify whether CXCL14 modifies insulin secretion directly from β-cells. 
Acute exposure of MIN6 cells to exogenous CXCL14 for 1 hour resulted in a reduction 
in insulin secretion at both 2mM and 20mM glucose with greater statistical 
significance observed at 2mM glucose (Figure 5.4.3). 
 
 
Figure 5.4.3 The effects of CXCL14 on insulin secretion from MIN6 cells. A dose 
dependent reduction in insulin secretion was observed with increasing concentrations 
of CXCL14. CXCL14 significantly reduced insulin secretion at both 2 and 20mM 
glucose. Data are expressed as mean + SEM, n=8 and represent three separate 
experiments. Statistics were performed using one-way ANOVA, *p<0.05, **p<0.01. 
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5.4.2.2 The effects of CXCL14 on insulin secretion from INS-1 cells 
The effects of CXCL14 on insulin secretion from the INS-1 rat β-cell line were 
assessed to determine whether the effects of CXCL14 on insulin secretion from MIN6 
cells could also be observed in an alternative rodent cell line. Data in Figure 5.4.4 
indicates that 2 and 20ng/ml of CXCL14 was able to significantly inhibit insulin 
secretion. Like with MIN6 cells, a greater significance in the reduction of insulin 
secretion was observed at lower glucose concentrations. 
 
 
Figure 5.4.4 The effects of CXCL14 on insulin secretion from INS-1 cells. 2 and 
20ng/ml of CXCL14 significantly inhibited insulin secretion independent of the 
glucose concentration. Data are expressed as mean + SEM, n=8 and represent two 
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5.4.2.3 The effects of CXCL14 on insulin secretion from mouse islets 
Following the revelation that CXCL14 inhibited insulin secretion from rodent β-cell 
lines, the effects of CXCL14 on insulin secretion from whole mouse islets were 
assessed. Mouse islets responded to glucose with a 15.03 fold increase in insulin 
secretion observed between 2mM (0.13±0.03ng/islet/hr) and 20mM (1.93±0.44) 
glucose. Acute exposure of mouse islets to exogenous CXCL14 resulted in a 
concentration dependent reduction in glucose-induced insulin secretion with 
increasing concentrations of CXCL14, with statistical significant observed with 
40ng/ml of CXCL14. (Figure 5.4.5). 
 
 
Figure 5.4.5 The effects of CXCL14 on insulin secretion from mouse islets. 
CXCL14 caused a dose dependent reduction in glucose-induced insulin secretion with 
statistical significance observed with 40ng/ml. Data are expressed as mean + SEM, 
n=8 and represent three separate experiments. Statistics were performed using one-
way ANOVA, *p<0.05. 
 
 
Chapter 5 – The effects of CXCL14 on islet function 
208 
 
5.4.2.4 The effects of CXCL14 on insulin secretion from human islets 
In order to determine whether the effects of CXCL14 on insulin secretion from mouse 
islets translated to human islets, a static insulin secretion experiment was also 
performed using human islets. Unlike with mouse islets and MIN6 cells, CXC14 did 
not significantly reduce insulin secretion from human islets (Figure 5.4.6). 
 
 
Figure 5.4.6 The effects of CXCL14 on insulin secretion from human islets. 
CXCL14 has no effect on human islet insulin secretion. Data are expressed as mean + 
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5.4.2.5 The effects of CXCL14 on β-cell line apoptosis 
In order to assess whether CXCL14 could induce pro- or anti-apoptotic effects on β-
cells, MIN6 cells and INS-1 cells were cultured with CXCL14 in the presence or 
absence of pro-apoptotic cytokines. 
 
Figure 5.4.7 The effects of CXCL14 on MIN6 cell apoptosis. CXCL14 had no effect 
on MIN6 cell apoptosis. Data are expressed as mean + SEM, n=6 and represent three 
separate experiments. Statistics were performed using one-way ANOVA. 
 
Figure 5.4.8 The effects of CXCL14 on INS-1 cell apoptosis. 40ng/ml CXCL14 
promoted apoptosis in the absence and presence of pro-inflammatory cytokines. Data 
are expressed as mean + SEM, n=6 and represent two separate experiments. Statistics 
were performed using one-way ANOVA, ***p<0.001. 
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5.4.2.6 The effects of CXCL14 on β-cell proliferation 
In order to assess whether CXCL14 could induce anti- or pro-proliferative effects on 
β-cells, MIN6 cells and INS-1 cells were cultured with CXCL14 in the presence or 
absence of serum (10% FCS). 
 
Figure 5.4.9 The effects of CXCL14 on MIN6 cell proliferation. CXCL14 had no 
effect on MIN6 cell proliferation in the presence or absence of serum. Data are 
expressed as mean + SEM, n=6 and represent two separate experiments. Statistics 
were performed using one-way ANOVA. 
 
Figure 5.4.10 The effects of CXCL14 on INS-1 cell proliferation. CXCL14 had no 
effect on INS-1 cell proliferation in the presence or absence of serum. Data are 
expressed as mean + SEM, n=6 and represent two separate experiments. Statistics 
were performed using one-way ANOVA. 
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5.4.3 The mechanisms involved in CXCL14-mediated reduction in insulin 
secretion. 
CXCL14 inhibited insulin secretion from both mouse islets and rodent β-cells lines, 
indicating that CXCL14 functions directly at the β-cell. Therefore, the MIN6 β-cell 
line was used for subsequent studies aimed at identifying the potential mechanisms 
involved in CXCL14-mediated regulation of insulin secretion. Potential mechanisms 
involved in the CXCL14-mediated inhibition of insulin secretion include a CXCL14-
mediated reduction in intracellular cAMP, either by agonism of a Gαi-coupled GPCR 
or inverse agonism of a Gαs-coupled GPCR, or by inhibition of glucose uptake and/or 
glucokinase activity. The methods described below aim to explore which of these 
mechanisms may be involved in the inhibitory effect of CXCL14 on insulin secretion. 
5.4.3.1 The effects of CXCL14 on intracellular cAMP production in MIN6 cells 
The effects of CXCL14 on intracellular cAMP production in MIN6 cells was assessed 
using Cisbio’s cAMP HTRF kit as described in section 5.3.5. The ability of CXCL14 
to function as an inverse agonist of a Gαs-coupled GPCR was assessed by treating 
MIN6 cells with exogenous CXCL14 to see if a reduction in basal cAMP was 
observed. In order to assess whether CXCL14 functions as Gαi-coupled GPCR 
agonist, MIN6 cells were treated with CXCL14 in the presence of forskolin. Forskolin 
functions by activating the transmembrane enzyme adenylate cyclase, which is 
responsible for increasing intracellular cAMP levels by converting ATP to cAMP and 
pyrophosphate. In order to determine an appropriate concentration of stimulating 
concentration of forskolin and cell density to use for subsequent experiments, a dose 
response to forskolin using various MIN6 cell densities was performed. 




Figure 5.4.11 Forskolin dose response curves with various seeded densities of 
MIN6 cells. A forskolin-induced increase in cAMP was observed for all cell densities 
tested. Data are expressed as mean ± SEM, n=3. 
 
Table 5.4.1 HTRF-cAMP Z factor calculations. 
Cell density µp µn δp δn Z factor 
2500 78.38 5.16 3.59 0.58 0.83 
5000 186.35 23.91 3.81 2.66 0.88 
7500 275.77 45.35 5.71 0.45 0.92 
10000 358.13 65.81 46.58 2.34 0.50 
 
As expected, an increase in basal intracellular cAMP was observed with increasing 
cell density. Forskolin dose response curves were generated for each cell density 
with a leftward shift in the EC50 values of forskolin observed with increasing cell 
density (Figure 5.4.11). Z factor calculations for each seeding density tested all fell 
within the ‘excellent assay’ range (Table 5.4.1). A comparison of the raw values 
generated for each cell density against the cAMP standard curve revealed that 2500 
cells/well was suitable for further studies as all data points fell within the linear 
region of the cAMP standard curve (Figure 5.4.12). 




Figure 5.4.12 Assessment of cell density suitability. 2500 cells/well generated levels 
of cAMP that could be reliably detected within the linear sensitivity range. Data are 
expressed as mean ± SEM, n=3. 
 
For the purpose of assessing CXCL14-mediated Gαi coupling in MIN6 cells, a 
stimulating forskolin concentration of 100nM was chosen. To determine that the 
correct concentration of stimulating forskolin was added to the assay, a forskolin dose 
response was performed on the same plate and the ‘actual’ stimulating concentration 
of forskolin added to the assay was determined by extrapolating the fluorescent signal 
from the forskolin dose response curve. For the represented Gαi assessment assay, the 
‘actual’ stimulating concentration of forskolin was determined as 64.5nM (Figure 
5.4.13), which was considered to be suitable. The stimulating forskolin concentration 
induced a cAMP response to a level within the assay’s detection range. The α2-
adrenergic agonist clonidine, which exerts its effects through Gαi coupling, was able 
to reduce a forskolin-induced increase in intracellular cAMP thus confirming assay 
proof of concept. CXCL14 however was unable to reduce a forskolin induced increase 
in cAMP (Figure 5.4.13B) and did not reduce basal cAMP levels (Figure 5.4.13C) in 
forskolin untreated MIN6 cells. 




Figure 5.4.13 Assessment of CXCL14 on intracellular cAMP levels in MIN6 cells. 
Graphs depicted show A) a forskolin dose response, B) Gαi agonism assessment of 
CXCL14 function and C) Gαs inverse agonist assessment of CXCL14 function. 
CXCL14 did not inhibit a forskolin-induced increase in cAMP and did not inhibit or 
stimulate basal cAMP levels. Data are expressed as mean ± SEM, n=3 and represent 
three separate experiments. 
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5.4.3.2 The effects of CXCL14 on glucose uptake in MIN6 cells. 
Previous studies have shown that CXCL14 both attenuates and promotes insulin-
dependent glucose uptake in adipocytes and monocytes respectively. In mouse β-cells 
glucose uptake is insulin-independent and is mediated through the GLUT2 glucose 
transporter. As insulin secretion is dependent on the influx of glucose into the β-cell 
through the insulin-independent GLUT2 transporter, experiments were designed to 
explore whether the mechanism by which CXCL14 inhibits insulin secretion is via the 
attenuation of insulin-independent glucose uptake in MIN6 cells. 
In order to assess the effect of CXCL14 on glucose uptake in MIN6 cells, assay 
conditions allowing for reliable assessment of glucose uptake needed to be optimised. 
Therefore, a matrix study assessing glucose uptake using various cell densities and 2-
deoxy-D-glucose (2DG) concentrations was performed (Figure 5.4.14). An increase 
in 2DG uptake was observed with increasing concentration of 2DG and cell density. 
For the purpose of subsequent studies assessing the effect of CXCL14 on glucose 
uptake, a cell density of 30,000 MIN6 cells/well and 2DG concentrations of 2 and 
20mM were chosen. CXCL14 appeared to reduce glucose uptake in MIN6 cells at 
both 2mM and 20mM of 2DG with statistical significance observed following 
treatment with 40 and 80ng/ml of CXCL14 (Figure 5.4.15). Similar to the effects of 
CXCL14 on insulin secretion from MIN6 cells, a greater degree of statistical 
significance was observed at lower concentrations of glucose/2DG. 




Figure 5.4.14 Glucose uptake assay optimisation with MIN6 cells. An increase in 
glucose uptake was observed with increasing cell density and 2DG concentration. Data 
are expressed as mean + range, n=2. 
 
 
Figure 5.4.15 The effects of CXCL14 on glucose uptake in MIN6 cells. A 
significant reduction in glucose uptake was observed following treatment with 40 and 
80ng/ml of exogenous CXCL14 at both 2 and 20mM 2DG. The glucose uptake 
transporter inhibitor cytochalasin-B (‘Cyt’ at 50µM) also significantly reduced 
glucose uptake. Data are expressed as mean + SEM, n=6 and represent two separate 
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5.4.3.3 The effects of CXCL14 on intracellular ATP generation 
In order to confirm the effects of CXCL14 on glucose uptake, and thus a predicted 
subsequent reduction in intracellular ATP generation, the effects of CXCL14 on 
intracellular ATP generation were assessed in MIN6 cells. 
Assay optimisation of cell density and glucose concentration was performed to ensure 
the levels of ATP generated by the MIN6 cells fell within the assay’s sensitivity range. 
 
 
Figure 5.4.16 ATP standard curve. Data are expressed as mean ± range, n=2 and 
represent one experiment. 




Figure 5.4.17 ATP assay MIN6 cell density study. Intracellular ATP concentration 
was directly proportional to cell density and glucose concentration. Data are expressed 
as mean + SEM of raw RLU, n=6 and represent one experiment. 
 
 
Figure 5.4.18 ATP assay MIN6 cell density study. An increase in generated ATP 
was directly proportional to cell density and glucose concentration. Data are expressed 
as mean + SEM (n=6) of extrapolated ATP concentration from the standard curve, and 
represent one experiment. 
 
 
Chapter 5 – The effects of CXCL14 on islet function 
219 
 
The concentrations of intracellular ATP generated at all cell densities fell within the 
kit’s limit of sensitivity irrespective of the concentration of glucose. For the purpose 
of assessing the effects of CXCL14 on intracellular ATP levels within MIN6 cells, 
30,000 cells/well were used. 
Exogenous CXCL14 did not reduce intracellular ATP generation in MIN6 cells unlike 
the ATP synthase inhibitor, oligomycin (Figure 5.4.19). 
 
Figure 5.4.19 The effects of CXCL14 on intracellular ATP generation in MIN6 
cells. CXCL14 did not affect intracellular ATP generation in MIN6 cells unlike 
100ng/ml of the positive control oligomycin (Olig). Data are expressed as mean + 
SEM of extrapolated ATP concentration, n=6 and represent two experiments. 
 
The effects of exogenous CXCL14 on intracellular ATP generation in mouse islets 
was also assessed (Figure 5.4.20). 20mM glucose promoted intracellular ATP 
generation above that of 2mM sub-stimulatory glucose concentration. The positive 
control oligomycon inhibited intracellular ATP generation at both 2 and 20mM 
glucose. In the presence of 20mM glucose, a dose responsive trend in the reduction of 
intracellular ATP generation was observed with increasing concentration of CXCL14, 
with statistical significance observed with <80ng/ml of CXCL14. At 2mM glucose, 
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CXCL14 did not significantly inhibit intracellular ATP production but a statistically 
non-sigificant reduction in ATP generation was observed with increasing CXCL14 
concentration. The glucose-dependent effects of CXCL14 on ATP production in 
mouse islets exhibits a smilar trend to that observed with insulin secretion from mouse 
islets (Figure 5.4.5). 
 
Figure 5.4.20 The effects of CXCL14 on intracellular ATP levels in mouse islets. 
80ng/ml of CXCL14 significantly inhibited glucose-induced insulin secretion as did 
100ng/ml of the positive control oligomycin (Olig). Data are expressed as mean + 
SEM, n=8 and represent two separate experiments. Statistics were performed using 
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5.4.4 Exploring the receptor/s responsible for CXCL14 function 
One of the aims within this chapter was to identify the receptor/s responsible for 
mediating CXCL14 function. By combining current knowledge of CXC-family 
ligand-receptor interactions along with the ‘GPCRome’ and ‘Secretome’ data 
generated in the previous chapters, a targeted approach to identifying a CXCL14 
receptor/s was employed. 
 
5.4.4.1 CXC-chemokine family ‘Interactome’ 
For the purpose of predicting which receptors may be responsible for mediating the 
function of CXCL14, an ‘Interactome’ of the CXC-chemokine family ligands and 
receptors was generated using data obtained from the IUPHAR database (Figure 
5.4.21). 
 
Figure 5.4.21 CXC-chemokine family 'Interactome'. Data were obtained from the 
IUPHAR/BPS guide to Pharmacology. 
 
The ‘Interactome’ data indicates that all CXC-chemokine ligands interact with at least 
one CXC-chemokine receptor, thus suggesting that CXCL14 is likely to do so also. 
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5.4.4.2 CXC-family-chemokine receptor expression 
In order to identify which CXC-receptor may be responsible for CXCL14 function, 
the mRNA expression profiles of all CXC-receptors in human islets, mouse islets and 
MIN6 cells were determined (Figure 5.4.22). 
 
Figure 5.4.22 mRNA expression of CXC-family receptors in human islets, mouse 
islets and MIN6 cells. Data are expressed as mean + SEM expression relative to 
GAPDH, n=4. T = trace expression; A = absent expression. 
 
mRNA expression analysis revealed that CXCR4 and CXCR7 are commonly 
expressed in human islets, mouse islets and MIN6 cells. This observation was 
particularly interesting as other groups have suggested that CXCL14 antagonises the 
actions of CXCL12 (Hara and Tanegashima, 2014), which functions at both the 
CXCR4 and CXCR7 receptors (Figure 5.4.21). According to the IUPHAR database, 
the principle signalling transduction pathways coupled to CXCR4 and CXCR7 are Gαi 
and β-arrestin respectively. Whilst we have already shown in section 5.4.3.1 that 
CXCL14 functions through a cAMP-independent mechanism, and thus unlikely to 
couple through a Gαi receptor, the fact that GPCRs are promiscuous and have the 
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ability to couple through atypical signalling pathways depending on which specific 
ligand interacts with the receptor (functional selectivity) justifies further exploration 
into the role of CXCR4 and CXCR7 in CXCL14 function. 
 
5.4.4.3 Assessment of CXCL14 interactions with CXCR4 and CXCR7 
For the purpose of assessing CXCL14 interaction at the CXCR4 and CXCR7 
receptors, β-arrestin recruitment assays were used. The benefit of running β-arrestin 
assays to assess ligand function is that the technology allows for the detection of ligand 
function irrespective of the G-protein coupling mechanisms involved, which is 
particularly useful as many GPCRs couple through various signal transduction 
cascades, some of which are only activated by specific ligands for that receptor 
(functional selectivity). This phenomenon is commonly observed with chemokine 
receptors (Anderson et al., 2016) (Rajagopal et al., 2013) (Steen et al., 2014). CXCL14 
function was assessed in agonist and antagonist mode at both the CXCR4 and CXCR7 
receptors with CXCL12 used as the natural ligand for both receptors. For antagonism 
studies, a dose response to CXCL12 in the presence of increasing concentrations of 
CXCL14 was performed. The benefit of this approach is that not only can antagonism 
be determined but the mode of antagonism, (orthosteric or allosteric) and/or 
modulation (positive or negative) can also be elucidated. Due to the fact that CXCL14 
inhibited insulin secretion from mouse islets and the mouse β-cell line, the MIN6 cell 
line, the mouse CXCR4 and CXCR7 β-arrestin assays were used to assess CXCL14 
receptor interaction at these receptors. 
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5.4.4.3.1 Assessment of CXCR4 involvement in CXCL14 function 
As expected, the natural ligand CXCL12 induced a dose dependent increase in β-
arrestin recruitment at the mCXCR4 receptor (Figure 5.4.23). An EC50 of 15.86nM 
was determined and a Hill slope of 1.079 indicated a 1:1 stoichiometry (one ligand to 
one binding site) i.e. no co-cooperativity, no multiple binding sites. CXCL14 on the 
other hand did not to promote β-arrestin recruitment, thus indicating that it is not an 
agonist for the CXCR4 receptor. 
 
Figure 5.4.23 Assessment of CXCL14 agonism at the mouse CXCR4 receptor. 
CXCL12 induced β-arrestin recruitment at the mouse CXCR4 receptor with an EC50 
of 15.86nM and a Hill slope of 1.079. CXCL14 did not promote β-arrestin recruitment. 
Data are expressed as mean±range, n=2 from one experiment. 
 
The potential antagonistic properties of CXCL14 for the mCXCR4 receptor were 
assessed by performing dose responses to the natural agonist, CXCL12, in the 
presence of increasing concentrations of CXCL14 (Figure 5.4.24). The data revealed 
that, CXCL14 did not alter the EC50 of CXCL12 with EC50s of 15.86, 13.98, 15.01, 
15.99 and 13.96nM produced in the presence of 0, 0.3, 3, 30 and 300nM CXCL14 
respectively. However, the Hill slope for the CXCL12 dose response did increase from 
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1.079 in the absence of CXCL14 to 1.720, 1.765, 1.593 and 1.996 in the presence of 
0.3, 3 30 and 300nM of CXCL14 respectively. The Emax of the CXCL12 dose response 
also increased in the presence of CXCL14 and together with the increase in Hill slope 
may suggest a positive modulatory effect of CXCL14 on CXCL12 function. However, 
it is worth noting that neither of these effects were dose responsive within the tested 
range of CXCL14 (0.3-300nM). 
 
Figure 5.4.24 The effects of CXCL14 on CXCL12 β-arrestin recruitment at the 
mouse CXCR4 receptor. CXCL14 increased both the Hill slope and the Emax of the 
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5.4.4.3.2 Assessment of CXCR7 involvement in CXCL14 function 
The study design for assessing whether CXCR7 is a receptor for CXCL14 was 
identical to that of the CXCR4 β-arrestin study as described above. To assess agonistic 
properties of CXCL14 at CXCR7, β-arrestin recruitment at CXCR7 following a 
90minute treatment with CXCL14 was assessed. Whilst the natural ligand CXCL12 
was able to induce β-arrestin recruitment, CXCL14 did not, thus concluding that 
CXCL14 is not an agonist for CXCR7 (Figure 5.4.25). 
 
Figure 5.4.25 Assessment of CXCL14 agonism at the mouse CXCR7 receptor. 
CXCL12 induced β-arrestin recruitment at the mouse CXCR7 receptor with an EC50 
of 31.29nM and a Hill slope of 1.134. CXCL14 did not promote β-arrestin recruitment. 
Data are expressed as mean ± range, n=2 from one experiment. 
 
The potential antagonistic properties of CXCL14 at the CXCR7 receptor were 
assessed by observing the ability of CXCL14 to alter CXCL12-induced β-arrestin 
recruitment. As observed in Figure 5.4.26, CXCL14 did not alter the EC50 of CXCL12 
with EC50s of 31.29, 37.80, 35.59, 33.75 and 23.35nM determined in the presence of 
0, 0.3, 3.0, 30 and 300nM of CXCL14. The Emax and Hill slope of the CXCL12 dose 
response were also unaffected, thus concluding that mouse CXCL14 is not an 
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antagonist for the mouse CXCR7 and that it does not modulate CXCL12 binding or 
efficacy to the mouse CXCR7 receptor. 
 
Figure 5.4.26 The effect of CXCL14 on CXCL12 β-arrestin recruitment at the 
mouse CXCR7 receptor. CXCL14 had no effect on CXCL12-induced β-arrestin 











An association between obesity and CXCL14 upregulation, and its subsequent effects 
on glucose homeostasis, has recently been reported (Hara and Tanegashima, 2012). In 
the few publications to date, the overall trend regarding CXCL14’s role in metabolism 
appears to be that of a detrimental one, with high fat diet fed CXCL14-knockout mice 
exhibiting improved insulin responsiveness, decreased hyperinsulinemia and 
decreased hyperglycaemia, (Nara et al., 2007) and protection from HFD-induced 
obesity (Tanegashima et al., 2010). Whilst these findings are interesting and present a 
justified rationale for exploring the effects of inhibiting CXCL14 expression or 
function as a possible therapeutic approach for T2DM, the revelation that CXCL14 
mRNA is expressed within mouse and human islets, (Chapter 4), provided additional 
intrigue into its role at the islet level. Therefore, the experiments presented in this 
chapter aimed to identify the localisation of CXCL14 mRNA expression within islets, 
to assess the effects of CXCL14 on islet and β-cell function, to identify the 
mechanisms responsible for any observed functional effects and lastly to attempt to 
elucidate the receptors responsible for mediating CXCL14 function. 
CXCL14 mRNA expression analysis, Chapter 4 (Figure 4.4.1), revealed that CXCL14 
is expressed by human islets and by islets from both inbred and outbred mouse strains, 
with higher expression observed in mouse islets. In an attempt to further reveal the 
localisation of CXCL14 within islets, mRNA expression analysis of CXCL14 in the 
MIN6 cell and Endoc-βH1 β-cell lines was performed. Results revealed that CXCL14 
mRNA expression was present in islets and adipose tissue but absent within both β-
cell lines (Figure 5.4.1), indicating that CXCL14 is not expressed within mouse and 
human β-cells. This observation is consistent with results obtained by Suzuki et al 
revealing that CXCL14 is co-expressed with somatostatin within the secretory vesicles 
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of δ-cells and not within islet α-, β- or PP cells. It has therefore been postulated that 
CXCL14 may be co-released with somatostatin to modulate insulin secretion in a 
paracrine fashion (Suzuki and Yamamoto, 2015). In order to confirm this prediction, 
a series of experiments were designed to elucidate the role of CXCL14 on islet 
function. 
One of the underlying characteristics of T2DM is β-cell dysfunction, which is 
characterised by a decrease in the secretion of insulin in response to glucose combined 
with a reduction in β-cell mass (Oh da and Olefsky, 2016). In order to assess the role 
of CXCL14 on β-cell dysfunction, the experiments described in this thesis were 
designed to observe the effects of exogenous CXCL14 on islet insulin secretion as 
well as CXCL14’s effects on β-cell mass by investigating the proliferative and 
apoptotic properties of CXCL14 on rodent β-cell lines. 
Insulin secretion experiments revealed that CXCL14 inhibited glucose-induced insulin 
secretion (20mM glucose) from mouse islets but not at sub-stimulatory (2mM) glucose 
concentrations (Figure 5.4.5), whereas a reduction in insulin secretion from MIN6 
cells was observed at both 2 and 20mM glucose, with a more pronounced effect at 
2mM glucose (Figure 5.4.3). A similar trend was observed with the rat INS-1 β-cell 
line, whereby CXCL14 also inhibited insulin secretion with a more pronounced effect 
observed at sub-stimulatory glucose concentrations (Figure 5.4.4). The observation 
that CXCL14 inhibits insulin secretion from both mouse islets and rodent β-cell lines, 
indicates that CXCL14 exerts its insulin reducing effects directly on the β-cell. 
However, the discrepancy in the effects of CXCL14 on insulin secretion at sub-
stimulatory glucose concentrations between mouse islets and the rodent β-cell lines 
suggests that there may be additional non-β-cell specific mechanisms involved. 
Alternatively, a more simple explanation may be that the assay window with mouse 
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islets at sub-stimulatory glucose concentrations is not sufficient enough to observe the 
inhibitory effects of CXCL14, thus restricting the assessment of CXCL14-mediated 
function on mouse islet insulin secretion at sub-stimulatory glucose concentrations. 
Whilst these observations, in combination with the findings from other research 
groups, indicate a detrimental effect of CXCL14 on islet function, glucose 
homeostasis and obesity, the role of CXCL14 in humans has not yet been evaluated.  
Our results indicate clear species differences in the effects of CXCL14 on insulin 
secretion between mouse and human islets. Data in Figure 5.4.6 reveal that, unlike 
with mouse islets, CXCL14 did not inhibit human islet insulin secretion at either sub-
stimulatory or stimulatory glucose concentrations, thus questioning the translational 
relevance of studying CXCL14 in relation to T2DM. One obvious explanation for the 
observed species difference may be due to a difference in the expression level of the 
receptor responsible for CXCL14 function. The absence of the receptor responsible 
for CXCL14 function in human islet β-cells would explain the species difference 
observed, as would a reduced receptor expression in human islets, but due to the fact 
that CXCL14 is an orphan ligand i.e. its receptor is unknown, this question cannot be 
easily resolved. 
In addition to the effects of CXCL14 on insulin secretion, the effects of CXCL14 on 
β-cell mass were studied using the MIN6 and INS-1 β-cell lines. Acute exposure to 
CXCL14 for 1 hour had no effect on MIN6 cell proliferation (Figure 5.4.9) nor 
apoptosis (Figure 5.4.7), whereas an anti-proliferative effect (Figure 5.4.10), which 
may be due to a pro-apoptotic effect (Figure 5.4.8), was observed with 40ng/ml of 
CXCL14 in INS-1 cells. CXCL14 is a homeostatic chemokine whose role is to 
regulate monocyte infiltration and thus regulate inflammatory processes (Takahashi et 
al., 2007), and therefore an ability to promote β-cell apoptosis through inflammatory 
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processes may well be possible, especially in a state where circulating CXCL14 is 
upregulated e.g. in obesity. However, such pro-apoptotic effects would be expected to 
be secondary to monocyte infiltration, yet the pro-apoptotic effects observed with 
CXCL14 on INS-1 cells suggests a direct effect of CXCL14 on β-cell apoptosis. 
Interestingly, it has been reported that overexpression of CXCL14 promotes apoptosis 
of HepG2 cells through caspase-dependent pathways (Wang et al., 2013). Such data 
suggest that CXCL14 is able to promote cell apoptosis independent of monocyte 
infiltration. 
An important consideration when assessing the effects of CXCL14 on islet function is 
the exposure time. Whilst 1 hour exposure of exogenous CXCL14 had no effect on 
insulin secretion from human islets at the concentrations tested, the chronic effects of 
CXCL14 on insulin secretion from human or mouse islets have not been assessed. It 
has been shown that serum levels of CXCL14 are upregulated in mice fed a high fat 
diet (Takahashi et al., 2007) and therefore chronic exposure of islets to increased 
circulating levels of CXCL14 may well have additional detrimental effects on islet 
function. Studies designed to assess the chronic effects of CXCL14 on islet function, 
which include the effects on both insulin secretion and β-cell mass, should be 
performed to gain a full insight into the role of CXCL14 on islet function and also to 
fully evaluate the species difference effects that we have observed. 
According to the data in this chapter, the predominant functional effect of acute 
exposure of islets to CXCL14 is an inhibition of insulin secretion through direct 
interaction with the β-cells. In order to identify the underlying mechanisms by which 
CXCL14 inhibits insulin secretion, mechanistic studies were performed in MIN6 cells. 
An obvious mechanism responsible for CXCL14 function on insulin secretion is 
through a reduction in intracellular cAMP, a process mediated either by agonist 
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activation of a Gαi-coupled GPCR or inverse agonism of a Gαs-coupled GPCR. 
Interestingly, it has been proposed that CXCL14 binds to the Gαi-coupled CXCR4 
receptor in THP-1 cells (Tanegashima et al., 2013), which provided additional 
justification for assessing the function of CXCL14 as a Gαi-coupled receptor agonist. 
However, our data revealed that CXCL14, unlike the positive control clonidine, was 
unable to reduce a forskolin-induced increase in intracellular cAMP in MIN6 cells 
indicating that it does not function through a Gαi-coupled receptor (Figure 5.4.13). 
Likewise, the data also revealed that CXCL14 did not reduce basal cAMP levels in 
MIN6 cells indicating that CXCL14 does not function as an inverse agonist for a Gαs-
coupled GPCR (Figure 5.4.13). These results conclude that the effects of CXCL14 on 
insulin secretion are mediated via a cAMP-independent mechanism. 
Another mechanism involved in the regulation of insulin secretion from β-cells is 
glucose uptake. Insulin secretion is regulated by glucose uptake through membrane 
localised GLUTs and intracellular glucokinase activity. Studies have shown that 
CXCL14 enhances insulin-dependent glucose uptake into adipocytes (Takahashi et al., 
2007) but conversely attenuates glucose uptake in cultured myocytes (Nara et al., 
2007). Whilst it appears that CXCL14 has contrasting effects on insulin-dependent 
glucose uptake depending on tissue type, the question remained whether CXCL14 
could modulate glucose uptake into β-cells, an insulin-independent mechanism. The 
results reveal that CXCL14 inhibits glucose uptake in MIN6 cells at both 2 and 20mM 
2DG with a more pronounced effect observed at 2mM 2DG, a trend which is 
remarkably similar to the effect of CXCL14 on insulin secretion from MIN6 cells and 
INS-1 cells. However, the glucose uptake assay used for the experiments described in 
this thesis does not distinguish between glucose transporter and glucokinase activity, 
so whether the observed effects of CXCL14 is due to an inhibition of glucose uptake 
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via the predominantly expressed GLUT-2 or an inhibition of glucokinase activity 
remains unclear. The mechanism by which CXCL14 enhances glucose uptake, and 
insulin sensitivity, in cultured adipocytes is proposed to be due to increased tyrosine 
phosphorylation of the insulin receptor and IRS-1, which is speculated to increase 
GLUT-4 translocation (Takahashi et al., 2007). However, the predominant GLUT in 
MIN6 cells is GLUT-2, which unlike GLUT-4, is an insulin-independent facilitative 
transporter that does not undergo translocation in β-cells. Therefore, whether CXCL14 
could interact directly with GLUT-2 to reduce glucose uptake and subsequent insulin 
secretion remains unclear. It is however worth noting that GLUT subtype expression 
differs between mouse and human β-cells where GLUT-1, -2 and -3 have been shown 
to be expressed in human β-cells, whilst GLUT-2 is the predominant transporter in 
mouse β-cells (Thorens, 2015). If CXCL14 does in fact inhibit GLUT-2 directly then 
the GLUT subtype expression differences between mouse and human β-cells may 
explain the species difference effect of CXCL14 on insulin secretion. 
The modulation of glucokinase activity by ligands that function through GPCRs has 
been demonstrated with the GLP-1 receptor. A study by Ding et al demonstrated that 
activation of the GLP-1 receptor by GLP-1 augmented glucose-dependent rises in 
NADPH in both βTC3 insulinoma cells and mouse islets in a manner that was 
consistent with post-translation activation of glucokinase by enhancing S-nitrosylation 
of the V367 amino acid of glucokinase (Ding et al., 2011). Whilst there is no 
confirmed evidence to suggest that CXCL14 does in fact function through a GPCR, 
the fact that all other CXC-family chemokine ligands couple through GPCRs and that 
glucokinase activity can be modulated through GPCR-mediated mechanisms, suggests 
that CXCL14 may possibly inhibit glucokinase activity through a GPCR-mediated 
mechanism. 
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In order to confirm the effects of CXCL14 on MIN6 cell glucose uptake, an assay was 
developed to assess ATP generation in MIN6 cells (Figure 5.4.18). In theory, 
intracellular ATP generation should be directly proportional to glucose uptake within 
a cell and therefore, inhibitors of glucose uptake should affect intracellular ATP 
generation. However, CXCL14 did not inhibit intracellular ATP levels in MIN6 cells 
(Figure 5.4.19) unlike the positive control oligomycin. An explanation for this absent 
effect could partly be due to the narrow assay window of ATP generation following 
glucose treatment, which suggests that MIN6 cells are highly metabolically active. 
However, the assessment of CXCL14-mediated effects on intracellular ATP 
generation in mouse islets revealed that CXCL14 significantly inhibited intracellular 
ATP generation in mouse islets at 20mM but not at 2mM glucose (Figure 5.4.20), a 
trend that is similar to the effects observed on insulin secretion from mouse islets. 
Whilst glucose uptake could not be confirmed in mouse islets due to technical 
limitations (data not shown), the data so far indicate that the observed inhibitory effect 
of CXCL14 on insulin secretion is likely to be due to an inhibition of glucose uptake 
and or/glucokinase activity, which consequently results in a reduction in intracellular 
ATP production and reduced insulin release. The discrepancy in the glucose-
dependent effects of CXCL14 on insulin secretion between MIN6 cells and mouse 
islets may suggest that CXCL14 exerts additional non-β-cell specific effects that also 
influence insulin secretion. 
The final aim of this chapter was to attempt to identify the receptor/s responsible for 
CXCL14 function. Using information obtained from the IUPHAR database, an 
interactive map, an ‘Interactome’, of all CXC-family ligands with their respective 
CXC-family receptors was generated (Figure 5.4.21). The Interactome information 
revealed that all CXC-family ligands function through at least one CXC-family 
Chapter 5 – The effects of CXCL14 on islet function 
235 
 
receptor, thus suggesting that CXCL14 is likely to do so also. mRNA expression 
analysis of the CXC-family receptors in human islets, ICR mouse islets and MIN6 
cells revealed abundant expression of the CXCR4 and CXCR7 receptors, which are 
the cognate receptors for CXCL12. Tanegashima et al reported that CXCL14 
antagonises CXCL12-mediated chemotaxis of CD34+ hematopoietic progenitor cells 
and binds with high affinity to the CXCR4 receptor in CXCR4 over-expressing THP-
1 cells (Tanegashima et al., 2013). However, a conflicting study reported that CXCL14 
did not affect the dose response profiles of CXCL12-induced CXCR4 
phosphorylation, calcium mobilisation, ERK1/2 phosphorylation or CXCR4 
internalisation in CXCR4 transfected HEK293 and Jurkat T cells (Otte et al., 2014). 
Despite conflicting evidence, we studied whether CXCL14 functioned as an agonist, 
antagonist or allosteric modulator at the CXCR4 receptor, in addition to the CXCR7 
receptor, using β-arrestin technology. β-arrestin technology was chosen to allow the 
detection of ligand function irrespective of the G-protein mechanisms involved 
following receptor activation, thus providing the opportunity to measure unpredicted 
pathway activation as a result of functional selectivity. The β-arrestin studies were 
designed to elucidate mechanism of action i.e. agonism, antagonism or modulation, in 
addition to potential mode of binding i.e. orthosteric or allosteric binding. Our studies 
revealed that CXCL14 did not induce β-arrestin recruitment at either the CXCR4 
(Figure 5.4.23) or CXCR7 (Figure 5.4.25) receptors, indicating that CXCL14 is not an 
agonist at these receptors. Likewise, antagonist studies revealed that CXCL14 did not 
antagonise or modulate CXCL12 affinity or efficacy at the CXCR7 receptor, 
indicating that CXCL14 is not an antagonist or modulator of CXCL12 activity at the 
CXCR7 receptor. However, an increase in the Hill slope and Emax of the CXCL12 
dose response curve at the CXCR4 receptor was observed following co-treatment with 
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CXCL14, suggesting that CXCL14 positively modulates both the binding and efficacy 
of CXCL12 at the CXCR4 receptor. It is however worth noting that these observed 
effects were minor and not dose responsive, suggesting that such observed effects are 
unlikely to be due to CXCL14 specifically, but more likely due to variability within 
the assay. 
The assumption that CXCL14 function is GPCR-mediated is speculative and is based 
on the GPCR receptor-activity relationships of fellow CXC-family ligands along with 
inconsistent literature data. Whether CXCL14 does in fact bind to a GPCR is 
debateable as CXCL14 homologs in all vertebrates differ structurally from all other 
chemokines by possessing an uncharacteristically short amino-terminus of only two 
amino acids located before the first disulphide bridge, a region which is typically 
required for triggering GPCR activation (Benarafa and Wolf, 2015). This evidence 
suggests that unlike its fellow CXC-family ligands, CXCL14 function may not be 
GPCR-mediated and thus efforts to elucidate the target responsible for mediating 
CXCL14 function should also consider alternative target classes. 
 
Summary and future perspectives 
It is clear from published studies that CXCL14 plays a role in rodent glucose 
homeostasis and the data within this chapter provides additional information into 
CXCL14’s role in inhibiting insulin secretion from rodent islets and β-cell lines, yet 
due to the absence of effect in human islets, the translational relevance of these 
observations remains unclear. Further studies are required to assess the chronic effects 
of CXCL14 on both mouse and human islet function to conclusively state whether 
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species differences exist and whether CXCL14 should be pursued further as a target 
of interest in relation to T2DM.  
The mechanism by which CXCL14 inhibits insulin secretion from MIN6 cells and 
mouse islets appears to be at least in part due to a reduction in glucose uptake leading 
to a subsequent reduction in ATP synthesis, but whether this is due to a direct effect 
on GLUT2 or glucokinase activity requires further clarification. The discrepancy in 
the glucose-dependent effects of CXCL14 on insulin secretion from MIN6 cells and 
mouse islets suggests that CXCL14 may also mediate functional effects on alternative 
cell types within islets. It may therefore be worth investigating the effects of CXCL14 
on somatostatin and glucagon release.  
Should CXCL14 function through a GPCR it may well be possible that the inhibitory 
effect of CXCL14 on glucose uptake could be due to a GPCR-mediated inhibition of 
glucokinase activity, but exploring this remains challenging due to CXCL14’s orphan 
status. Contrasting reports combined with the results obtained within this chapter 
suggest that, unlike other CXC-family chemokines, CXCL14 is unlikely to function 
through a CXC-family receptor. There is evidence to suggest inter-chemokine-family 
ligand-receptor interactions exist (Huang, 2002) (Kufareva et al., 2015) and the 
GPCRome data revealed within this thesis could identify potential receptor candidates 
that are worth of exploring, such as CCR2, CCR3, CCR5 and CCR10. It is however 
also possible that CXCL14 does not function through a GPCR-mediated mechanism 
and therefore alternative target classes should also be considered. 
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T2DM is a metabolic disorder that accounts for approximately 90% of all diabetes 
cases and is estimated to affect 371 million people worldwide (Guariguata, 2012). It 
is characterised by hyperglycaemia, which is a consequence of insufficient insulin 
secretion, insulin resistance in metabolically active tissues and inadequate suppression 
of glucagon production (Spellman, 2010). The principle causal factors contributing to 
the increase in incidence of T2DM worldwide include relative over-nutrition and 
sedentary activity, both of which are a result of a global transition to a more modern 
westernised lifestyle (Zimmet, 1999). In the UK alone, approximately 9% of the NHS 
budget is spent on treating diabetes and its associated complications, equating to 
approximately £10 billion per year (Meetoo et al., 2007). This figure is certain to rise 
further with projected increases in incidences, and therefore efforts are being made to 
develop suitable therapies to treat T2DM and to prevent its associated complications. 
The primary aim of T2DM therapies is to maintain glucose homeostasis for as long as 
possible following diagnosis, thereby reducing the onset of associated complications 
(Kahn et al., 2014). Numerous therapies with varying mechanisms of action have been 
developed but limitations in drug safety profiles and efficacy mean that the search for 
improved therapies are ongoing. One particular target class that is receiving such 
attention is the GPCR family. Historically, GPCRs have proven to be a successful 
target class for many indications accounting for approximately 17% of all approvals 
since 1982 (Rask-Andersen et al., 2011). However, despite this success for a variety 
of conditions, only one GPCR, the GLP-1 receptor, has proven to be clinically 
successful in treating T2DM. Part of the issue contributing the limited success of 
targeting GPCRs for T2DM is the poor functional characterisation of the majority of 
islet-expressed GPCRs. This issue is further exacerbated by the limited availability of 
human islets required to study GPCR function, and as a result rodent islets, particularly 
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mouse islets, are relied upon as translational models. Structural differences between 
rodent and human islets are well documented (Steiner et al., 2010), which poses a 
question of the suitability of using rodent islets, in particular mouse islets, as 
translational models for predicting GPCR-mediated regulation of human islet 
function. Therefore, the experiments described in this thesis aimed to quantify and 
compare the mRNA expression levels of non-odorant GPCRs and GPCR peptide 
ligands in mouse and human islets in order to assess the suitability of using mouse 
islets to predict GPCR and GPCR peptide ligand function in human islets. 
Furthermore, this thesis also highlights how such gene expression data can be utilised 
to identify islet-expressed GPCR peptide ligands whose role in islet function is yet to 
be characterised, and how both the Secretome and GPCRome data can be employed 
to explore the mechanism of action of such peptides in islet function, as exemplified 
by CXCL14. 
 
6.1 GPCRome comparison 
GPCR mRNA expression analyses detailed in Chapter 3 revealed that a high 
proportion of non-odorant GPCRs are expressed within both human and mouse islets 
of Langerhans. Of the 376 GPCRs assessed for expression within human islets, 284 
GPCR mRNAs (75%) were shown to be expressed by human islets, whereas of the 
335 mouse orthologue GPCR genes screened in mouse islets, 281 (84%) and 230 
(67%) GPCRs were expressed in ICR and C57 mouse islets respectively. This high 
proportion of GPCR expression is unsurprising given the fact that GPCRs play an 
important role in regulating islet function, that islets are comprised of numerous cell 
types and that islet function is regulated by various GPCR-dependent inputs such as, 
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neural input from the CNS, by gastrointestinal peptides, bile acids and also circulating 
nutrients, fatty acids and amino acids (Reimann and Gribble, 2016). 
Despite the fact that a large proportion of the total GPCRs quantified were shown to 
be expressed in both human and mouse islets, regression analysis (r2) revealed that 
GPCR expression levels differed between human islets and mouse islets: human vs. 
ICR = 0.360 and human vs. C57 = 0.304. Part of the cause of this variation is likely to 
be the difference in the proportions of endocrine cells between human and mouse 
islets. However, this does not explain the exclusive expression of certain GPCRs 
within each islet group. 
The observation that the degree of overall GPCR expression in human islets is more 
similar to that of the ICR mouse strain than the C57 strain is likely to be due the degree 
of genetic variability between the two mouse strains, as one would presume that a 
greater degree of gene expression variability is likely to be observed within the outbred 
ICR strain. This degree of genetic variability between biological replicates of the ICR 
strain could result in a greater degree of inconsistency in expression compared to the 
C57 strain, thus preferentially skewing the data in favour of using ICR islets as suitable 
surrogate models for human islet studies. Furthermore, the use of outbred models is 
likely to introduce a degree of genetic variability consistent with the human situation, 
and thus be more translationally relevant. 
The data within Chapter 3 suggest that mouse islets can be utilised to predict the 
involvement of GPCRs in human islet function, but that suitability is receptor-specific. 
For example, the expression levels of the 14 selected GPCRs that exhibit functional 
characteristics appropriate for the treatment of T2DM indicate that mouse islets would 
indeed be suitable (r2 = 0.531). However, whilst it can be postulated that mouse islets 
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are suitable surrogate models based on mRNA expression analysis, further functional 
studies are required confirm such claims. For example, assessment on whether the 
GPCR mRNA is translated into protein, whether the receptor localises to the plasma 
membrane or whether the cellular machinery required for protein function is present 
in islets should be determined, in addition to assessing which endocrine cell types 
express which GPCRs. 
 
6.2 Secretome comparison 
A high proportion of GPCR peptide ligand mRNAs are expressed within both human 
and mouse islets. Of the 159 GPCR peptide ligands screened for expression in human 
islets, 128 (81%) were shown to be expressed, whilst of the 145 mouse orthologues 
screened, 109 (75%) and 86 (59%) were expressed in ICR and C57 mouse islets 
respectively. This expression of a variety of peptide ligands is likely to be expected of 
endocrine cells whose primary function is to secrete a multitude of factors which 
regulate not only processes within the islet microenvironment but also the processes 
of other body tissues through delivery via the systemic circulation (Brereton et al., 
2015). 
However, similar with GPCR expression, despite the fact both human and mouse islets 
express a multitude of peptide ligands, the degree of mRNA expression of those 
peptide ligands varies between human and mouse islets. This is highlighted by 
regression analysis (r2), which indicates that human vs. ICR = 0.245 and human vs. 
C57 = 0.225. As discussed previously, the disparity in expression level is likely to be 
due to differences in the proportion of endocrine cells present within islets between 
the species. Interestingly, the number of GPCR peptide mRNAs expressed within C57 
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mouse islets was less than in ICR mouse islets, a trend that was also observed for 
GPCR expression (Figure 3.4.4, Figure 3.4.5). This trend is likely to be attributed to 
the greater genetic variability of the outbred ICR strain compared to the more 
homogeneous inbred C57 mouse strain, where expression between biological 
replicates is more consistent. As previously mentioned, the use of outbred models, 
such as ICR mice, is more comparable with the human situation and thus more 
translationally relevant. This fact that is further reinforced by the regression analysis 
data which revealed that human islets are more similar to ICR mouse islets than C57 
mouse islets with regards to GPCR peptide ligand gene expression (human vs. ICR = 
0.245 and human vs. C57 = 0.225). 
While the principal aim of the Secretome comparison was to highlight similarities and 
differences in peptide ligand expression between human and mouse islets, the data 
generated also offered the opportunity to identify islet-expressed GPCR peptide 
ligands whose role in islet function has yet to be determined. Such examples include, 
C1QL1, EDN3 and CXCL14. Interestingly, CXCL14 has been shown to play a role in 
rodent glucose metabolism and obesity, yet the role of CXCL14 on islet function is 
not understood. Furthermore, the receptor to which CXCL14 binds is also unknown. 
Therefore, the final results chapter in this thesis aimed to reveal not only the role of 
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6.3 The effects of CXCL14 on islet function 
An association between obesity and CXCL14 upregulation, and its subsequent effects 
on glucose homeostasis, has recently been reported (Hara and Tanegashima, 2012). In 
the few publications to date, the overall trend regarding CXCL14’s role in metabolism 
appears to be that of a detrimental one, with high fat diet fed CXCL14-knockout mice 
exhibiting improved insulin responsiveness, decreased hyperinsulinaemia and 
decreased hyperglycaemia (Nara et al., 2007), while also being protected from HFD-
induced obesity (Tanegashima et al., 2010). Whilst these findings are interesting and 
present a justified rationale for exploring the effects of inhibiting CXCL14 expression 
or function as a possible therapeutic approach for T2DM, the revelation that CXCL14 
mRNA is expressed within mouse and human islets, (Chapter 4), provided additional 
intrigue into its role at the islet level. 
Prior to undertaking this project, the localisation of CXCL14 within islets was not 
known. According to the data presented in this thesis, CXCL14 mRNA is not 
expressed within β-cells as indicated by the absence of mRNA expression in the 
Endoc-βH1 and MIN6 human and mouse β-cell lines. During the course of performing 
such studies, a recently published study revealed that CXCL14 is co-expressed with 
somatostatin within mouse δ-cells but not expressed within α-, β- and PP cells (Suzuki 
and Yamamoto, 2015), a finding which was consistent with the expression data in this 
thesis. It was therefore postulated that CXCL14 may be co-released with somatostatin 
to regulate insulin secretion, so functional studies assessing the role of CXCL14 on 
insulin secretion and β-cell mass were performed. 
Treatment of both MIN6 cells and INS-1 cells with CXCL14 resulted in a significant 
inhibition of insulin secretion with a more pronounced effect observed at sub-
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stimulatory glucose concentrations. Interestingly, CXCL14 also inhibited insulin 
secretion from mouse islets, but only at stimulatory glucose levels. The differences in 
effects seen with the cell lines and islets suggests that whilst the inhibitory effects of 
CXCL14 appear to be β-cell-specific, it may also act at other cell types in whole islets. 
In order to confirm the translational relevance of such findings, the effects of CXCL14 
on insulin secretion from human islets were studied. Unlike the data obtained with 
mouse islets, CXCL14 did not inhibit insulin secretion indicating a clear species-
specific effect, which is likely to be explained by a disparity in the expression of the 
receptor responsible for CXCL14 function. However, due to the orphan status of 
CXCL14, this cannot be easily determined. 
In addition to assessing the effects of CXCL14 on insulin secretion, effects on β-cell 
mass were also explored. CXCL14 did not modulate MIN6 cell proliferation or 
apoptosis but a decrease in INS-1 cell proliferation and an increase in INS-1 cell 
apoptosis were observed at the highest concentration of CXCL14 tested (40ng/ml). 
Interestingly, it has been reported that overexpression of CXCL14 promotes apoptosis 
of a liver cell line (HepG2) through caspase-dependent pathways (Wang et al., 2013), 
thus suggesting that CXCL14 exhibits pro-apoptotic properties. Such published 
findings, in addition to the data generated in this thesis, suggest that CXCL14 may 
impact β-cell mass through the promotion of apoptosis, but further experiments are 
required to establish whether these observations in INS-1 cells are also seen in primary 
islets. 
Exploration of the mechanisms involved in CXCL14’s regulation of insulin secretion 
indicate that it does not function through a cAMP-dependent mechanism but instead 
inhibits either glucose uptake via GLUT2 or β-cell glucokinase activity. Such a mode 
of action was further reinforced following the observation that acute treatment (1 hour) 
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with exogenous CXCL14 inhibited ATP production in mouse islets. Furthermore, the 
effects of CXCL14-mediated inhibition of ATP production in mouse islets appear to 
be glucose-dependent, an effect also observed for its effects on insulin-secretion from 
mouse islets. The combination of such functional data suggests that CXCL14 inhibits 
insulin secretion by impairing glucose uptake or glucokinase activity, thus reducing 
glucose metabolism through the glycolytic and TCA pathways and resulting in a 
reduction intracellular ATP production. However, whether such effects are due to 
GLUT-2 or glucokinase inhibition are unclear. Should CXCL14 function via a GPCR, 
like fellow members of its chemokine class, it could be postulated that glucokinase 
activity may be the underlying factor involved as GPCR-mediated modulation of 
glucokinase activity has been previously been demonstrated, such as with GLP1R 
(Ding et al., 2011). If inhibition of GLUT-2 activity was the underlying factor then 
this may explain the species-selective effect of CXCL14 on insulin secretion due to 
the GLUT subtype expression differences observed between human and mouse β-cells 
(Thorens, 2015). Further studies are required to distinguish between GLUT-2 and 
glucokinase involvement in CXCL14-mediated reduction in insulin secretion and 
whether such effects are in fact facilitated by a GPCR mechanism.  
The experiments within this thesis rule out the involvement of both CXCR4 and 
CXCR7 in CXCL14 function in β-cells, despite reports suggesting that CXCR4 
interacts with CXCL14 (Tanegashima et al., 2013). There is evidence to suggest the 
existence of inter-chemokine-family ligand-receptor interactions (Huang, 2002)  
(Kufareva et al., 2015) and the GPCRome data revealed within this thesis could 
identify potential receptor candidates that are worth exploring, such as CCR2, CCR3, 
CCR5 and CCR10. However, whether CXCL14 does in fact bind to a GPCR is 
debateable as CXCL14 homologues in all vertebrates differ structurally from all other 
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chemokines by possessing an uncharacteristically short amino-terminus of only two 
amino acids located before the first disulphide bridge, a region which is typically 
required for triggering GPCR activation (Benarafa and Wolf, 2015). This evidence 
suggests that unlike its fellow CXC-family ligands, CXCL14 function may not be 
GPCR-mediated and thus efforts to elucidate the mechanism responsible for mediating 
CXCL14 function should also consider alternative target classes. 
 
6.4 Concluding remarks 
The islet GPCR and peptide ligand mRNA quantifications described in this thesis 
reveal a large amount of data that can be evaluated to assess the suitability of utilising 
mouse islets to study GPCR and peptide ligand involvement in human islet function. 
Understanding translation model suitability is fundamental to the research work flow 
before time and resources are committed. This point is exemplified by the limited 
success of strategies directed at developing GPR119 agonists as T2DM therapeutics, 
which has been attributed to efficacy differences between rodent and human species 
(Ritter et al., 2016). Furthermore, gene expression data also provide a resource of 
information that can be utilised to identify receptors and peptides whose role in islet 
function are yet to be characterised, for example, CXCL14, thus furthering our 
understanding of islet function and offering additional opportunities to identify novel 
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